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Abstract 
Epithelial tissue is characterized by close cell-cell and cell-extracellular matrix (ECM) contacts as well as by apico-basal po-
larization. Integrity of these two features is important for functionality of epithelium. Additionally, proteins regulating polarity 
and cell junctions have been linked to cell cycle and apoptosis control. Consequently, defects in many of the polarity proteins 
have been linked to oncogenic events and loss of polarity is a hallmark of advanced cancers but whether it is causal to tumor-
igenesis is yet unknown. However, large body of knowledge on apico-basal polarity regulation and its connection on homeo-
stasis control is derived from studies in Drosophila. This is mainly due to fact that efficient high throughput organotypic three 
dimensional (3D) culture methods enabling apico-basal polarization have not been available until the last decade. Large 
screens for epithelial polarity regulators have not been carried out in mammalian cells. Moreover, as cancer is the leading 
cause of death in developed countries and most of the cancers originate from epithelial tissues, knowledge of polarity regula-
tion can be medically relevant. 
 
Oncogene MYC is overexpressed or amplified in variety of human cancers. The tumorigenic function of MYC is mainly due to 
its ability to drive cell cycle. We have previously shown that intact epithelial architecture is protective from cell cycle deregu-
lating activities of MYC in 3D MCF10A mammary epithelial cell model and in vivo. This resistance can be overcome by inacti-
vating LKB1 which is the human homologue of the polarity protein PAR4 implying a tumour suppressive role for epithelial 
architecture in mammalian cells. 
 
To identify regulators of epithelial architecture in mammalian cells, we have established lentiviral shRNA library (human epi-
thelial architecture library, hEAL) encompassing 219 constructs targeting 77 genes associated with polarity regulation in Dro-
sophila. We have previously screened the shRNA constructs for downregulation and quantified their effects on acinar mor-
phology in the MCF10A 3D model. 
  
In this Master’s Thesis I have validated the downregulation and phenotypes observed in a subset of the shRNAs during pri-
mary screening of the constructs of the library. Additionally, the possible co-operation with downregulation of the polarity 
regulators and conditional activation of MYC was determined. Most dramatically, downregulation of Wnt pathway gene DVL3 
was shown to cause formation of enlarged multiacinar structures, which have increased proliferation. Additionally, downregu-
lation of another Wnt pathway gene, GSK3β, resulted in acini with increased size and filled lumens. Thus these results pro-
pose a role for these genes in epithelial architecture regulation and tumour suppression in the used model even though api-
co-basal polarization of the acini was intact and no synergy with MYC was observed. Interestingly, no role in epithelial archi-
tecture regulation for Hippo pathway related genes FAT4 and MOBKL1A was found. Importantly, this study was able to vali-
date primary screen showing relevance of the pipeline. Lastly, the study characterized the synthetic lethality phenotype found 
in the primary screen caused by downregulation of GTPase RHOA and chronic MYC activation. The shRHOA acini exhibited 
perturbed α6-integrin localization. When combined with MYC activation, the percentage of apoptotic acini was significantly 
increased. Importantly, the results suggest the observed synthetic lethality to be specific for the 3D context and to be associ-
ated with MEK/ERK and ROCK pathways.  
 
Taken together, in this study I have validated the role of novel epithelial architecture regulators and candidate tumour sup-
pressors in MCF10A cells which may have medical relevance by helping to characterize tumorigenic processes. Furthermore, 
I characterized a novel 3D specific RHOA-MYC synthetic lethal interaction, which may prove to have therapeutic significance 
in MYC-driven cancers in future. 
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   Wiskott–Aldrich	  syndrome	  protein	  	  
WD40	   Repeat	  of	  40	  amino	  acids	  often	  terminating	  into	  tryptophan	  (W)-­‐aspartic	  acid	  (D)	  dipeptide	  
Wg	  	   wingless	  
WW45	   Mammalian	  Salvador	  homologue	  
YAP	   Yes-­‐activated	  protein	  
YWHAZ	   tyrosine	  3-­‐monooxygenase/tryptophan	  5-­‐monooxygenase	  activation	  protein,	  zeta	  polypeptide	  
ZEB1	   zinc	  finger	  E-­‐box	  binding	  homeobox	  1	  
ZNF	   Zinc	  finger	  protein	  
ZO	  	   Zonula	  occludens	  
ZONAB	   ZO-­‐1-­‐associated	  nucleic	  acid-­‐binding	  protein	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This	  Master’s	  Thesis	  is	  based	  on	  the	  following	  publications:	  
1.	  Faulty	  epithelial	  polarity	  genes	  and	  cancer,	  Review,	  Adv	  Cancer	  Research	  vol	  111.	  
(2011)	   Tervonen	   T,	   Partanen	   J,	   Saarikoski	   S,	  Myllynen	  M,	  Marques	   E,	   Paasonen	   K,	  
Moilanen	  A,	  Wohlfart	  G,	  Kovanen	  P,	  Klefström	  J.	  -­‐	  Review	  
2.	   Lentiviral	   shRNA	  based	   identification	   of	   human	   epithelial	   architectyre	   regulating	  
genes	   with	   tumor	   suppressor	   functions,	   (in	   preparation).	   Partanen	   J,	   Tervonen	   T,	  
Myllynen	  M,	  Mäkelä	  A,	  Laakso	  M,	  Hautaniemi	  S,	  Klefström	  J.	  
REVIEW	  OF	  THE	  LITERATURE	  
1.	  Epithelial	  tissue	  and	  signalling	  mechanisms	  
1.1.	  Epithelial	  architecture	  and	  organization	  	  
Barrier,	  absorbing	  surface,	  secretory	  gland	  –	  these	  all	  are	  functions	  of	  epithelial	  tissue.	  Epithelial	  
tissue	  can	  be	  stratified,	  for	  example	  in	  thorax,	  where	  it	  is	  under	  constant	  physical	  stress	  and	  needs	  
to	  be	  strong.	  On	  the	  other	  hand,	   in	   intestine	   the	  epithelium	   is	   single	   layered	   to	  enable	  efficient	  
absorbtion	  of	  nutrients.	  Additionally,	  epithelium	  may	  differentiate	  into	  glandular	  structures	  as,	  for	  
example,	   the	  acinar	   structures	   in	  mammary	  gland.	   In	   spite	  of	   these	   certain	   specific	   features,	   all	  
epithelial	   tissues	   have	   one	   fundamental	   feature:	   cells	   are	   tightly	   bound	   to	   each	   other	   and	  
basement	  membrane	  surrounging	  them.	  In	  addition,	  epithelial	  tissue	  is	  rich	  of	  cells	  and	  has	  very	  
little	  extracellular	  matrix	  (ECM)	  in	  contrast	  to	  e.g.	  connective	  tissue.	  As	  close	  cell-­‐cell	  and	  cell-­‐ECM	  
contacts	  are	  a	  hallmark	  of	  epithelial	  cells,	  these	  contacts	  play	  a	  pivotal	  role	  in	  a	  life	  of	  an	  epithelial	  
cell	   (Fig	   1).	   Correct	   organization	   and	   formation	   of	   the	   contacts	   control	   and	   regulate	   various	  
intracellular	   signalling	   pathways	   including	   those	   involved	   in	   proliferation	   and	   apoptosis	   (1).	   Via	  
these	  contacts	   individual	  cells	  can	  interact	  with	  each	  other	  and	  form	  a	  cohesively	  working	  tissue	  
which	  is	  important	  for	  homeostasis	  and	  functionality	  of	  the	  epithelial	  tissue	  (1).	  Another	  hallmark	  
of	  epithelial	  cell	  is	  the	  apico-­‐basal	  polarization	  (Fig	  1).	  The	  epithelial	  cell	  is	  divided	  into	  apical	  and	  
basal	  (basolateral)	  domains	  (2).	  These	  domains	  are	  to	  great	  extent	  governed	  by	  cell	  junctions	  and	  
cell	  polarity	  regulates	  physical	   localization	  of	  the	  junctions.	  Therefore	  regulation	  of	  cell	   junctions	  
and	  apico-­‐basal	  polarity	  are	  tightly	  interwoven	  (3).	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Figure	  1	  Structure	  of	  a	  mammary	  acinus,	  cell	  polarity	  domains	  and	  the	  localization	  and	  compostion	  of	  cell	  junctions	  in	  epithelial	  cells.	  Desmosomes	  
and	  gap	  junctions	  are	  left	  out	  for	  clarity.	  Epithelial	  cell	  is	  divided	  into	  apical	  and	  basolateral	  domains	  with	  border	  marked	  by	  the	  tight	  junctions.	  Cell	  
junctions	  are	  connected	  through	  intracellular	  proteins	  to	  cytoskeleton	  (intermediate	  filaments,	  actin).	  In	  the	  acinus,	  red	  marks	  the	  normal	  staining	  
pattern	  of	  apical	  Golgi	  protein	  GM130	  and	  pink	  the	  basal	  α6-­‐integrin.	  ECM;extracellular	  matrix,	  BP;binding	  protein.	  
1.2.	  Cell	  junctions	  and	  basement	  membrane	  
1.2.1.	  Tight	  junctions	  	  
Tight	  junctions	  (TJ)	  are	  in	  the	  apical	  domain	  of	  the	  cell	  (Fig	  1).	  TJs	  are	  responsible	  for	  forming	  the	  
paracellular	  barrier	  between	  adjacent	  cells	  which	  blocks	  the	  paracellular	  route	  for	  flow	  of	  fluids	  or	  
molecules	  between	  the	  cells.	  TJs	  between	  cells	  form	  the	  basis	  for	  the	  barrier	  function	  of	  epithelial	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cell	  between	  two	  different	  surroundings	  (1).	  E.g.	  it	  is	  important	  that	  in	  intestine	  the	  absorbtion	  of	  
substances	  is	  controlled	  and	  the	  foreign	  substances	  and	  agents	  (including	  bacteria)	  cannot	  move	  
freely	   from	   intestine	   to	   body	   and	   vice	   versa	   (1,	   4).	   	   Importantly,	   tight	   junctions	   also	  mark	   the	  
boundary	  of	   the	  membrane	  domains,	  by	  blocking	  the	  diffusion	  of	  membrane	  proteins	  and	   lipids	  
into	  different	  domains	  (5).	  
Molecularly	  TJs	  are	  formed	  through	  interactions	  of	  three	  transmembrane	  protein	  classes,	  claudins,	  
occludins	   and	   Junctional	  Adhesion	  Molecules	   (JAMs),	  which	   contact	   corresponding	  molecules	   in	  
adjacent	  cells	  forming	  a	  zipper-­‐like	  junction	  (Fig	  1).	  Intracellularly	  these	  proteins	  are	  attacthed	  to	  
Zonula	  Occludens	  proteins	  (ZO)	  (Fig	  1)	  (5,	  6).	  More	  is	  known	  of	  claudin	  function	  in	  TJs	  compared	  to	  
occludins	   (5,	   7).	   Importantly,	   ZO	   proteins	   link	   TJs	   to	   actin	   cytoskeleton	   inside	   the	   cell	   and	   can	  
therefore	   influence	  cell	  signalling	  (1,	  5,	  6).	   In	  addition,	  ZO-­‐2	  has	  been	  shown	  to	  shuttle	  between	  
nucleus	  and	  junctions	  and	  could	  therefore	  affect	  transcription	  ((8).	  
1.2.2.	  Adherens	  junctions	  	  
Adherens	  junctions	  (AJ)	  are	  situated	  below	  the	  apical	  TJs	  in	  the	  basolateral	  domain	  (Fig	  1)	  (9).	  They	  
are	   defined	   as	   a	   sticker-­‐like	   interface	   between	   cells,	   which	   has	   strength	   to	   govern	   the	   cell	  
adhesion	  in	  tissue	  but	  is	  readily	  modifiable	  when	  needed	  (10).	  AJs	  connect	  the	  actin	  cytoskeletons	  
of	   the	  neighbouring	  cells	  as	  explained	  below.	  Extracellularly	  AJs	  are	   formed	   through	  homophilic	  
interaction	  of	  cadherin-­‐transmembrane	  proteins	  (1,	  10).	  With	  their	  intracellular	  domain	  cadherins	  
are	  linked	  to	  intracellular	  anchor	  proteins	  such	  as	  p120-­‐catenin	  and	  α-­‐	  and	  β-­‐catenins	  (Fig	  1)	  (10).	  
These	  anchoring	  proteins	   connect	  AJs	   to	   the	  actin	   cytoskeleton	   ((6,	  10)).	   In	  epithelial	   cells	   actin	  
usually	   forms	   subapical	   adhesion	   belt	   that	   encircles	   the	   cell	   and	   is	   connected	   to	   adjacent	   cell	  
through	   AJs	   ((11)).	   Associating	   with	   myosin-­‐molecules	   the	   adhesion	   belt	   can	   contract	   which	   is	  
essential	  for	  the	  epithelial	  morphogenetic	  processes	  such	  as	  invagination	  (1,	  11).	  Cell-­‐cell	  contacts	  
in	   AJ	   are	   also	   contributed	   by	   a	   family	   of	   adhesion	   molecules	   called	   nectins.	   Nectins	   are	   Ca2+-­‐
independent	   immunoglobulin-­‐like	   proteins,	   which	   in	   human	   cells	   have	   four	   members.	  
Intracellularly	   nectins	   bind	   to	   afadin	  which	   can	   directly	   link	   them	   to	   actin	   cytoskeleton	   (Fig	   1).	  
Moreover,	   afadin	   also	   binds	   α-­‐catenin	   by	   which	   mechanism	   the	   nectin	   based	   adhesion	   is	   also	  
linked	  to	  the	  actin	  cytoskeleton.	  Nectins	  have	  been	  shown	  to	  contribute	  to	  the	  E-­‐cadherin	  based	  
adhesion	  thereby	  having	  an	  important	  role	  in	  adherens	  junction	  strength	  and	  signalling	  (12).	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1.2.3.	  Desmosomes	  	  
Desmosomes,	   which	   are	   found	   basal	   to	   AJs,	   closely	   resemble	   AJs	   structurally	   (3,	   10,	   13).	   In	  
desmosomes	   adjacent	   cells	   connect	   each	   other	   through	  desmoglein	   and	   desmocollin	  molecules	  
which	  belong	  to	  the	  cadherin	  family.	  Intracellular	  tails	  of	  desmoglein	  and	  desmocollin	  are	  bound	  
to	  plakoglobin	   (γ-­‐catenin)	  and	  plakophilin	   (relative	  of	  p120-­‐catenin)	   (13).	  Whereas	  AJs	  attach	   to	  
actin	  cytoskeleton,	  desmoplakin	  links	  plakoglobin	  and	  plakophilin	  to	  the	  intermediate	  filaments	  of	  
the	  (1,	  13).	   In	  epithelial	  cells	  the	  attachment	   is	  usually	  to	  keratins.	  Desmosomes	  are	  responsible	  
for	  giving	  mechanical	  strenght	  to	  tissue	  in	  co-­‐operation	  with	  adherens	  junctions	  (1).	  
1.2.4.	  Hemidesmosomes	  	  
Epithelial	   cells	   attach	   to	   basement	   membrane,	   which	   is	   a	   specialized	   form	   of	   ECM,	   via	  
hemidesmosomes	  (Fig	  1)	  (14).	  The	  connection	  to	  the	  ECM	  is	  mediated	  by	  integrins,	  which	  attach	  
to	  the	  components	  of	  basement	  membrane	  such	  as	  laminin,	  collagen	  and	  fibronectin	  (15).	  Integrin	  
molecules	   are	  heterodimers	   composed	  of	  α	   and	  β	   subunits,	  which	  are	  non-­‐covalently	  bound	   to	  
each	   other.	   In	   humans	   at	   least	   24	   forms	   of	   integrins	   exist	   (15).	   23	   of	   them	   form	   intracellular	  
linkage	  via	  talin	  and	  additional	   intracellular	  anchorage	  proteins	  (e.g.	  vinculin)	  which	  link	  them	  to	  
actin	  filaments	  (Fig	  1)	  (15).	  In	  epithelial	  hemidesmosomes,	  which	  are	  important	  in	  connecting	  cells	  
to	   the	   underlying	   basement	   membrane,	   the	   connection	   is	   formed	   specifically	   through	   α6β4-­‐
integrin	  heterodimer,	  which	  on	  the	  extracellular	  side	  attaches	  to	  laminin	  of	  basement	  membrane	  
(Fig	   1)	   (14).	   The	  α6β4-­‐integrin	   is	   connected	   intracellularly	   through	   adapter	   proteins	   plectin	   and	  
bullous	  pemphigoid	  antigen	  1e	  (BPAG1e)/dystonin	  to	  the	  keratin	  filaments	  in	  contrast	  to	  the	  actin	  
linkage	  of	  other	  integrins	  (Fig	  1)	  (14,	  15).	  Integrins	  also	  form	  other	  kinds	  of	  structures	  with	  ECM,	  
such	  as	  focal	  adhesions	  (15).	  	  
Integrins	  have	  been	  implicated	  in	  various	  functions,	  for	  example	  in	  immunological	  signalling	  (16).	  
In	   similar	   manner	   to	   cadherins	   in	   AJs	   and	   desmosomes,	   integrins	   can	   serve	   as	   an	   interface	  
mediating	   interactions	   and	   signals	   between	   epithelium	   and	   basement	   membrane.	   Change	   in	  
intracellular	  or	  extracellular	  circumstances	  e.g.	  tension	  applied	  to	  epithelium	  can	  affect	  signalling	  
input	  and	  output	  in	  both	  compartments	  through	  these	  cell	  adhesion	  molecules	  (17-­‐20).	  Ability	  of	  
the	   integrins	   to	   conformationally	   change	   from	   active	   to	   inactive	   forms	   is	   a	   key	   factor	   to	   this	  
feature.	  (19).	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1.2.5.	  Gap	  junctions	  	  
Gap	  junctions	  are	  small,	  direct,	  passageways	  between	  adjacent	  cells.	  They	  connect	  neighbouring	  
cells	  electrically	  and	  metabolically.	  Transmembrane	  proteins	  connexins	  establish	  gap	   junction	  by	  
forming	  a	  channel	  with	  a	  diameter	  of	  1,5nm	  and	  and	  2-­‐3nm	  gap	  between	  cells	  allowing	  neutral	  
molecules	   and	   ions	   up	   to	   1kDa	   pass	   through	   them	   (21-­‐24).	   However,	   whether	   gap	   junctions	  
contribute	  to	  the	  formation	  and	  maintenance	  of	  epithelial	  architecture	  and	  apico-­‐basal	  polarity	  is	  
not	  well	  known	  as	  gap	  junctions	  have	  mainly	  been	  studied	  in	  electrically	  excitable	  cell	  types	  such	  
as	   neurons	   and	   muscle	   cells.	   Their	   importance	   in	   cell-­‐cell	   communication,	   by	   enabling	   flow	   of	  
small	  molecules	   between	   adjacent	   cells,	   is	   highlighted	   by	  myocardial	   cells	   in	  which	   the	   electric	  
signal	  spreads	  fast	  throughout	  the	  muscle.	  Interestingly,	  gap	  junctions	  have	  been	  associated	  with	  
ZO	  proteins	  of	  the	  TJs	  and	  some	  of	  the	  AJ	  proteins	  (23,	  25,	  26).	  	  
1.2.6.	  Basement	  membrane	  	  
Epithelial	   cells	   are	   connected	   to	   a	   dense	   protein	   network	   which	   is	   a	   specialized	   form	   of	   ECM,	  
secreted	   by	   the	   epithelial	   and	   stromal	   cells	   in	   epithelial	   tissues.	   Importantly,	   the	   basement	  
membrane	  (also	  known	  as	  basal	  lamina)	  gives	  epithelial	  cells	  spatial	  cues	  by	  marking,	  which	  is	  the	  
basal	   side	   of	   the	   cell,	   serving	   as	   an	   attachment	   point	   for	   integrins	   (Fig	   1).	   Consequently,	   it	   is	  
essential	  in	  the	  apicobasal	  polarization	  and	  organization	  of	  epithelial	  tissue	  (27-­‐30).	  
Basement	   membrane	   is	   mainly	   consisting	   of	   fibrous	   proteins	   and	   proteoglycans.	   The	   main	  
individual	  protein	  components	  of	  basement	  membrane	  are	  glycoproteins	  laminin	  and	  collagen	  IV	  
(31-­‐33).	   Laminin	   is	   a	   cross	   formed	  molecule.	   	   It	   is	   assembled	   of	   three	   long	   polypeptide	   chains	  
which	  attach	   to	  each	  other	   through	  disulfilde	  bond	  and	  have	  multiple	   interaction	  domains	  with	  
other	   basement	   membrane	   components	   and	   cell	   surface	   receptors	   (30,	   33).	   Like	   laminin,	   also	  
collagen	   IV	   is	   formed	   through	   interweaving	   of	   three	   individual	   polypeptide	   chains	   forming	   a	  
superhelix.	  Through	   terminal	  domains	  collagen	   IV	  molecules	   can	   form	  a	  network	  of	   interactions	  
which	  gives	  basement	  membrane	  flexibility	  and	  tensile	  strength	  (31,	  32).	  	  
In	  addition	  to	  the	  major	  basement	  membrane	  components,	  additional	  proteins	  are	  needed	  for	  the	  
formation	   of	   functional	   basement	   membrane.	   At	   least	   glycoprotein	   nidogen	   and	   proteoglycan	  
perlecan	  are	  thought	  to	  be	  needed	  to	  mediate	  interaction	  between	  laminin	  and	  collagen	  IV	  and	  to	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form	   a	   functional	   basement	   membrane	   (31-­‐33).	   This	   is	   demonstrated	   by	   common	   interaction	  
partners	  in	  the	  basement	  membrane	  shared	  by	  laminin	  and	  collagen	  IV.	  (31-­‐33).	  
1.3.	  Apico	  basal	  polarity	  	  
The	  second	  predominant	   feature	  of	  epithelial	   tissue	   is	   that	   cells	  are	  polarized	  along	   the	  vertical	  
axis	   (apico-­‐basally).	  Apico-­‐basal	  polarization	  has	   to	  be	  distinguished	   from	   ‘the	   front	  and	  rear’	  or	  
anterior-­‐posterior	  polarization	  that	  many	  migrating	  cell	  types	  exhibit,	  although	  these	  two	  different	  
processes	  are	  to	  some	  extent	  regulated	  by	  same	  proteins	  (3).	  As	  mentioned	  the	  cell	  is	  divided	  into	  
apical	  and	  basolateral	  domains.	  
Apico-­‐basal	   polarity	   is	   initiated	   by	   formation	   of	   primordial	   AJ	   junctions	   containing	   both	   AJ	  
components	   such	   as	   E-­‐cadherin	   and	   nectin	   and	   future	   TJ	   components	   ZO-­‐1,	   JAM-­‐A	   and	   key	  
constituents	  occluding	  and	  claudin.	  In	  the	  proceeding	  events	  governed	  by	  the	  recruitment	  of	  the	  
PAR	   complex	  members	   (section	   1.3.1.	   Polarity	   proteins)	   to	   the	   complex	   and	   its	   regulators,	   the	  
primordial	  AJs	  are	  separated	  to	  develop	  the	  mature	  AJs	  and	  more	  apical	  TJs.	  The	  initial	  formation	  
of	  the	  primordial	  AJs	  is	  thought	  to	  be	  a	  key	  positional	  cue	  in	  the	  formation	  of	  apico-­‐basal	  polarity	  
(12,	  34).	  
Apical	  domain	  forms	  the	  upmost	  part	  of	  the	  cell.	  The	  apical	  domain	  faces	  ‘the	  exterior’	  –	  which	  is	  
the	  lumen	  in	  intestine	  or	  in	  mammary	  acinus.	  	  The	  lower	  border	  of	  apical	  domain	  is	  lined	  by	  TJs	  by	  
mechanism	  including	  physical	  blocking	  of	  membrane	  protein	  diffusion	  and	  recruitment	  of	  certain	  
lipid	  regulatory	  proteins	  (5)	  (Section	  1.3.2.2.	  PTEN-­‐PI3K	  pathway	  and	  lipid	  asymmetry).	  Basolateral	  
domain	  is	  formed	  of	  the	  lateral	  side	  of	  the	  cell	  below	  the	  TJs	  and	  the	  basal	  part	  that	  connects	  the	  
cell	  to	  basement	  membrane	  (9).	  The	  AJs,	  desmosomes	  and	  hemidesmosomes	  are	  situated	  in	  the	  
basolateral	   domain	   (Fig	   1)	   (3,	   9).	   It	   is	   of	   particular	   importance	   that	   the	   protein	   and	   lipid	  
composition	  of	  the	  apical	  and	  basolateral	  domains	  differ	  from	  each	  other	  e.g.	  proteins	  regulating	  
tight	  junction	  are	  in	  the	  apical	  domain	  and	  membrane	  lipid	  group	  phosphoinositols	  affect	  protein	  
sorting	   through	   their	   asymmetric	   distribution	   (3)	   (Section	   1.3.2.2.	   PTEN-­‐PI3K	   pathway	   and	   lipid	  
asymmetry).	  This	  distinction	  is	  important	  for	  the	  different	  functional	  roles	  of	  these	  domains	  which	  
will	   be	   discussed	   in	   detail	   throughout	   the	   study.	   The	   intracellular	   domains	   are	   formed	   and	  
maintained	   by	   dynamic	   interplay	   between	   the	   cell	   junctions	   and	   a	   set	   of	   proteins	   that	   control	  
polarity	   and	   the	   cell	   junctions	   as	   described	  below.	   Consequently,	   defects	   in	   components	   of	   the	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polarity	  regulation	  cause	  changes	  in	  the	  rest	  of	  the	  polarity	  machinery	  (e.g.	  defective	  cell	  junction	  
often	  compromises	  polarity	  protein	  localization)(3,	  9).	  	  
1.3.1.	  Polarity	  proteins	  	  	  
The	   study	  of	   polarity	   proteins	  was	   initiated	  by	   research	  done	  on	   asymmetrical	   cell	   division	   and	  
early	  development	  of	   lower	  eukaryote	  models	  such	  as	  nematode	  Caenorhabditis	  elegans	  and	  fly	  
Drosophila	  melanogaster	  (35,	  36).	  These	  studies	  revealed	  that	  there	  seems	  to	  be	  a	  defined	  set	  of	  
core	   polarity	   complexes	   (PAR,	   CRUMBS	   and	   SCRIBBLE	   (SCRIB)	   complex)	   which	   were	   later	  
discovered	  to	  be	  functionally	  conserved	  also	  in	  vertebrates	  (Fig	  2)	  (37).	  	  
	  
Figure	  2	  Core	  components	  of	  polarity	  regulation	  in	  mammalian	  cell.	  Shown	  are	  three	  polarity	  complexes	  (CRUMBS,	  PAR	  and	  SCRIB),	  which	  reciprocally	  regulate	  each	  other’s	  localization	  and	  activity.	  PAR3	  recruits	  PTEN	  to	  tight	  junction	  which	  in	  co-­‐operation	  with	  PI3K	  regulates	  the	  apical/basolateral	  distribution	  of	  PIP2/PIP3	  lipids.	  Polarity	   is	   further	  regulated	  by	  additional	  polarity	  proteins	  (e.g.	  basal	  PAR1	  inhibits	  basolateral	  diffusion	  of	  PAR3)	  and	  regulatory	  proteins	  (RHO	  GTPases	  CDC42,	  RHOA	  and	  RAC1)	  which	  are	  essential	   in	  timely	  and	  dynamic	  regulation	   of	   the	   complexes	   and	   cytoskeleton.	   PIP	   asymmetry,	   golgi	   transport	   regulation	   and	   microtubule	   polarity	   and	   dynamics	   are	  important	   for	   targeting	  proteins	   to	  correct	   the	  domain.	  Cell	   senses	   its	  environment	   in	   the	   tissue	   in	  part	   through	  contacts	  with	  other	  cells	  which	   are	   formed	   by	   specialized	   proteins	   and	   are	   connected	   to	   the	   cytoskeleton.	   The	   signal	   (e.g.	   contact	   dependence	   of	   proliferation)	   is	  conveyed	   further	   intracellularly	   via	   junctional	   proteins	   to	   the	   connected	   cytoskeleton	   affecting	   various	   pathways.	   Arrows	  depict	   positive	  relationship	  or	  activation,	  blunt-­‐ends	  depict	  inhibition.	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1.3.1.1.	  PAR	  complex	  	  
Par	   proteins	   (Partitioning	   defective)	   were	   originally	   found	   in	   a	   screen,	   where	   defective	   Par	  
proteins	  caused	  misdistribution	  of	  P-­‐particles	  in	  C.	  elegans	  oocytes	  and	  consequently	  defective	  cell	  
division	   (35).	   Six	   different	   par	   genes	   were	   found	   in	   C.	   elegans	   in	   this	   study.	   Members	   of	   this	  
functionally	  polarity	  related	  protein	  class	  belong	  structurally	  to	  various	  protein	  classes.	  PAR1	  and	  4	  
are	  serine-­‐treonine	  kinases	  whereas	  PAR3	  and	  6	  are	  scaffold	  proteins.	  PAR5	  belongs	  to	  the	  14-­‐3-­‐3	  
proteins	   class	   and	  PAR2,	  which	  only	   found	   in	  C.elegans,	   has	   a	  RING-­‐finger	  domain	   (RING,	   really	  
interesting	  new	  gene)	  involved	  in	  ubiqitinylation	  events.	  To	  this	  date,	  only	  five	  PAR	  proteins	  have	  
been	   found	   from	   mammals.	   The	   localization	   of	   PAR3	   and	   PAR6	   is	   apical	   whereas	   Par1	   is	  
basolateral.	  Par4	  and	  Par5	  do	  not	  have	  distinct	  localization	  (38,	  39).	  	  
PAR3	   and	   PAR6	   together	  with	   the	   atypical	   protein	   kinase	   C	   (aPKC)	   are	   components	   of	   the	   PAR	  
complex,	   which	   is	   one	   of	   the	   three	   core	   polarity	   complexes	   and	   critical	   in	   determining	   and	  
maintaining	   the	   apical	   domain.	   PAR	   complex	   proteins	   include	   several	   interaction	   domains	   to	  
facilitate	   interactions	  within	   the	   complex	   and	  with	   other	   polarity	   proteins.	   PAR3	   contains	   three	  
Post	  synaptic	  density	  95,	  discs	  large	  and	  ZO-­‐1-­‐domains	  (PDZ).	  Through	  PDZ-­‐domains	  found	  in	  both	  
PAR3	  and	  (one)	  in	  PAR6,	  these	  two	  proteins	  are	  in	  contact	  (37,	  40,	  41).	  In	  addition,	  PAR3	  contains	  
a	   conserved	   region	   for	   interaction	   with	   aPKC	   (37).	   This	   interaction	   with	   aPKC	   is	   inhibitory	   as	  
phosphorylation	  by	  serine-­‐treonine	  kinase	  domain	  of	  aPKC	  inhibits	  PAR3	  binding	  to	  aPKC	  (39).	  As	  
described	   in	   section	   1.2.1.	   Tight	   junctions,	   intracellular	   protein	   assembly	   of	   TJs	   contains	   ZO	  
proteins	  and	  cytoplasmic	  tails	  of	  JAM	  proteins.	  PAR3	  interacts	  through	  its	  PDZ	  domain	  with	  JAMs	  
PDZ	  binding	  domain.	  This	   interaction	   is	   thought	  to	  be	   important	   for	  PAR3	   localization	   in	  TJs	  and	  
facilitate	  recruitment	  of	  other	  PAR	  complex	  members	  to	  forming	  TJs	  (12,	  42,	  43).	  In	  addition	  to	  the	  
PDZ	  domain,	  PAR6	  has	  one	  Phox	  Bem1	  domain	   (PB1)	  and	  a	   semi-­‐CDC42	  Rac	   interacting	  binding	  
domain	   (CRIB).	  With	   the	  PB1	  domain	  PAR6	   is	   in	  contact	  with	   the	  PB1	  domain	  of	  aPKC	   (37).	  This	  
interaction	  is	  crucial	  for	  activation	  of	  aPKC	  and	  thought	  to	  be	  important	  for	  formation	  of	  TJs	  (40,	  
44).	  The	  activation	  is	  thought	  to	  happen	  as	  Ras	  homology	  GTPase	  (RHO	  GTPases)	  CDC42	  binds	  to	  
PAR6	  to	  its	  CRIB	  domain	  and	  induces	  a	  change	  in	  its	  conformation.	  This	  enables	  aPKC	  to	  become	  
active.	   However,	   it	   is	   still	   under	   investigation	  what	   is	   the	  mechanism	   by	  which	   aPKC	   facilitates	  
formation	  of	  mature	  TJs	  (12,	  37,	  39,	  44,	  45).	  In	  addition	  to	  its	  crucial	  function	  in	  regulation	  of	  TJs,	  
PAR	   complex	   regulates	   apico-­‐basal	   polarity	   by	   its	   interactions	   with	   other	   polarity	   associated	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proteins	   (as	   described	   above	   for	   CDC42)	   and	   with	   the	   other	   core	   polarity	   complexes.	   These	  
interactions	  will	  be	  discussed	  later	  in	  this	  study	  in	  sections	  1.3.1.4.	  Cross	  regulation	  of	  the	  polarity	  
complexes,	   1.3.2.1.1.	   RHO	   GTPases	   and	   1.3.1.5.	   PAR	   protein	   network.	   Mechanistically	   the	  
fundamental	  role	  of	  PAR	  complex	  in	  determining	  the	  apical	  domain	  is	  thought	  to	  be	  achieved	  by	  
dynamic	  regulation	  of	  other	  polarity	  complexes	  as	  well	  as	  its	  fundamental	  role	  in	  regulation	  of	  TJs	  
which	  act	  as	  a	  border	  between	  apical	  and	  basolateral	  domains	  (12,	  38,	  42,	  46).	  
1.3.1.2.	  CRUMBS	  complex	  	  
In	  addition	  to	  the	  PAR	  complex,	  the	  CRUMBS	  complex	  forms	  and	  maintains	  the	  apical	  domain	  in	  
epithelial	  cells.	  CRUMBS	  complex	  consists	  of	  three	  proteins:	  CRUMBS3	  (CRB3),	  Protein	  Associated	  
with	   Lin	   Seven1	   (PALS1)	   and	   PALS1	   Associated	   Tight	   Junction	   protein	   (PATJ).	   This	   complex	  was	  
originally	  identified	  by	  using	  Drosophila	  embryos	  in	  which	  depletion	  of	  the	  proteins	  led	  to	  similar	  
developmental	   and	   polarity	   defects	   (37,	   47).	   In	   certain	   tissues	   (e.g.	   heart,	   brain	   and	   placenta)	  
protein	   called	   Multiple	   PDZ	   domain	   protein	   (MUPP1),	   with	   high	   homology	   to	   PATJ,	   has	   been	  
detected.	   In	   this	   study	   PATJ	   is	   reviewed	   since	   it	   is	   more	   often	   expressed	   in	   epithelial	   tissues.	  
Additionally,	  mammalian	  genome	  harbours	  three	  CRB	  genes	  (1-­‐3)	  of	  which	  is	  CRB-­‐3	  is	  dominantly	  
expressed	  in	  epithelial	  tissues.	  (37).	  Transmembrane	  protein	  CRB3	  is	  attached	  to	  the	  apical	  plasma	  
membrane	   and	   it	   has	   very	   short	   extracellular	   and	   intracellular	   domains	   (37).	   It	   interacts	   with	  
PALS1	   by	   binding	   to	   PALS1	   PDZ	   domain	   (48).	   In	   addition,	   CRB3	   contains	   Ezrin-­‐Radixin-­‐Moesin	  
domain	   (ERM)	   (37,	   45).	   However,	   how	   interactions	   through	   this	   domain	   contribute	   to	   polarity	  
signalling,	  remain	  to	  be	   identified	  (45).	  PALS1	  has	  two	  Lin2	  Lin7-­‐domains	  (L27),	  a	  PDZ	  domain,	  a	  
Src	  homology	  domain	  3	  (SH3)	  and	  a	  Guanylate	  kinase	  domain	  (GUK)	  of	  which	  the	  function	  of	  the	  
latter	  two	  remain	  to	  be	  established	  (37).	  PALS1	  is	  directly	  connected	  to	  PATJ	  through	  one	  of	  the	  
L27	  domains	  (49).	  PATJ	  consist	  of	  one	  L27	  domain	  and	  ten	  PDZ	  domains	  (37,	  45,	  50).	  	  
The	   CRUMBS	   complex	   has	   also	   shown	   to	   be	   important	   for	   functional	   TJs.	   The	   regulation	   may	  
happen	  through	  both	  direct	  and	  indirect	  mechanism.	  TJ	  protein	  ZO-­‐3	  has	  shown	  to	  interact	  with	  
PATJ	   (51).	   CRB3	   can	   also	   directly	   interact	   with	   PAR	   complex	   component	   PAR6	   or	   PALS1	   may	  
mediate	  the	  interaction	  between	  these	  proteins	  (52,	  53).	  Also	  aPKC	  has	  been	  shown	  to	  bind	  and	  
phosphorylate	   directly	   to	   Crumbs	   proteins	   in	   Drosophila	   (37,	   54).	   The	   importance	   of	   CRUMBS	  
complex	  to	  TJs	  is	  highlighted	  by	  several	  studies.	  Knockdown	  of	  both	  PALS1	  and	  PATJ	  compromises	  
TJ	  formation	  and	  function	  (12,	  55,	  56).	  Overexpression	  CRB3	  delays	  TJ	  formation	  in	  Madine	  Darby	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Canine	   Kidney-­‐cells	   (MDCK)	   and	   causes	   de	   novo	   formation	   of	   TJs	   in	   MCF10A	   cell	   line,	   which	  
normally	  lacks	  tight	  junctions	  (57,	  58).	  	  	  
1.3.1.3.	  SCRIBBLE	  complex	  	  
The	  third	  core	  polarity	  complex	  is	  called	  SCRIB	  complex.	  In	  contrast	  to	  the	  apical	  PAR	  and	  CRUMBS	  
complexes,	   the	   SCRIB	   complex	   is	   localized	   to	   the	   basolateral	   domain.	   Proteins	   included	   in	   the	  
complex	  (Scribble	  (SCRIB),	  Discs	  large	  (DLG)	  and	  Lethal	  giant	  larvae	  (LGL))	  were	  originally	  identified	  
in	  Drosophila	  where	  deletion	  of	  any	  of	   the	  genes	  caused	  similar	  phenotype	  affecting	  embryonic	  
epithelial	   morphogenesis	   (37,	   59).	   Eventually	   altogether	   four	  DLG	   genes	   and	   two	   LGL	   genes	   in	  
addition	  to	  a	  single	  SCRIB	  gene	  have	  been	  identified	  in	  mammalian	  genome	  (60).	  Despite	  the	  lack	  
of	  evidence	  of	  existence	  of	  an	  actual	  physical	  complex	  of	  SCRIB,	  DLG	  and	  LGL	  in	  mammalian	  cells,	  
the	   three	   proteins	   are	   often	   referred	   as	   SCRIB	   complex	   or	   SCRIB	   polarity	  module	   in	   literature.	  
Importantly,	  in	  Drosophila	  cells	  correct	  localization	  of	  any	  of	  the	  proteins	  dependent	  on	  the	  other	  
two	  (59,	  60).	  
In	  Drosophila	   epithelium	  Scribble	   is	   localized	   to	   septate	   junctions	   (SJ),	  which	   correspond	   to	   the	  
mammalian	  TJs	  and	  are	  in	  Drosophila	  basal	  to	  the	  AJs,	  in	  contrast	  to	  the	  mammalian	  cell.	  However,	  
according	  to	  the	  current	  knowledge	  SCRIB	  is	  associated	  with	  the	  lateral	  plasma	  membrane	  and	  AJs	  
in	  mammalian	  cells	  (60,	  61).	  SCRIB	  protein	  contains	  16	  leucine	  rich	  repeat	  domains	  (LRR)	  and	  four	  
PDZ	  domains.	  Both	  LRR	  and	  PDZ	  domains	  are	  thought	  to	  be	  important	  for	  correct	  localization,	  and	  
therefore	   function	  of	   SCRIB	   (60,	   61).	   Interestingly,	   one	   study	   also	  demonstrated	   that	   SCRIB	   can	  
interact	  with	  TJ	  components	  such	  as	  ZO-­‐1	  and	  its	  depletion	  compromises	  reassembly	  of	  TJs	  (62).	  
DLG	   contains	   three	   PDZ-­‐domains,	   a	   SH3	   domain	   and	   GUK	   domain	   (37,	   60).	   The	   second	   PDZ	   is	  
thought	   to	   be	   crucial	   for	   correct	   localization	   of	   Dlg	   in	   Drosophila	   cells	   (63).	   Additionally,	   in	  
Drosophila	   GUK	   domain	   of	   Dlg	   and	   the	   second	   PDZ	   domain	   of	   Scribble	   interact	   through	   GUK-­‐
holder	   linker	   protein	   (64).	   In	   mammalian	   cells	   DLG	   co-­‐localizes	   with	   SCRIB	   in	   the	   basolateral	  
domain	  but	  whether	   they	  directly	   interact,	  as	   they	  do	   in	  Drosophila,	   remains	   to	  be	  shown	  even	  
though	  supporting	  evidence	  is	  starting	  to	  exist	  (37,	  60,	  65).	  Third	  member	  of	  the	  SCRIB	  complex,	  
LGL,	  contains	  five	  WD40	  repeats	  and	  is	  associated	  to	  the	  basolateral	  domain	  in	  proximity	  of	  SCRIB	  
and	  DLG	  (60).	  However,	  in	  contrast	  to	  constantly	  basolaterally	  associated	  SCRIB	  and	  DLG,	  LGL	  can	  
in	   some	  occasions	  diffuse	   to	   the	   apical	   side	  of	   the	   cell	   and	   regulate	  polarity	   signalling	   there	  by	  
counteracting	   the	   apical	   identity	   (66,	   67)	   (Section	   1.3.1.4.	   Cross-­‐regulation	   of	   the	   polarity	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complexes).	  In	  mammalian	  cells	  SCRIB	  has	  been	  shown	  to	  interact	  with	  LGL2	  with	  its	  LRR	  domain	  
(60,	  68).	  	  
Similar	   to	   knockdown	   of	   SCRIB,	   also	   depletion	   of	   DLG	   delays	   TJ	   formation.	   However,	   the	  
mechanism	   is	   still	   unknown	   (12,	   62,	   69).	   Nevertheless,	   after	   formation	   of	   cell	   junctions	   SCRIB	  
complex	   proteins	   are	   thought	   to	   act	   in	   basolateral	   domain	   and	   evidence	   exist	   that	   they	   are	  
needed	   for	   the	  existence	  of	  AJs.	   E-­‐cadherin	   in	  basolateral	  plasma	  membranes	   is	  needed	   for	  AJs	  
and	   indeed,	   correlation	   for	   localization	   of	   E-­‐cadherin	   and	   SCRIB	   complex	   members	   has	   been	  
observed.	  More	   specifically,	   E-­‐cadherin	   is	  needed	   for	  SCRIB	  protein	   to	   localize	   in	   the	  AJs	  and	  E-­‐
cadherin	  depletion	  in	  colorectal	  carcinoma	  Caco2	  cell	  line	  correlates	  with	  mislocalization	  of	  SCRIB	  
(61).	   However,	   no	   direct	   relationship	   between	   SCRIB	   and	   E-­‐cadherin	   has	   been	   shown.	   Similar	  
correlation	  for	  E-­‐cadherin	  localization	  has	  been	  shown	  for	  DLG	  in	  Caco2	  cells	  (9,	  70).	  
To	   conclude,	   all	   the	   three	   core	   polarity	   complexes	   are	   essential	   for	   establishment	   and	  
maintenance	  of	  apico-­‐basal	  polarity	  and	  cell-­‐cell	   junctions.	   Importance	  of	  cell	   junctions,	  polarity	  
complexes,	   and	   their	   reciprocal	   regulation	   in	  maintenance	  of	   tissue	  homeostasis	   underlines	   the	  
key	  role	  of	  this	  interplay.	  However,	  the	  polarity	  complexes	  have	  also	  been	  shown	  to	  cross	  regulate	  
each	   other	   and	   interact	  with	   various	   other	   cellular	   components	   thereby	   regulating	  many	   other	  
aspects	   of	   asymmetry	   (such	   as	   lipid	   composition	   of	   plasma	   membrane).	   In	   following,	   I	   will	  
summarize	  the	  current	  knowledge	  of	  these	  interactions.	  	  
1.3.1.4.	  Cross	  regulation	  of	  the	  polarity	  complexes	  	  
In	  addition	  to	  several	  interactions	  with	  junctional	  proteins,	  the	  three	  core	  polarity	  complexes	  have	  
also	   been	   shown	   to	   cross	   regulate	   each	   other’s	   localization	   and	   activity	   (Fig	   2).	   The	   PAR	   and	  
CRUMBS	   complexes	   are	   localized	   to	   and	   regulate	   apical	   domain.	   Similarly,	   SCRIB	   complex	  
maintains	  the	  basolateral	  domain.	  However,	  the	  SCRIB	  complex	  member	  LGL	  has	  been	  shown	  to	  
be	   able	   to	   diffuse	   to	   apical	   side	   of	   the	   cell	   and	   bind	   PAR6	   and	   aPKC,	   excluding	   PAR3	   from	   the	  
complex	   and	   inactivating	   the	   complex.	   Once	   aPKC	   phosphorylates	   LGL,	   it	   dissociates	   off	   the	  
complex	  and	  returns	  to	  the	  basolateral	  domain	  enabling	  the	  PAR	  complex	  to	  be	  active	  (37,	  42,	  66,	  
67,	  71).	  	  
Studies	  have	  also	  observed	  Crumbs	  to	  be	  phosphorylated	  by	  aPKC	   in	  Drosophila	  and	  aPKC	  to	  be	  
needed	  for	  the	  correct	  localization	  and	  function	  of	  the	  CRUMBS	  complex	  (37,	  46,	  54).	  Additionally,	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the	  aPKC-­‐CRUMBS	   interaction	  also	  enhances	  aPKC	  activity	  and	   is	   important	   for	   the	  capability	   to	  
inhibit	   basolateral	   determinants,	   like	   LGL,	   in	   the	   apical	   domain	   of	   the	   cell	   (46).	   The	   described	  
cross-­‐regulative	  actions	  of	  the	  different	  polarity	  complexes	  are	  essential	  for	  maintenance	  of	  apico-­‐
basal	   polarization	   and	  perturbation	  of	   this	   subtle	   balance	  has	   been	   shown	   cause	  defects	   in	   the	  
polarity.	   For	  example,	  manipulating	  CRB3	  and	  aPKC	  or	   LGL	   levels	   causes	   changes	   in	   the	  domain	  
sizes	   –	   depleting	   LGL	  will	   extend	   the	   apical	   domain	   as	   the	   apical	   complexes	   are	   not	   any	  more	  
antagonized	  by	  LGL	  binding	  (67,	  72).	  Introduction	  of	  exogenous	  Crumbs3	  to	  plasma	  membrane	  will	  
change	  its	  identity	  to	  apical	  domain	  (73).	  Additionally,	  overexpression	  of	  Crumbs	  has	  been	  shown	  
to	  phenocopy	  depletion	  of	  SCRIB	  complex	  members	  (42).	  The	  relationships	  of	  the	  three	  complexes	  
seem	  to	  be	  conserved.	  However,	  despite	  the	  central	  role	  of	  these	  three	  hubs	  in	  polarity	  signalling,	  
the	  exact	  mechanisms	  of	  apico-­‐basal	  polarity	  regulation	  remain	  still	  to	  be	  elucidated.	  
1.3.1.5.	  PAR	  protein	  network	  	  
As	  earlier	  described,	  in	  addition	  to	  the	  PAR	  complex	  proteins,	  also	  other	  PAR	  proteins	  are	  found	  in	  
in	  Drosophila	   and	  mammalian	   cells.	   According	   to	   current	   knowledge,	   they	   seem	   to	   be	   able	   to	  
regulate	  both	  PAR	  complex	  and	  each	  other.	  	  
In	   mammalian	   cells	   the	   gene	   encoding	   par4	   homologue	   is	   called	   STK11/LKB1	   (hereafter	   called	  
LKB1).	   This	   serine-­‐threonine	   kinase	   has	   14	   target	   kinases	   that	   it	   activates	   (2,	   38,	   74).	   LKB1	   has	  
been	  implicated	  in	  regulation	  of	  metabolism	  and	  cell	  polarity	  (38).	  In	  regard	  to	  polarity	  regulation,	  
the	  most	   obvious	   target	   is	   the	   basolaterally	   located	  Par1	   (Fig	   2),	  which	   in	  mammalian	   cells	   has	  
evolved	  into	  family	  of	  kinases	  called	  microtubule	  activity	  regulating	  kinases	  (MARK)	  (39,	  74).	  The	  
family	   covers	   proteins	   MARK1-­‐4.	   Downstream,	   MARKs	   regulate	   microtubule	   dynamics	   and	  
orientation	  by	  phosphorylating	  microtubule	   associated	  proteins	   (MAPs)	   (2,	   39,	   75).	  However,	   in	  
Drosophila	   Par1	   has	   also	   been	   shown	   to	   phosphorylate	   Par3	   in	   the	   PAR	   complex.	   This	  
phosphorylation	  has	  been	  suggested	  to	  restrict	  Par3	  localization	  away	  from	  the	  basal	  side	  (Fig	  2),	  
where	  Par1	  is	  situated,	  by	  making	  it	  bind	  to	  the	  the	  14-­‐3-­‐3/Par5	  protein	  which	  sequesters	  it	  away	  
from	   the	  basal	   side,	   and	  by	   this	  mechanism	  adds	  diversity	   to	   the	  antagonizing	  actions	  between	  
polarity	  complexes	  (38,	  76,	  77).	  However,	  also	  the	  microtubule	  dynamics	  regulation	  is	  important	  in	  
polarity	   maintenance,	   as	   microtubules	   are	   used	   for	   trafficking	   protein	   containing	   vesicles	  
asymmetrically	  to	  the	  plasma	  membrane	  (29).	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Interestingly,	   in	   some	   studies	   with	   mammalian	   cells	   the	   relationship	   between	   PAR1	   and	   PAR	  
complex	  has	  been	  demonstrated	  to	  be	  also	  the	  opposite.	  aPKC	  seems	  to	  be	  able	  to	  phosphorylate	  
PAR1	  (78).	  In	  this	  context	  aPKC	  mediated	  phosphorylation	  happens	  in	  TJs	  and	  the	  phosphorylation	  
enhances	  PAR1	  binding	  to	  the	  14-­‐3-­‐3/PAR5-­‐protein	  sequestering	  it	  away	  from	  the	  apical	  domain	  
and	  restricting	  its	  actions	  to	  the	  basal	  domain	  (79).	  Whether	  these	  two	  mechanisms	  have	  diverged	  
during	  the	  evolution	  or	  they	  exist	  side-­‐by-­‐side	  in	  mammalian	  cells,	  is	  still	  under	  investigation.	  This	  
model	  illustrates	  the	  value	  of	  PAR5	  in	  polarity	  control	  despite	  its	  uniform	  distribution	  in	  a	  cell.	  
Another	   interesting	   LKB1	   downstream	   kinase	   is	   AMP	   activated	   protein	   kinase	   (AMPK).	  
Interestingly,	   in	  a	  model	  of	   a	   single	   intestinal	   epithelial	   cell,	   LKB1	  activity	  has	  been	  observed	   to	  
able	  polarize	  even	  individual	  cells	  (80).	  The	  downstream	  kinase	  behind	  this	  phenomenon	  seems	  to	  
be	  AMPK,	  despite	  the	  fact	  AMPK	  is	  usually	  thought	  to	  be	  responsible	  for	  the	  metabolic	  control	  of	  
the	   cell,	   being	   activated	  under	   low-­‐energy	   conditions	   (38,	   81).	  However,	   the	   exact	  mechanisms	  
behind	   LKB1-­‐AMPK	   and	   PAR	   polarity	   machinery	   still	   remain	   to	   be	   elucidated.	   In	   more	   recent	  
studies,	   LKB1	   depletion	   in	   three	   dimensional	   (3D)-­‐organotypic	   cultures	   has	   been	   linked	   to	  
disruption	   of	   epithelial	   integrity	   and	   proliferation	   control	   (82).	   The	   conclusive	   molecular	  
mechanism,	  by	  which	  PAR4/LKB1	  affects	  cell	  polarity,	  however,	  is	  yet	  unknown.	  
1.3.2.	  Other	  polarity	  associated	  pathways	  and	  proteins	  
1.3.2.1.	  Small	  	  GTPases	  	  	  
Throughout	  the	  lifespans	  of	  epithelial	  cells,	  whether	  it	  is	  during	  initial	  polarization	  or	  maintenance	  
of	  tissue	  homeostasis,	  there	  is	  a	  need	  to	  convey	  messages	  from	  extracellular	  milieu	  to	  inside	  the	  
cell	  or	  between	  different	  structures	  of	  the	  cell.	  To	  this	  end,	  cells	  need	  to	  have	  proteins	  that	  can	  
cycle	  between	  active	  and	  inactive	  states	  and	  which	  can	  be	  precisely	  regulated.	  
The	  protein	  family	  of	  small	  RHO	  GTPases	  and	  family	  of	  Ras-­‐like	  GTPases	  RABs	  seem	  to	  be	  able	  to	  
act	   in	   this	   role	   in	  polarity	   regulation.	   	   The	  GTPases	  cycle	  between	   inactive	  GDP	  and	  active	  GTP-­‐
bound	  states.	  When	  GTP	  nucleotide	  binds	  to	  the	  GTPase,	  it	  changes	  conformation	  and	  governs	  the	  
interaction	  with	  downstream	  pathways.	  The	  nucleotide	  change	  is	  mediated	  by	  guanine	  exchange	  
factors	   (GEFs).	   The	   Rho	   GTPases	   have	   intrinsic	   GTPase	   activity	   which	   is	   increased	   by	   GTPase	  
activating	  proteins	  (GAPs),	  which	  inactivate	  the	  GTPase.	  In	  addition,	  GTPases	  can	  be	  regulated	  by	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guanine-­‐nucleotide	  dissociation	  inhibitors	  (GDI),	  which	  lock	  the	  GTPase	  into	  the	  GDP-­‐bound	  state	  
(83).	  	  
1.3.2.1.1	  RHO	  GTPases	  	  
The	   protein	   family	   of	   RHO	   GTPases	   comprises	   20	   members	   and	   its	   most	   well-­‐known	   and	  
characterized	  members	  in	  the	  context	  of	  epithelial	  architecture	  and	  polarity	  are	  CDC42,	  RAC1	  and	  
RHOA,	  which	  are	  discussed	  in	  this	  study.	  
1.3.2.1.1.1.	  CDC42	  	  	  
In	  polarity	  regulation	  RHO	  GTPases	  seem	  to	  be	  most	  intimately	  connected	  to	  the	  PAR	  complex	  (Fig	  
2),	  and	  in	  literature	  CDC42	  is	  sometimes	  considered	  as	  a	  member	  of	  the	  PAR	  complex	  (46).	  CDC42	  
promotes	  PAR	  complex	  activation	  as	  its	  binding	  to	  CRIB	  domain	  of	  PAR6	  is	  thought	  to	  change	  the	  
conformation	   of	   PAR6	   enabling	   it	   to	   activate	   aPKC,	   as	   described	   earlier	   in	   Section	   1.3.1.1.	   PAR	  
complex	  (40,	  44,	  46,	  83,	  84).	  This	  may	  be	  crucial	  for	  formation	  of	  TJs	  and	  many	  other	  PAR	  complex	  
dependent	  polarity	  events	  (38,	  44).	  Whether	  the	  CDC42	  is	  absolutely	  needed	  for	  TJ	  maturation,	  as	  
it	  is	  not	  needed	  for	  TJ	  maturation	  in	  keratinocytes,	  or	  there	  exist	  some	  compensatory	  and	  parallel	  
mechanisms,	  possibly	  mediated	  by	  other	  GTPases,	   is	  still	  under	  research	  (46,	  83,	  85,	  86).	  During	  
junctional	  morphogenesis	  which	  initiates	  apicobasal	  polarization,	  CDC42	  is	  activated	  already	  when	  
adjacent	  cells	   contact	  and	  E-­‐cadherin	  enriches	   to	   the	  primordial	   junctions	   (87).	  Also	  nectins	  can	  
activate	  CDC42	  (88).	  CDC42	  also	  contributes	  to	  actin	  and	  microtubule	  dynamics	  through	  Wiskott–
Aldrich	   syndrome	   protein	   (WASP)	   and	   P21	   protein	   (Cdc42/Rac)-­‐activated	   kinase	   (PAK),	  
respectively	  (83).	  
A	   significant	   number	   of	   different	   GTPases,	  many	   of	   the	   RHO	  GTPases,	   have	   been	   implicated	   in	  
directed	   and	   asymmetrical	   vesicle	   trafficking.	   Asymmetrical	   protein	   trafficking	   to	  membranes	   is	  
essential	   for	   the	   epithelial	   polarity.	   Depleting	   CDC42	   has	   been	   shown	   to	   be	   inhibitory	   for	  
membrane	  trafficking	  in	  MDCK	  cells	  causing	  specifically	  basolateral	  membrane	  proteins	  to	  become	  
depolarized	   (89-­‐91).	   It	   is	   not	   exactly	   known	   what	   is	   the	   mechanism	   responsible	   for	   the	  
phenomenon.	   This	  may	  be	  due	   to	   fact	   that	   CDC42	   is	   implicated	   in	   various	   processes	   related	   to	  
vesicle	   trafficking.	   For	   example,	   CDC42	   regulates	   microtubule	   orientation	   and	   dynamics	   of	  
microtubules	  which	  are	  important	  in	  orienting	  vesicle	  traffic	  (91,	  92).	  Additionally,	  CDC42	  seems	  to	  
be	  able	  to	  regulate	  targeting	  of	  the	  vesicle	  into	  membrane	  domains,	  which	  could	  be	  attributable	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to	  the	  ability	  of	  CDC42	  to	  control	  activity	  of	  the	  polarity	  complexes	  and	  regulate	  their	  activation	  
spatially	  (91).	  Moreover,	  CDC42	  has	  been	  shown	  to	  indirectly	  be	  associated	  with	  a	  component	  of	  
the	  exocyst	  complex	  which	  is	  known	  to	  be	  important	  for	  vesicle	  delivery	  in	  various	  organisms	  (91,	  
93).	   Also	   other	   RHO	  GTPases	   have	   been	   implicated	   in	   vesicle	   trafficking	   and	   distribution	  which	  
underlines	  the	  importance	  of	  the	  family	  in	  creating	  and	  maintaining	  polarity	  (92,	  94,	  95).	  
1.3.2.1.1.2.	  	  RAC1	  	  
RAC1	   seems	   to	   be	   activated	   through	   similar	   mechanisms	   as	   CDC42	   during	   epithelial	  
morphogenesis	   as	   primordial	   junctions	   form	   (83,	   96).	   RAC1	   activity	   has	   been	   linked	   to	   core	  
polarity	   proteins	   through	   its	   connection	   with	   GEF	   T-­‐cell-­‐lymphoma	   invasion	   and	   metastasis-­‐1	  
(TIAM1)	   which	   contacts	   PAR3.	   This	   interaction	   activates	   aPKC	   and	   downstream	   signalling	   (86).	  
However,	   unexpected	   results	   showing	   that	   TIAM1	   inactivation	   or	   sequesteriation	   by	   PAR3	   is	  
needed	  for	  TJ	  stabilization	  have	  been	  presented	  (85).	  In	  contrast	  to	  what	  was	  stated	  in	  the	  Section	  
1.3.2.1.1.1.	  CDC42,	  it	  has	  been	  reported	  also	  that	  that	  RAC1	  would	  be	  the	  GTPase	  being	  the	  most	  
important	  in	  epithelial	  polarization	  and	  that	  CDC42	  role	  in	  the	  process	  would	  be	  less	  clear,	  as	  it	  is	  
not	   needed	   for	   TJ	   assembly	   in	   keratinocytes	   (83,	   86).	   In	   conclusion,	   both	   of	   the	   previously	  
described	  GTPases	  have	  clearly	  been	  shown	  to	  interact	  with	  polarity	  proteins	  and	  have	  an	  effect	  
on	  their	  activity	  and	  functions.	  Which	  of	  them	  is	  predominant,	  remains	  to	  be	  clarified.	  	  
1.3.2.1.1.3.	  	  RHOA	  	  
The	  RHO	  GTPase	  RHOA	  is	  most	  well-­‐known	  for	  controlling	  actin	  cytoskeleton	  and	  to	  be	  needed	  for	  
actomyosin	   contraction	   and	   stress	   fiber	   formation	   (Fig	   2).	   	   Additionally,	   RHOA	   has	   a	   set	   of	  
downstream	   effectors	   unrelated	   to	   actomyosin	   dynamics	   e.g.	   phospholipase	   C,	   PLC	   –	   second	  
messenger	  production.	  The	  cytoskeleton	  related	  effectors	  are	  mammalian	  diaphanous	  (mDia)	  and	  
Rho	  associated	  kinase	  (ROCK)	  (83).	  Through	  ROCK	  activation	  RHOA	  directly	  regulates	  actomyosin	  
stability	   and	   stress	   fiber	   formation	   (83,	   97,	   98).	   Active	   ROCK	  phosphorylates	  Myosin	   light	   chain	  
phosphatase	   (MYPT)	   and	   prevents	   it	   from	   inactivating	   Myosin	   light	   chain	   (MLC),	   which	  
consequently	   increases	   actin-­‐myosin	   interaction	   activity	   (97,	   99).	   ROCK	   kinase	   also	   directly	  
phosphorylates	  MLC	   (100).	   In	   addition,	   ROCK	   phosphorylates	   LIM-­‐kinase	  which	   is	   important	   for	  
activation	  of	  various	  actin	  regulatory	  proteins	  affecting	  actin	  stability	  (83,	  97,	  101).	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Despite	   not	   being	   directly	   related	   to	   the	   control	   of	   polarity	   complexes,	   RHOA	   appears	   to	   be	  
important	   for	   polarization.	   This	   role	   is	   exerted	   probably	   through	   the	   RHOA	   regulation	   of	   actin	  
cytoskeleton,	   since	   actomyosin	   contraction	   is	   needed	   during	   the	   initial	   cell	   adhesion	   prevailing	  
polarization	   and	   by	   the	   fact	   that	   tight	   junctions,	   adherence	   junctions	   and	   some	   of	   the	   integrin	  
based	   junctions	   are	   linked	   to	   the	   actin	   cytoskeleton	   (83,	   102).	   However,	   also	   CDC42	   and	   RAC1	  
contribute	  to	  the	  actin	  signalling	  (83).	  RHOA	  functions	  in	  forming	  junctions	  and	  has	  thought	  to	  be	  
mainly	  inactivated	  after	  maturation	  of	  the	  cell	  junctions,	  yet	  some	  activity	  seems	  to	  remain	  even	  
in	   the	  stable	  monolayer	  cultures	   for	   remodelling	  purposes	   (83,	  103,	  104).	   Interestingly,	  a	   recent	  
study	   described	   a	   GEF	   that	   specifically	   activates	   RHOA	   in	   junctions	   and	   is	   required	   for	   tight	  
junction	  function,	  underlining	  the	   importance	  of	  accurate	  spatial	  and	  temporal	  regulation	  of	  the	  
GTPases	  (105).	  	  
RHO	  GTPases	  exert	  also	  cross	  regulative	  actions.	  RAC1	  has	  been	  shown	  to	  be	  able	  to	  downregulate	  	  
RHOA	   activity	   through	   p190GAP	   during	   cadherin	   dependent	   cell	   contact	   formation	   (106).	   In	  
contrast,	  RHOA	  is	  able	  to	  suppress	  RAC1	  activity	  by	  inducing	  PAR3	  phosphorylation	  by	  ROCK	  and	  
preventing	  the	  GEF	  TIAM1	  mediated	  activation	  of	  RAC1	  (83,	  107).	  The	  GTPase	  machinery	  including	  
large	   numbers	   of	   regulatory	   proteins	   is	   probably	   needed	   to	   be	   able	   to	   fine-­‐tune	   the	   activities	  
temporally	  and	  spatially.	  Many	  aspects	  of	  the	  regulation	  are	  still	  unknown.	  	  
1.3.2.1.1.4.	  	  RHO	  GTPase	  effects	  on	  epithelial	  morphogenesis	  in	  vitro	  	  
Interestingly,	  RHO	  GTPases	  seem	  to	  be	  especially	  important	  for	  apicobasal	  polarity	  in	  3D-­‐cultures	  
where	   they	   are	   cultured	   on	   ECM-­‐scaffolds.	   Manipulating	   activities	   of	   GTPases	   causes	   severe	  
defects	  in	  the	  polarization.	  Originally,	  it	  was	  described	  that	  blocking	  RAC1	  signalling	  with	  mutated	  
RAC1,	  or	  later	  by	  blocking	  β1-­‐integrin	  signalling,	  inverts	  the	  polarity	  of	  MDCK	  cell	  cyst	  turning	  the	  
normally	   lumen	  facing	  side	  to	  face	  ECM.	  The	  defect	  was	  rescued	  by	  applying	  exogenous	   laminin	  
and	  therefore	  it	  seems	  to	  be	  integrin-­‐related	  (27).	  Later	  it	  was	  shown	  that	  the	  phenotype	  is	  due	  to	  
overactive	   RHOA	   (28).	   In	   contrast,	   CDC42	   activity	   is	   needed	   for	   proper	   lumen	   formation	   in	   3D-­‐
cultures	   (83,	  108-­‐110).	  These	   results	  underline	   the	  context	  dependence	  of	  polarity	  proteins	  and	  
the	   importance	  of	   in	  vivo-­‐like	  culture	  methods,	  which	  will	  be	  discussed	   later	   in	  Chapter	  3	  Three	  
dimensional	  (3D)-­‐cell	  culture	  method.	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1.3.2.1.2.	  Ras-­‐like	  GTPases,	  RABs	  	  
Another	   family	   of	   GTPases	   shown	   to	   especially	   important	   for	   vesicle	   trafficking	   is	   the	   Ras-­‐like	  
GTPase	   family	   RABs,	   consisting	   of	   over	   60	  members	   in	   human	   cells.	   Different	   family	   members	  
have	  been	  shown	  to	  act	  in	  different	  stages	  and	  functions	  in	  vesicle	  trafficking.	  RABs	  are	  involved	  in	  
secretion	  pathways	  starting	  from	  departure	  of	  vesicles	  from	  Golgi	  all	  the	  way	  to	  the	  transportation	  
and	   to	   fusion	   with	   the	   plasma	  membrane	   (111).	   On	   the	   other	   hand	   RABs	   are	   also	   involved	   in	  
endosomal	   trafficking	  playing	   a	   role,	   for	   example,	   in	   clathrin	  mediated	  endocytosis	   (111).	  More	  
specifically,	  for	  example	  RAB	  Sec4	  has	  been	  shown	  to	  interact	  with	  the	  exocyst	  complex	  in	  docking	  
of	  the	  vesicle	  into	  membrane,	  whereas	  RAB5	  is	  thought	  to	  be	  involved	  in	  the	  clathrin	  endocytosis	  
possibly	  in	  part	  by	  being	  involved	  in	  the	  lipid-­‐regulation	  as	  phosphatidyl	  inositol	  3	  kinase	  (PI3K)	  is	  
one	  of	  its	  effectors,	  as	  described	  in	  the	  next	  section	  (111-­‐113).	  Interestingly,	  RAB13	  is	  associated	  
with	   recycling	   of	   the	   TJ	   components	   and	   RAB25	   in	   intergrin	   transport	   thereby	   having	   a	   role	   in	  
maintenance	  of	  the	  apico-­‐basal	  polarity	  (111,	  114-­‐116).	   	  	  
1.3.2.2.	  PTEN-­‐PI3K	  pathway	  and	  lipid	  asymmetry	  	  
In	  addition	  to	  protein	  asymmetry	   in	  epithelial	  cells,	  also	  some	  lipids	  have	  been	  demonstrated	  to	  
be	   asymmetrically	   distributed	   in	   the	   plasma	   membrane.	   	   In	   regards	   to	   epithelial	   polarity,	   the	  
asymmetry	  of	  phosphatidyl	  inositols	  (PIPs)	  is	  considered	  to	  be	  of	  great	  importance.	  Epithelial	  cells	  
harbour	  phosphatidyl	  (4,5)	   inositols	  (PIP2)	  and	  phosphatidyl	  (3,4,5)	   inositols	  (PIP3).	  There	  exists	  a	  
sharp	   contrast	   in	   their	   localization;	   PIP2	   is	   exclusively	   localized	   to	   the	   apical	   plasma	  membrane	  
whereas	  PIP3	  localization	  is	  basolateral	  (Fig	  2)	  (3,	  117,	  118).	  	  
The	  PIP	  asymmetry	  is	  mainly	  thought	  to	  be	  generated	  by	  localized	  recruitment	  of	  PI3K	  and	  PTEN-­‐
phosphatase	  (Phosphatase	  and	  Tensin	  homologue)	  (3,	  119).	  PAR3	  is	  able	  to	  recruit	  PTEN	  to	  TJs	  (Fig	  
2)(3,	  120,	  121).	  Similarly,	  there	  is	  evidence	  that	  DLG	  affects	  recruitment	  of	  PI3K	  to	  the	  basolateral	  
domain	  (70).	  According	  the	  model	  of	  localized	  recruitment,	  PI3K	  adds	  phosphate	  group	  to	  the	  3-­‐
position	  of	  the	  PIP2	  and	  generates	  PIP3.	  If	  the	  PIP3	  is	  on	  its	  way	  to	  diffusing	  to	  the	  apical	  domain,	  TJ	  
associated	   PTEN	   cleaves	   off	   the	   3-­‐positioned	   phosphate	   group	   generating	   again	   PIP2	   and	  
maintaining	   the	   PIP2/PIP3	   asymmetry	   between	   the	   apical	   and	   basolateral	   domains	   (117,	   119).	  	  
However,	  there	  has	  been	  discussion	  that	  also	  other	  mechanisms	  to	  create	  PIP2	  might	  exist,	  since	  
PIP3	  is	  a	  minor	  lipid	  in	  a	  cell	  (122).	  However,	  there	  seems	  to	  be	  clear	  role	  for	  PTEN	  in	  generating	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the	  fence-­‐feature	  for	  lipids	  in	  tight	  junctions	  and	  in	  co-­‐operation	  with	  PI3K	  in	  generating	  PIP2/PIP3	  
asymmetry	  and	  consequently	  directing	  polarized	  trafficking.	  
PIPs	   importance	   in	   maintenance	   of	   epithelial	   polarity	   is	   emphasized	   by	   their	   ability	   to	   target	  
signalling	  (Fig	  2).	  In	  the	  apical	  domain,	  PIP2	  has	  been	  shown	  to	  have	  an	  important	  role	  in	  protein	  
targeting	   to	   the	  apical	  plasma	  membrane	  as	   artificial	   addition	  of	  PIP2	   to	   the	  basolateral	  plasma	  
membrane	  causes	  apical	  membrane	  proteins	  to	  extend	  their	  domain	  identity	  to	  that	  area	  (3,	  117,	  
119).	   The	   exact	   mechanisms	   behind	   the	   link	   between	   PIP2/3	   and	   protein	   asymmetries	   are	   not	  
conclusively	  clear.	  	  
Several	  mechanisms	  have	  been	  proposed	  to	  underlie	  the	  asymmetry	  in	  protein	  targeting	  regarding	  
PIP	  asymmetry.	  In	  the	  apical	  membrane	  PIP2	  has	  been	  shown	  to	  bind	  Annexin	  II	  which	  is	  needed	  
for	  apical	  deposition	  for	  certain	  proteins.	  Additionally,	  Annexin	  II	  has	  been	  shown	  to	  be	  needed	  in	  
co-­‐operation	  with	  CDC42,	  to	  which	  it	  also	  binds	  to,	  for	  polarization	  and	  lumen	  formation	  in	  MDCK	  
cells	   in	   3D-­‐environment	   (117,	   119,	   123).	   Also	   a	   component	   of	   the	   mammalian	   multiprotein	  
exocyst	   complex	  has	  been	   shown	   to	  bind	  PIP2	   (119,	  124),	  which	   is	  needed	   for	   formation	  of	   the	  
mature	   complex	   and	   consequently	   for	   fusion	  of	   the	   post-­‐Golgi	   transport	   vesicles	   to	   the	  plasma	  
membrane.	   However,	   this	   interaction	   is	   in	   strong	   contrast	   to	   the	   results	   which	   imply	   that	   in	  
mammalian	  cells	  exocyst	  is	  specifically	  responsible	  for	  the	  deposition	  of	  the	  basolateral	  membrane	  
proteins	   (125,	   126).	   On	   the	   other	   hand,	   also	   PIP3	   has	   been	   shown	   to	   interact	   with	   exocyst	  
components	  (124).	  	  Via	  the	  contact	  with	  CDC42	  and	  Annexin	  II	  PIP2	  may	  also	  be	  able	  to	  recruit	  PAR	  
complex	  to	  the	  apical	  plasma	  membrane,	  which	  determines	  the	  apical	  domain	  and	  can	  also	  affect	  
cytoskeleton	  polarization	  which	  can	  also	  affect	   trafficking	   (119).	  Additionally,	   also	   the	  PIPs	  have	  
been	  shown	  to	  interact	  with	  various	  actin-­‐regulating	  proteins	  (127).	  
As	  docking	  to	  the	  membrane	  before	  fusion	  is	  a	  key	  event	  in	  vesicle	  trafficking	  to	  the	  membrane,	  
molecules	   involved	   in	   the	   docking	   appear	   to	   be	   important	   for	   recognition	   of	   appropriate	  
membrane.	   One	   class	   of	   these	   molecules	   is	   called	   Soluble	   NSF	   Attachment	   Protein	   receptors	  
(SNAREs).	   V-­‐SNARE	   (v	   for	   vesicle)	   molecules	   and	   t-­‐SNARE	   (t	   for	   target)	   molecules	   on	   target	  
membranes	  make	   specific	   interactions	   e.g.	   specific	   t-­‐SNARE	   needs	   to	  meet	   specific	   v-­‐SNARE	   in	  
order	  to	  deposit	  proteins	  to	  the	  membrane	  (29).	  Similar	  to	  PIP	  asymmetry,	  also	  t-­‐SNARE	  molecules	  
syntaxin-­‐3	   and	   syntaxin-­‐4	   are	   asymmetrically	   localized	   between	   apical	   and	   basolateral	   plasma	  
membranes	  and	  their	  mislocalization	  causes	  similar	  polarity	  reverting	  phenotype	  compared	  to	  the	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artificial	   addition	   of	   PIPs	   to	   their	   non-­‐natural	   domains	   (119,	   128,	   129).	   Whether	   these	   two	  
asymmetries	   in	   the	  membrane	   are	   related	   or	   not,	   is	   not	   yet	   known.	   Yet	   other	  mechanisms	   for	  
asymmetrical	  protein	  targeting	  exist	  as	  glycophosphoinositol	   (GPI)	  anchoring	  has	  been	  shown	  to	  
sort	  proteins	  to	  the	  apical	  membrane	  (130).	  To	  conclude,	  several	  mechanisms	  exist	  for	  targeting	  
proteins	   asymmetrically	   in	   a	   cell.	   The	   asymmetry	   of	   molecules	  mediating	   these	  mechanisms	   is	  
pivotal	  for	  apico-­‐basal	  polarity.	  For	  the	  PIP	  asymmetry,	  a	  structural	  explanation,	  involving	  the	  core	  
polarity	  complex	  proteins,	  has	  been	  established.	  
1.3.2.3.	  Hippo	  pathway	  	  
Multicellular	  animals	  need	  to	  maintain	  homeostasis	  within	  tissues	  and	  organs,	  and	  there	  needs	  to	  
be	  a	  mechanism	   for	   controlling	   their	   size.	   Studies	   in	  Drosophila	   and	  mammals	  have	   shown	   that	  
Hippo	  pathway	  could	  be	  at	  least	  in	  part	  responsible	  for	  controlling	  organ	  size	  by	  regulating	  target	  
genes	  related	  to	  inhibition	  of	  proliferation	  and	  apoptosis	  regulation.	  (131),	  (132).	  	  
In	  mammals,	  the	  Drosophila	  Hippo-­‐kinase	  homologue	  Mammalian	  sterile-­‐20-­‐like	  kinase	  type	  1	  and	  
type	  2	  (MST1/2)	  phosphorylates	  Large	  tumour	  suppressor	  1/2	  (LATS1/2)	  kinase,	  which	  thereafter	  
phosphorylates	   transcription	   factor	   Yes-­‐activated	   protein	   (YAP)	   (Fig	   3).	   The	   phosphorylation	  
inhibits	   YAP	   from	   translocating	   to	   nucleus	   and	   functioning	   as	   transcription	   factor	   (133).	   In	  
Drosophila,	  YAP	  homologue	  Yorkie	  target	  genes	  include	  cell	  cycle	  promoting	  cyclin	  E	  and	  apoptosis	  
inhibitor	  Drosophila	  inhibitor	  of	  apoptosis	  protein	  1	  (diap1).	  Therefore	  Hippo	  pathway	  needs	  to	  be	  
active	   to	   restrict	   organ	   overgrowth	   (132).	   Also	   additional	   proteins	   have	   been	   observed	   in	   the	  
regulation	   of	   the	   core	   of	   the	   pathway.	   MOBKL1A	   (Mps	   One	   Binder	   kinase	   activator-­‐like	   1A,	  
homologous	  to	  Drosophila	  Mats,	  Mob	  as	  tumor	  suppressor)	  has	  been	  shown	  to	  be	  phosphorylated	  
by	  MST1/2.	  This	  phosphorylation	  increases	  MOBKL1A	  affinity	  to	  LATS1/2	  and	  increases	  its	  activity	  
therefore	   contributing	   to	  Hippo	  pathway	   regulation	   (Fig	   3)	   (133,	   134)).	  Additionally,	   Sav/WW45	  
(Drosophila	   Salvador)	   binds	   MST	   and	   facilitates	   the	   LATS	   phosphorylation	   by	   MST,	   possibly	   by	  
acting	  as	  a	  scaffold	  protein	  (Fig	  3)(132).	  
There	  has	  been	  some	  ambiguity	  concerning	  the	  mechanism	  responsible	  for	  activating	  Hippo/MST.	  
It	   has	   been	   hypothesized	   that	   Hippo/MST	   could	   become	   activated	   through	   autophosporylation	  
(131).	  Players	  shown	  to	  be	  able	  to	  regulate	  Hippo	  pathway	  activity	  are	  atypical	  cadherin	  molecules	  
FATs	   (Fig	   3)(FAT	   1-­‐4	   in	   mammals,	   Ft	   in	  Drosophila)	   (132).	   In	  Drosophila	   activated	   Ft	   has	   been	  
shown	   to	   inhibit	   Warts	   (LATS	   homologue)	   degradation	   through	   inhibition	   of	   unconventional	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myosin	   Dachs,	   which	   decreases	  Warts	   level	   (135).	   However,	   in	   mammals	   no	   clear	   relationship	  
between	   Fat	   and	   organ	   size	   control	  mechanism	   of	   Hippo	   pathway	   has	   been	   shown	   (132,	   133).	  
Another	   suggested	   mechanism	   acts	   through	   membrane-­‐associated	   Expanded	   (Ex)	   and	   Merlin	  
(Mer)	  proteins,	  which	  have	  been	  shown	  to	   increase	  Warts	  activity	  and	  phosphorylation	   through	  
the	   Hippo-­‐kinase	   in	   Drosophila	   (Fig	   3)(132).	   Moreover,	   they	   have	   also	   been	   shown	   to	   be	  
transcriptional	  targets	  of	  Yorkie	   implying	  involvement	  of	  a	  negative	  feedback	  loop.	  Furthermore,	  
Ex	  is	  able	  to	  sequester	  Yorkie	  in	  cytoplasm	  (131,	  136).	   Interestingly,	  Ft	  has	  been	  shown	  to	  affect	  
the	   localization	   and	   protein	   level	   of	   Ex	   (133,	   137).	   Therefore	   Ex	   could	   be	   responsible	   for	  
connecting	  Ft	   to	  Hippo	  core	  components.	  However,	   the	  mammalian	  Hippo-­‐signalling	   is	   less	  well	  
studied	   and	   also	   in	  Drosophila	   there	   is	   a	   lack	   of	  molecular	   level	   evidence	   elaborating	   signalling	  
between	   Ex/Mer	   and	   the	   downstream	   Hippo	   pathway	   components	   (131-­‐133).	   Finally,	   Merlin	  
seems	  to	  be	  linked	  to	  AJs	  through	  α-­‐catenin	  and	  contribute	  in	  contacting	  actin	  cytoskeleton	  (138).	  
Intriguingly,	  Hippo	  pathway	  has	  been	  shown	  to	  be	  regulated	  core	  cell	  polarity	  proteins.	  In	  several	  
recent	  studies	  Crumbs	  has	  been	  linked	  to	  the	  apical	  Ex	  scaffold	  protein	  in	  Drosophila	  (Fig	  3).	  More	  
specifically,	  Crumbs	  has	  been	  shown	  to	  be	  important	  for	  apical	   localization	  of	  Ex,	  and	  bind	  to	  Ex	  
through	   its	   ERM	  motif	   (131,	   139,	   140).	   Interestingly,	   there	   seems	   to	  be	  a	  balancing	  mechanism	  
behind	  Crumbs-­‐Ex	  regulation	  as	  both	  over-­‐	  and	  underexpression	  of	  Crumbs	  causes	  mislocalization	  
of	  Ex	  (139,	  141).	  Furhermore	  Crumbs	  has	  been	  implied	  in	  phosphorylation	  of	  Ex,	  which	  leads	  to	  its	  
decrease	  in	  Ex	  protein	  level	  and	  thus	  decreases	  the	  activity	  of	  the	  Hippo	  pathway	  (131,	  139).	  Also	  
other	   members	   of	   the	   CRUMBS	   complex,	   PALS1	   and	   PATJ,	   have	   been	   shown	   to	   affect	   Hippo	  
pathway	  activity	  in	  mammalian	  cells	  (131,	  142).	  
Additionally,	   aPKC	   and	   Lgl	   have	   been	   observed	   to	   affect	   Hippo	   pathway	   activity	   in	   a	   reciprocal	  
fashion.	   Overexpression	   of	   aPKC	   seems	   to	   cause	   Hippo-­‐kinase	   mislocalization	   and	   consequent	  
decrease	  in	  the	  activity	  of	  the	  pathway.	  In	  accordance	  with	  the	  regulation	  between	  aPKC	  and	  Lgl	  
described	  earlier,	  Lgl	  depletion	  causes	  mislocalization	  of	  Hippo.	  In	  other	  words,	  Lgl	  activates	  Hippo	  
pathway	  by	  opposing	  aPKC	  (131,	  141).	  Polarity	  proteins	  are	   involved	  in	  relaying	  and	  interpreting	  
signals	   from	  outside	   the	   cell,	   via	   cell	   junction	   signalling	   to	   cytoskeleton	   for	   example,	   and	   affect	  
both	   proliferation	   and	   apoptosis	   (discussed	   in	   detail	   in	   Chapter	   2	   in	   cancer	   context).	   It	   is	   of	  
interest	  that	  they	  do	  this	  at	  least	  in	  part	  through	  regulation	  of	  the	  Hippo	  pathway.	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Figure	  3	  Core	  components	  of	  the	  Hippo-­‐	  and	  Wnt	  pathways	  in	  mammals.	  Cascade	  of	  MST	  phosphorylation	  followed	  by	  LATS	  phosphorylation	  and	  YAP	  exclusion	  from	  nucleus	  has	  been	  established	  in	  mammals.	  The	  physical	  mechanism	  of	  upstream	  activation	  and	  regulation	  by	  Fat,	  Expanded	  and	  NF2	  (Merlin)	  are	  yet	  to	  be	  identified	  in	  mammals.	  The	  apical	  Crumbs	  complex	  has	  been	  shown	  to	  regulate	  the	  YAP	  localization	  in	  mammals	   and	   Expanded	   (Ex)	   in	  Drosophila.	   Activation	   of	   the	  Wnt	   pathway	   by	   the	   ligand	   (WNT)	   causes	   inactivation	   of	   the	   β-­‐catenin	  destruction	   complex	   leading	   to	   nuclear	   accumulation	   of	   β-­‐catenin	   and	   target	   gene	   activation.	   Solid	   lines:	   the	   relationship	   established	   in	  mammals,	  dashed	  lines:	  relationship	  established	  in	  Drosophila.	  Arrows	  depict	  positive	  relationship	  or	  activation,	  blunt-­‐ends	  depict	  inhibition.	  P,	  phosphorylation;	  Ub,	  ubiqitinylation.	  
1.3.2.4.	  Wnt	  pathway	  	  	  
Wnt	   pathway	   was	   originally	   discovered	   in	   the	   developmental	   biology	   studies	   of	   Drosophila	  
(Drosophila	   wingless,	   wg).	   In	   the	   studies	   Wnt	   pathway	   was	   observed	   to	   important	   for	  
development	  of	  Drosophila	  larvae	  and	  adult,	  and	  furthermore	  wg	  gene	  was	  later	  identified	  to	  be	  
one	   of	   the	   segment	   polarity	   genes	   controlling	   patterning	   of	   the	   larvae	   (143).	   Later	   on	   the	  Wnt	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pathway	   has	   been	   shown	   to	   play	   important	   developmental	   role	   in	   a	   wide	   variety	   of	   other	  
metazoans	  including	  C.elegans	  and	  mammals	  (143-­‐145).	  	  
The	   pathway	   is	   named	   according	   to	   its	   ligand,	  WNT	   (which	   name	   derives	   from	   the	  Drosophila	  
wingless	   and	   Int1	   which	   was	   the	   first	   discovered	   wg	   homologue).	   WNT	   ligands	   are	   secreted	  
glycoproteins	   and	   in	   mammals	   there	   exist	   19	   different	   WNT	   ligands	   (145).	   WNT	   signals	   are	  
recognized	  on	  plasma	  membrane	  by	  seven	  pass	  transmembrane	  receptor	  family	  Frizzled	  (Fz)	  in	  co-­‐
operation	  with	  Low	  density	  lipoprotein	  receptor-­‐related	  protein	  (LRP)	  (Fig	  3).	  Binding	  of	  the	  ligand	  
activates	   downstream	   Dishevelled	   (DVL)	   which	   inactivates	   the	   β-­‐catenin	   destruction	   complex	  
composed	   of	   AXIN,	   Glycogen	   synthase	   kinase-­‐3	   β	   (GSK3β)	   and	   Casein	   kinase	   1	   (CK1)	   and	  
Adenomatous	   polyposis	   coli	   (APC)	   (Fig	   3).	  Without	   the	   ligand	   activating	   the	   pathway,	   β-­‐catenin	  
becomes	  phosphorylated,	   subsequently	   ubiquitinylated	   and	  degraded	   (Fig	   3).	   By	  preventing	   the	  
degradation,	   active	   Wnt	   pathway	   enables	   β-­‐catenin	   to	   accumulate	   and	   translocate	   to	   nucleus	  
where	   it	   regulates	   gene	  expression	   in	   co-­‐operation	  with	   TCF/LEF	   (Fig	   3)(145),	   (146).	  Wnt	   target	  
genes	  include	  a	  vast	  array	  of	  components	  belonging	  into	  different	  homeostatic	  and	  developmental	  
pathways.	  Wnt	  target	  genes	  control	  developmental	  proliferation	  (e.g.	  c-­‐MYC,	  cyclin	  D1,	  c-­‐JUN,	  and	  
control	   developmental	   processes	   (Twist,	   neurogenin),	   contribute	   to	   ECM	   (fibronectin)	   and	  
cytoskeleton	  regulation	  (TIAM1)	  (Fig	  3).	  Wnt	  pathway	  has	  also	  been	  implicated	  in	  immunological	  
responses	  (interleukin	  genes)	  (145,	  147).	  
In	   addition	   to	   the	   canonical	   Wnt	   pathway	   described	   above,	   also	   non-­‐canonical	   Wnt-­‐signalling	  
exists.	  The	  non-­‐canonical	  pathway	  is	  thought	  to	  act	  through	  cytoplasmic	  effectors	  such	  as	  the	  RHO	  
GTPases	  and	  it	  appears	  to	  have	  a	  β-­‐catenin	  independent	  transcriptional	  control	  program	  (145,	  146,	  
148).	  The	  Wnt	  pathway	  divides	  to	  canoninal	  and	  non-­‐canonical	  pathways	  after	  DVL.	  The	  cellular	  
localization	  of	  Dvl	  (membrane/cytoplasm)	  has	  been	  suggested	  to	  dictate	  the	  decision	  between	  the	  
pathways	   (145,	   149).	   The	   non-­‐canonical	   pathway	   is	   implicated	   for	   example	   in	   controlling	   the	  
planar	  cell	  polarity	  (145,	  148).	  
Wnt	  pathway	  has	  also	  been	  to	  be	  connected	  to	  the	  apicobasal	  polarity	  in	  vertebrates.	  For	  instance,	  
overexpression	   of	   PAR1	   has	   been	   shown	   activate	   canonical	   Wnt	   signalling	   through	  
phosphorylation	   of	   DVL	   (150).	   Interestingly,	   this	   phosphorylation	   inhibits	   the	   non-­‐canonical	  
pathway	   (145,	   150).	   In	   addition,	   many	   other	   polarity	   proteins	   and	   effectors	   have	   been	   shown	  
interact	  with	  Wnt	  pathway.	  The	  PAR	  complex	  member	  aPKC	  and	  DVL	  interact	  and	  this	  interaction	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increases	   aPKC	   ability	   to	   phosphorylate	   and	   inactivate	   Par1	   (151,	   152).	   Interestingly,	   LKB1	   has	  
been	  shown	  to	  both	   inhibit	  and	  activate	  Wnt	  pathway,	  either	   through	  phoshorylating	  PAR1	  and	  
preventing	   it	   to	   activate	   canonical	   Wnt	   signalling,	   or	   inhibiting	   GSK3β	   thereby	   activating	   the	  
pathway	  (145,	  153,	  154).	  The	  SCRIB	  complex	  member	  LGL	  has	  been	  connected	  to	  Wnt	  pathway	  in	  
Xenopus	  as	  manipulating	  dvl	  or	  fz	  protein	  leves	  perturbs	  basolateral	  localization	  of	  lgl	  in	  Xenopus	  
embryos.	   In	   this	   experiment	   also	   aPKC	   localization	  was	   affected,	   and	   therefore	   the	   finding	   is	   in	  
unison	  with	   previously	   described	   antagonistic	   contest	   between	  basolateral	   LGL	   and	   apical	   aPKC	  
(155).	  Moreover,	  APC,	  the	  component	  of	  the	  β-­‐catenin	  destruction	  complex,	  has	  been	  shown	  bind	  
DLG	  (156).	  As	  described	  earlier	  some	  important	  genes	  in	  apico-­‐basal	  polarity	  have	  been	  described	  
as	   Wnt	   target	   genes,	   including	   integrin	   ligand	   fibronectin	   and	   GEF	   TIAM1.	   Interestingly,	   the	  
distribution	  of	  the	  Fz	  receptors	  is	  not	  symmetrical	  between	  two	  Fz	  proteins	  encoded	  by	  Drosophila	  
genome.	   Fz1	   has	   been	   shown	   to	   localize	   apically	   whereas	   Fz2	   localization	   is	   ubiquitous	   on	   the	  
membrane.	  Furthermore,	  only	  Fz1	  acts	  in	  the	  non-­‐canonical	  pathway	  but	  both	  of	  the	  receptors	  are	  
involved	   in	   the	   canonical	   signalling	   thereby	   contributing	   to	   the	   pathway	   specificity	   as	   was	  
previously	   proposed	   for	   DVL	   (145,	   157).	   In	   addition,	   in	  Drosophila	   embryo	   the	  wg	   morphogen	  
mRNA	  has	  been	  shown	  to	  have	  asymmetrical	  localization	  (158).	  Therefore	  the	  correct	  apico-­‐basal	  
polarization	  can	  be	  important	  for	  Wnt-­‐signalling	  (145).	  	  
Taken	   together,	   studies	   in	   various	  model	   organisms	  demonstrate	   that	   the	  polarity	   proteins	   and	  
Wnt	  pathway	  can	  affect	  each	  other	  reciprocally.	  Considering	  the	  important	  role	  of	  Wnt	  pathway	  in	  
development	  and	  proliferation	  control,	  intact	  polarity	  can	  again	  viewed	  to	  be	  essential	  for	  healthy	  
tissue.	  
1.4.	  Integrated	  polarity	  and	  homeostasis	  control	  	  
In	  previous	  chapters	  I	  have	  demonstrated	  that	  apico-­‐basal	  polarity	  of	  epithelium	  is	  regulated	  in	  co-­‐
operation	  of	  various	  cellular	  processes.	  Intact	  polarity	  is	  thought	  to	  be	  coordinated	  by	  regulation	  
of	  a	  defined	   set	  of	   core	  polarity	  proteins	  and	  by	  a	  vast	  array	  of	   their	  effectors.	  However,	   these	  
processes	  affect	  and	  need	  the	  regulation	  of,	  for	  example,	  cytoskeleton,	  vesicle	  trafficking,	  cell-­‐cell	  
junctions	  and	  receptor	  asymmetry.	  
As	   described	   in	   earlier	   chapters,	   the	   formation	   and	  maintenance	   of	   cell	   junctions	   is	   in	   intimate	  
relationship	  with	  core	  polarity	  complexes.	  These	  complexes	  are	  directly	  or	  indirectly	  connected	  to	  
cytoskeleton	  which	   in	   turn	   is	   also	   connected	   in	   some	   form	   to	  all	   of	   the	   cell	   junctions.	   Together	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these	   polarity	   regulating	   factors	   influence	   the	   vesicle	   trafficking	   and	   responses	   of	   the	   cell	   to	  
various	  stimuli.	   In	   larger	  scale,	  cells	   in	  the	  epithelial	  tissue	  need	  connection	  with	  each	  other	  and	  
basement	  membrane	  to	  provide	  spatial	  cues	  of	  their	  orientation	  and	  to	  be	  able	  to	  signal	  and	  sense	  
the	   current	   situation	   in	   the	   tissue.	   To	   be	   able	   to	   fulfil	   this	   task,	   the	   cells	   need	   to	   be	   properly	  
polarized	   and	   connected	   to	   each	   other.	   Therefore,	   epithelial	   polarity	   and	   tissue	   integrity	   are	  
interwoven	  in	  many	  levels.	  	  
It	   is	   also	   evident	   that	   these	   processes	   need	   to	   be	   dynamically	   controlled	   and	   cannot	   be	  
permanently	  fixed.	  In	  many	  epithelial	  tissues	  cells	  are	  under	  constant	  stress	  and	  have	  to	  therefore	  
be	  able	  to	  renew	  themselves.	  This	  calls	  for	  ability	  to	  be	  able	  to	  modify	  the	  described	  processes	  in	  
order	  to	  remove	  the	  old	  cells	  and	  to	  generate	  and	  correctly	  position	  new	  cells	  (159).	  Interestingly,	  
processes	   that	   control	   epithelial	   polarity	   have	   also	   been	   recently	   shown	   to	   be	   able	   to	   control	  
proliferation	  and	  apoptosis	  (2,	  46,	  60),	  as	  there	  needs	  to	  be	  a	  balance	  between	  the	  two	  processes.	  
Defects	   in	   them	   can	   lead	   to	   tissue	   injury	   (not	   being	   able	   to	   renew)	   or	   neoplastic	   proliferation	  
possibly	  leading	  to	  cancer	  (not	  being	  able	  to	  control	  the	  renewing).	  There	  is	  a	  growing	  amount	  of	  
evidence	   that	   defects	   in	   the	   regulation	   of	   apico-­‐basal	   polarity	   and	   epithelial	   architecture	   are	  
causal	   to	   defects	   in	   these	   processes	   and	   not	   merely	   consequences.	   For	   this	   reason	   I	   will	   next	  
concentrate	  on	  the	  current	  knowledge	  about	  epithelial	  polarity	  and	  architecture	  in	  cancer.	  
2.	  Epithelial	  polarity	  and	  architecture	  as	  tumour	  suppressor	  mechanisms	  	  
Cancer	  is	  the	  leading	  cause	  of	  death	  in	  the	  developed	  countries	  (160).	  Also,	  as	  people	  live	  longer	  
and	   developing	   countries	   become	   ‘westernized’	   its	   impact	   is	   thought	   become	   even	   more	  
dominant	   (160).	   80%	  of	   all	   cancers	   are	   carcinomas,	  which	  are	   cancers	  of	   epithelial	   origin	   (161).	  
These	   reasons	  warrant	   deeper	   knowledge	   of	   epithelial	   tissues	   and	   their	   regulation.	   Considering	  
the	  vast	  array	  of	  mechanisms	  by	  which	  cell	  polarity	  is	  regulated	  and	  cell-­‐cell/cell-­‐ECM	  signalling	  is	  
maintained	   in	   epithelial	   tissues,	   it	   is	   not	   surprising	   that	   loss	   of	   apicobasal	   polarity	   and	   tissue	  
organization	  is	  considered	  to	  be	  one	  of	  the	  hallmarks	  of	  cancer	  (162).	  However,	   it	   is	  still	  unclear	  
whether	   the	   loss	   of	   polarity	   and	   tissue	   architecture	   is	   merely	   a	   consequence	   of	   uncontrolled	  
proliferation	   caused	   by	   mutated	   oncogenes	   and	   classical	   tumour	   suppressors,	   or	   a	   tumour	  
suppressor	  mechanism	  by	  itself	  that	  cells	  need	  to	  surpass	  in	  order	  to	  cause	  cancer.	  During	  recent	  
years,	   growing	   amount	   of	   evidence	   has	   been	   building	   up	   supporting	   the	   latter	   proposition.	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Epithelial	   architecture,	   integrity	  and	  more	  closely	   their	   regulator,	  epithelial	  polarity,	   seem	   to	  be	  
also	   regulators	   of	   proliferation,	   apoptosis	   and	  migration	   	   -­‐	   key	   oncogenic	   processes	   –	   that	   are	  
deregulated	  by	  oncogenes	  (82,	  84,	  163,	  164).	  In	  general,	  the	  contribution	  of	  epithelial	  cell	  polarity	  
proteins	   in	   cancer	   has	   been	   recently	   excellently	   reviewed	   by	   Huang	   et	   al.	   (161)	   and	   Martin-­‐
Belmonte	  et	  al.	  (34).	  
2.1.	  Defective	  epithelial	  polarity	  signalling	  contributes	  to	  cancer	  
2.1.1.	  Core	  polarity	  proteins	  in	  cancer	  	  
Originally,	  the	  proposition	  for	  polarity	  regulators	  ability	  to	  possess	  tumour	  suppressive	  properties	  
came	   from	  Drosophila	   studies	  where	  deletion	  of	  any	  of	   the	  SCRIB	  complex	  genes	   together	  with	  
oncogenic	  Ras	  were	  observed	  to	  cause	  massively	  synergistic	  and	  invasive	  growth	  in	  Drosophila	  eye	  
imaginal	  discs.	  This	  prompted	  the	  formation	  of	  group	  called	  neoplastic	  tumour	  suppressor	  genes	  
(nTSG)	  which	  consist	  of	   the	  SCRIB	  complex	  and	  additional	  genes	   (2,	  165,	  166).	   Since	   then	  many	  
other	   polarity	   associated	   genes	   have	   shown	   to	   have	   tumour	   suppressive	   properties	   also	   in	  
mammalian	  systems.	  
2.1.1.1.	  PAR	  proteins	  	  
All	  members	  of	  the	  PAR	  complex	  have	  been	  shown	  to	  contribute	  tumorigenic	  processes.	  PAR6	  has	  
been	   implicated	   in	   various	   oncogenic	   signalling	   processes.	   Epithelial-­‐to-­‐mesenchymal	   transition	  
(EMT),	   which	   is	   key	   event	   on	   the	   road	   to	   metastasis,	   can	   be	   induced	   by	   activation	   of	   the	  
Transforming	   growth	   factor	  β	   (TGFβ)	   signalling.	   TGFβ	   induction	   increases	  PAR6	  phosphorylation	  
and	  causes	  dissolution	  of	  TJs	  in	  addition	  to	  normal	  EMT	  markers	  such	  as	  vimentin	  expression	  (167).	  
PAR6	  seems	  to	  be	  key	  factor	  in	  the	  phenotype	  as	  it	  interacts	  with	  TGFβ	  receptor	  and	  blocking	  the	  
TGFβ-­‐dependent	   PAR6	   signalling	   partly	   rescues	   the	   formation	   of	   the	   protrusive	   acinus-­‐like	  
structures	   observed	   in	   mouse	   mammary	   carcinoma	   cell	   line	   EMT6,	   which	   has	   autocrine	   TGFβ	  
signalling	  (168).	  The	  regulation	  of	  TJ	  dissolution	  seems	  to	  be	  affected	  by	  RHOA	  SMURF-­‐mediated	  
ubiqitinylation.	  Interestingly,	  perturbation	  of	  TGFβ-­‐PAR6	  link	  rescues	  RhoA	  levels	  (167).	  Moreover,	  
interfering	   with	   PAR6	   signalling	   in	   orthotopic	   mouse	   model	   with	   the	   EMT6	   cells	   decreased	  
metastasis	   to	   lungs	   (168).	   Additionally,	   PAR6	   pathway	  was	   associated	  with	   the	   BRCA1	   negative	  
basal	  breast	  cancer	  signature	  in	  human	  microarray	  study	  (168).	  	  Activation	  of	  ErbB2,	  a	  commonly	  
overexpressed	   receptor	   especially	   in	   breast	   cancers,	   causes	   disruption	  of	   polarity	   in	   addition	   to	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increased	  proliferation	  and	   inhibition	  of	  apoptosis	   in	  3D	  cell	  culture	  model	  with	  MCF10A	  human	  
mammary	   cells.	   The	   polarity	   defect	   has	   been	   shown	   to	   be	   due	   to	   ErbB2	   association	   with	   PAR	  
complex	  and	  by	  its	  ability	  to	  force	  PAR3	  out	  of	  the	  complex.	  Interestingly,	  ErbB2	  association	  with	  
the	  remaining	  PAR6-­‐aPKC	  complex	  seems	  to	  be	  important	  for	  the	  inhibition	  of	  the	  apoptosis	  but	  
dispensable	  for	  the	  increased	  proliferation	  (169).	  However,	  overexpression	  of	  PAR6	  has	  been	  also	  
shown	  to	  cause	  increased	  Epidermal	  growth	  factor	  (EGFR)-­‐independent	  proliferation	  in	  aPKC	  and	  
CDC42-­‐dependent	  way	  in	  3D	  (170).	  	  
The	   three	   isoforms	   of	   mammalian	   PAR6	   (PAR6	   α,β	   and	   γ,	   encoded	   by	   PARD6A,	   PARD6B	   and	  
PARD6G	   respectively)	   act	  mainly	   in	   similar	  manner	   in	   a	   cell,	   yet	   isoform	   specific	   differences	   in	  
interacting	   partners	   and	   localization	   exist	   (171).	   However,	   PAR6β	   seems	   to	   be	   most	   strongly	  
implicated	  in	  defective	  signalling	  and	  cancer,	  as	  its	  overexpression	  has	  been	  shown	  to	  disrupt	  TJs	  
and	  their	  formation	  (53,	  171).	  This	  has	  been	  suggested	  to	  happen	  through	  association	  with	  PALS1	  
and	  preventing	  it	  to	  take	  part	  in	  TJ	  regulation	  (53,	  171).	  The	  isoform	  specific	  notions	  of	  PAR6	  are	  
supported	   by	   data	   from	   human	   cancers.	   For	   instance,	   it	   has	   been	   demonstrated	   the	   loci	   for	  
PARD6B	   is	   frequently	  amplified	   in	  breast	  cancer	  samples,	  whereas	   loci	   for	  PARD6B	  and	  PARD6G	  
are	  not	  observed	  to	  be	  amplified	  (170).	  The	  distinction	  is	  also	  demonstrated	  by	  the	  Copy	  Number	  
Analysis	   database	   (CONAN)	   at	   Wellcome	   Trust	   Sanger	   (http://www.sanger.ac.uk/cgi-­‐
bin/genetics/CGP/conan/search.cgi)	   where	   PARD6B	   can	   be	   found	   amplified	   in	   cancer	   cell	   lines	  
originating	   from	   various	   tissues,	   including	   breast,	   whereas	   amplifications	   for	   the	   two	   other	  
isoforms	   are	   rare.	   Transcriptome	   study	   targeted	   to	   find	   gene	   fusions	   in	   cancer	   found	   PARD6B	  
fusion	   with	   transcription	   factor	   gene	   ZNF667	   in	   prostate	   cancer	   cell	   line	   but	   whether	   this	  
contributes	  to	  oncogenic	  processes	  or	  is	  collateral	  damage,	  is	  unknown	  (172).	  	  	  	  
In	  contrast	  to	  PAR6,	  the	  polarity	  protein	  PAR3	  encoded	  by	  PARD3	  and	  PARD3B,	  is	  more	  often	  seen	  
to	   be	   lost	   or	   downregulated	   in	   cancers	   demonstrated	   by	   several	   recent	   studies.	   PAR3	   was	  
observed	   to	   be	   homozygously	   deleted	   in	   certain	   esophageal	   cell	   lines	   and	   in	   15%	   of	   studied	  
primary	   tumours	   (173).	   Moreover,	   the	   PAR3	   expression	   has	   been	   shown	   to	   be	   needed	   for	  
junctional	   localization	  of	  ZO	  proteins	   in	   the	  cell	   lines	   (173,	  174).	  However,	   in	  PAR3	  reexpression	  
studies	  PAR3	  has	  been	  shown	  to	  both	  inhibit	  and	  activate	  proliferation	  in	  2D	  monolayer	  (174,	  175).	  
Interestingly,	   PAR3	   expression	   still	   inhibits	   growth	   of	   prostate	   cancer	   cells	   in	   3D	   (175).	   The	  
different	  nature	  of	  PAR3	  compared	   to	  PAR6	   is	   also	  demonstrated	  by	  CONAN	  where	  PARD3	   and	  
PARD3B	   possess	   more	   often	   homozygous	   deletions	   than	   amplifications	   in	   strong	   contrast	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especially	   to	   PARD6B.	   Interestingly,	   an	   array	   screen	   done	   for	   684	   cancer	   lines	   and	   93	   primary	  
tumours	   in	   order	   to	   find	   intragenic	   homozygous	   microdeletions	   identified	   196	   novel	   tumour	  
suppressor	   candidates.	   Remarkably,	   these	   genes	   included	   core	   polarity	   genes	   PARD6G,	   PARD3,	  
PARD3B,	  MPDZ	   (MUPP1)	   and	  DLG,	   of	  which	  PARD3	  was	   found	   to	   be	  most	   often	   deleted	   (174).	  
Finally,	  the	  TGFβ	  induced	  EMT	  phenotype	  described	  above	  for	  PAR6	  seems	  to	  also	  involve	  PAR3	  as	  
TGFβ	  treatment	  has	  been	  shown	  to	  downregulate	  PAR3	  (176).	  	  
The	   third	  member	   of	   the	   PAR	   complex,	   aPKC,	  which	   has	   two	   isoforms	   known	   as	   aPKCzeta	   and	  
aPKCiota/lambda,	   has	   provided	   interesting	   aspects	   into	   the	   polarity	   as	   tumour	   suppressor	  
discussion.	  Uncontrolled	  aPKC	  has	  been	  suggested	   to	  play	  an	  oncogenic	   role	  originally	  based	  on	  
the	  Drosophila	  studies	  where	  overexpression	  of	  constitutively	  active	  form	  caused	  loss	  of	  polarity	  
and	  increased	  proliferation	  (177).	  These	  findings	  are	  supported	  by	  CONAN	  in	  which	  aPKC	  isoforms	  
are	   observed	   to	   be	   amplified.	   	   Importantly,	   aPKC	   has	   been	   also	   found	   to	   be	   overexpressed	   in	  
various	   tumour	  samples	   from	  breast,	  ovaries,	   lung	  and	  pancreas	   (177-­‐180).	  aPKCiota	  expression	  
has	  been	  shown	  correlate	  with	  tumour	  grade	  and	  survival	  in	  ovarian	  cancer	  and	  to	  be	  important	  
for	   prognosis	   in	   non-­‐small	   cell	   lung	   cancer	   (177,	   179,	   181).	   Also	   increase	   in	   the	   zeta	   isoform	  
expression	  has	  been	  observed	   in	  cancers	  of	   several	   tissues	  such	  as	  ovary,	  pancreas	  and	  bladder	  
being	   important	  for	  metastatic	  potential	  and	  grade	   in	  the	   last	  one	  (180,	  182,	  183).	   Interestingly,	  
aPKCzeta	  has	  also	  been	  shown	  be	  to	  dowregulated	  in	  androgen	  insensitive	  metastatic	  rat	  prostate	  
carcinoma	  cell	  lines	  possibly	  implying	  cell	  and	  tissue	  specific	  differences	  (184).	  Both	  aPKC	  isoforms,	  
when	  overexpressed,	  are	  often	  found	  to	  be	  mislocalized	  and	  sometimes	  accumulate	  to	  cytoplasm	  
(178,	   182,	   185,	   186).	   It	   has	   been	   suggested	   that	   their	   oncogenic	   potential	  would	   be	   unleashed	  
when	   they	   are	   in	   too	   great	   extend	   moved	   away	   from	   their	   normal	   role	   in	   regulation	   of	   PAR	  
complex	  and	  cell	  junctions	  (46,	  185).	  In	  line	  with	  the	  antagonistic	  model	  of	  apical	  and	  basolateral	  
identities,	   defective	   expression	   and	   localization	   of	   aPKC	   has	   been	   also	   noticed	   to	   affect	   the	  
localization	  of	  its	  opponent,	  LGL	  (182).	  However,	  it	  has	  also	  been	  reported	  that	  in	  Drosophila	  the	  
cytoplasmic	   accumulation	  would	   not	   affect	   polarity	   and	   proliferation	   possibly	   reflecting	   species	  
specific	  regulation,	  as	  humans	  have	  evolved	  to	  have	  two	  isoforms	  (182).	  Moreover,	  aPKC	  activity	  
has	   also	   been	   implicated	   in	   control	   of	   proliferation	   pathways	   such	   as	   EGFR	   pathway,	   which	  
consequently	   increases	   proliferation.	   Furthermore,	   aPKC	   has	   been	   shown	   to	   contribute	   EGF-­‐
dependent	   tumour	   growth	   in	  malignancies	   such	   as	   squamous	   cell	   carcinoma	  of	   head	   and	  neck,	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even	  though	  PAR	  complex	  disruption	  was	  shown	  to	  be	  dispensable	  for	  proliferation	  in	  the	  context	  
of	  ErB2	  overexpression	  in	  breast,	  as	  described	  above	  (169,	  187).	  	  
The	  studies	  described	  above	  depict	  the	  central	  significance	  of	  PAR	  complex	  in	  epithelial	  tissue	  and	  
consequently	  its	  impact	  on	  cancer.	  The	  findings	  also	  underline	  the	  dynamic	  nature	  and	  balance	  of	  
PAR	  complex	  revealing	  the	  oncogenic	  activity	  of	  some	  of	  its	  members	  even	  though	  the	  polarity	  in	  
whole	  has	  been	  proposed	  to	  be	  tumour	  suppressive.	  The	  different	  roles	  of	  PAR	  complex	  proteins	  
is	  underlined	  by	  the	  fact	  that	  the	  defects	  found	  in	  the	  regulation	  of	  the	  complex	  cover	  variety	  of	  
mechanisms	   (amplifications,	   overactivity)	   not	   expected	   if	   a	   protein	   would	   be	   solely	   a	   tumour	  
suppressor.	   In	   addition	   to	   the	   PAR	   proteins	   in	   the	   PAR	   complex,	   also	   some	   of	   the	   other	   PAR	  
proteins	  have	  implicated	  to	  have	  a	  role	  in	  oncogenic	  processes.	  	  
The	  Par4	  homologue	  LKB1	  is,	  most	  prominently,	  an	  established	  tumour	  suppressor.	  LKB1	  loss	  has	  
been	   shown	   to	   be	   causal	   to	   the	   Peutz	   Jeghers	   Syndrome	   (PJS)	   in	   which	   patients	   develop	  
hamartomatous	  polyps	  in	  their	  gastrointestinal	  tract	  and	  have	  also	  significantly	  increased	  lifetime	  
risk	  to	  develop	  cancer	  in	  general	  (188,	  189).	  LKB1	  has	  14	  downstream	  kinases,	  and	  thus	  it	  has	  been	  
difficult	  to	  pinpoint	  which	  one	  of	  them	  is	  downstream	  target	  of	  LKB1	  in	  PJS	  (2,	  189).	  In	  addition	  to	  
the	   PJS,	   sporadic	   LKB1	   alterations	   have	   been	   found	   in	   cancers.	   Especially	   lung	   cancer	   samples	  
seem	   to	   have	   LKB1	   deletions	   and	   inactivating	  mutations	  whereas	   allelic	   losses	   and	   loss	   protein	  
expression	   has	   been	   found	   in	   small	   percentage	   of	   breast	   cancer	   samples.	   (190-­‐193).	   However,	  
LKB1	   lacks	  somatic	  mutations	   in	  breast	  cancer	  samples	   (194).	   Interestingly,	   in	   lung	  cancers	  LKB1	  
loss	   appears	   to	   co-­‐operate	   especially	   with	   mutated	   KRAS	   oncogene	   demonstrated	   by	   mouse	  
experiments	  and	   lung	  cancer	  cell	   lines	  enriched	  with	  both	  mutations	   (190,	  195).	   LKB1	  depletion	  
has	  been	   shown	   to	  disrupt	   the	  epithelial	  organization	  and	  affect	  proliferation	   control	   in	   in	   vitro	  
3D-­‐system	  (82).	  One	  of	  the	  possibilities	  to	  be	  one	  of	  the	  effectors	  is	  suggested	  to	  be	  mammalian	  
target	   of	   rapamycin	   (mTOR),	   downstream	   of	   LKB1	   target	   AMPK,	   which	   controls	   cell	   cycle	  
progression	  (196).	  Additionally,	  LKB1	  regulates	  Par1	  (MARK1-­‐4	  in	  mammals)	  which,	  in	  addition	  to	  
the	   polarity	   role,	   has	   been	   also	   shown	   be	   associated	   with	   some	   of	   the	   cell	   cycle	   regulating	  
molecules	   such	  as	  MARK3	  with	  CDC25c	  and	   to	   regulate	   the	  MAPK	  pathway	  downstream	  of	  RAS	  
(197).	   Also,	   MARK4	   overexpression	   has	   been	   linked	   to	   cancers	   of	   the	   neural	   system	   (198).	  
Interestingly,	  recently	  LKB1	  was	  shown	  to	  boost	  mammary	  tumorigenesis	  in	  mice	  in	  co-­‐operation	  
with	   MYC,	   and	   to	   be	   linked	   to	   basement	   membrane	   disruption	   through	   desmosomal	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transmembrane	   protease	   hepsin	   (193).	   However,	   the	   exact	   molecular	   mechanism	   of	   the	   LKB1	  
tumour	  suppressor	  activity	  requires	  further	  elucidation.	  
The	  14-­‐3-­‐3	  protein	  PAR5	  has	  also	  been	  implicated	  in	  cancer.	  In	  mammals	  there	  exist	  many	  14-­‐3-­‐3	  
proteins	  of	  which	  the	  14-­‐3-­‐3ζ/YWHAZ	  is	  the	  closest	  homologue	  to	  the	  C.	  elegans	  par5	  (199,	  200).	  
14-­‐3-­‐3	   proteins	   have	   been	   implicated	   in	   regulation	   of	   a	   plethora	   of	   cellular	   processes	   including	  
cytoskeleton,	   proliferation	   and	   apoptosis	   in	   addition	   to	   the	   described	   polarity	   protein	   function	  
(200).	  In	  specific,	  PAR5	  has	  been	  shown	  affect	  Wnt-­‐signalling	  by	  enhancing	  β-­‐catenin	  export	  from	  
nucleus	  thereby	  antagonizing	  Wnt-­‐activity,	  which	  is	  one	  of	  the	  pathways	  frequently	  overactive	  in	  
cancer	  (201)	  (section	  2.1.7.	  Wtn	  pathway	  in	  cancer).	  Previous	  notion	  implies	  tumour	  suppressive	  
role	  for	  PAR5	  since	  its	  loss	  would	  enhance	  oncogenic	  activity.	  However,	  in	  human	  overexpression	  
or	  amplifications	  of	  PAR5/14-­‐3-­‐3ζ	  have	  been	  observed	  in	  several	  cancers	  originating	  from	  tissues	  
such	   as	   breast,	   lung	   and	   stomach,	  which	   is	   in	   line	  with	   the	   in	   vitro	   notion	   that	   overexpression	  
PAR5	  disrupts	  apicobasal	  polarity	   (199,	  202-­‐204).	  Amplification	  of	  14-­‐3-­‐3	  encoding	  genes	   is	   also	  
evident	   in	  CONAN.	  As	  14-­‐3-­‐3	  proteins	  are	   involved	   in	  apoptosis	   regulation	  by	   sequestering	  pro-­‐
apoptotic	   proteins,	   protection	   of	   apoptosis	   has	   been	   proposed	   to	   be	   one	   of	   the	   reasons	   why	  
PAR5/14-­‐3-­‐3ζ	   is	   found	   overexpressed	   in	   cancers	   (200,	   203).	  What	   is	   the	   role	   of	   the	   apico-­‐basal	  
polarity	  function	  of	  PAR5	  in	  these	  malignancies	  is	  yet	  poorly	  investigated.	  	  
2.1.1.2.	  CRUMBS	  complex	  	  
Evidence	   for	  CRUMBS	  complex	  association	   to	  cancer	   is	  yet	  much	  more	   limited	  compared	   to	   the	  
PAR	   and	   SCRIB	   complexes.	   However,	   CRB	   proteins	   have	   been	   implicated	   in	   some	   oncogenic	  
processes	   and	   especially	   they	   seem	   to	   modulate	   pathways	   commonly	   associated	   with	   tumour	  
suppression	  such	  as	  Hippo	  pathway.	  	  	  
One	   factor	   thought	   to	   contribute	   to	   tumorigenesis	   is	   viral	   targeting	   of	   proteins	   usually	   causing	  
them	  to	  be	  degraded.	  Also	  polarity	  proteins	  have	  been	  implicated	  to	  be	  targets	  and	  this	  aspect	  to	  
tumorigenesis	   is	   thoroughly	   reviewed	   by	   Javier	   (205).	   CRB3	   and	   and	   MUPP1	   of	   the	   CRUMBS	  
complex	  proteins	  have	  also	   shown	   to	  be	   targeted	  by	  oncogenic	   viruses.	  Human	  Papilloma	  Virus	  
(HPV)	  E6	  oncoprotein	  and	  adenovirus	  E4-­‐ORF1	  targets	  these	  proteins	  for	  degradation	  (206,	  207).	  	  
Consequently,	   this	   can	   be	   seen	   to	   be	   potentially	   remarkable	   for	   epithelial	   function	   as	   TJs	   are	  
shown	   to	   be	   in	   part	   controlled	   by	   CRUMBS	   complex	   proteins	   as	   described	   earlier	   in	   Chapter	   1	  
Section	  1.3.1.2.	  CRUMBS	  complex.	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Crb3	  was	   identified	   to	  be	   the	  most	  downregulated	  gene	   in	  an	   in	   vivo	   tumour	   screen	  done	  with	  
baby	  kidney	  epithelial	  cells	  (208).	  Further	  in	  vitro	  characterization	  showed	  CRB3	  to	  be	  needed	  for	  
epithelial	   architecture	   and	   TJ	   formation,	   whereas	   its	   depletion	   increased	   contact	   independent	  
growth	   and	   migration.	   In	   vivo	   CRB3	   re-­‐expression	   was	   shown	   suppress	   metastasis.	   Another	  
mechanism	   for	   CRUMBS	   complex	   to	   regulate	   growth	   has	   been	   proposed	   to	   occur	   through	  
controlling	   the	  mTOR	  pathway.	  CRUMBS	  complex	  was	  shown	  to	  co-­‐localise	  and	  directly	   interact	  
with	  Tuberous	  Sclerosis	  Complex	  2	   (TSC2).	  TSC2	   is	  an	  established	  tumour	  suppressor,	  and	  when	  
lost	  causes	  hamartomas	  (209).	  The	  mTOR	  pathway	  senses	  the	  nutritional	  and	  energy	  status	  of	  the	  
cell	   and	   with	   additional	   proteins	   forms	   a	   complex	   mTORC1	   which	   controls	   cell	   growth.	   TSC2	  
negatively	   regulates	   mTORC1.	   Interestingly,	   PATJ	   depletion	   causes	   increase	   in	   mTORC1	   activity	  
suggesting	   a	   growth	   regulatory	   role	   for	   CRUMBS	   complex	   through	   interaction	  with	   TSC2	   (209).	  
Furthermore,	  as	  described	  earlier	  in	  Chapter	  1	  Section	  1.3.2.3.	  Hippo	  pathway,	  Crumbs	  has	  been	  
shown	  to	  regulate	  the	  organ	  size	  controlling	  Hippo	  pathway.	  As	  described	  earlier	  Crumbs	  has	  been	  
shown	   to	   control	   Ex	   localization	   and,	   possibly,	   degradation	   thereby	   affecting	   activity	   of	   Hippo	  
pathway	  to	  which	  Ex	  contributes.	  Consequently,	  manipulation	  of	  Crumbs	  levels	  have	  been	  shown	  
to	   upregulate	   Hippo	   pathway	   activity	   and	   cause	   overproliferation	   and	   increased	   cell	   survival	   in	  
Drosophila	  wing	  imaginal	  discs	  providing	  more	  evidence	  for	  CRUMBS	  complex	  in	  growth	  regulation	  
(140,	  141,	  210).	  Additionally,	   in	  mammalian	  cells,	  CRB3	  has	  been	  shown	  to	  directly	   interact	  with	  
Hippo	   pathway	   target	   YAP	   and	   has	   been	   proposed	   to	   facilitate	   YAP	   phosphorylation	   and	  
consequent	  cytoplasmic	  retention	  of	  this	  transcription	  factor.	  Interestingly,	  this	  interaction	  seems	  
to	  be	  coupled	  to	  cell	  density,	  thereby	  giving	  CRUMBS	  complex	  a	  role	  in	  cell	  density	  signalling	  and	  
providing	   another	  mechanism	   of	   Hippo	   pathway	   inhibition	   (142).	   Furthermore,	   CRB3	   has	   been	  
shown	  to	  be	  downregulated	  by	  EMT	  associated	  transcription	  factor	  Snail	  thereby	  contributing	  loss	  
of	  epithelial	   features	   in	  EMT	  as	  was	  discussed	  earlier	   (164).	   Finally,	  data	   from	  CONAN	  does	  not	  
support	   tumour	   suppressive	   role	   for	   the	  CRUMBS	  complex	  proteins	   as	   alterations	   for	  CRB3	  and	  
PATJ	  are	  non-­‐existent	  and,	  interestingly,	  PALS1	  is	  documented	  to	  be	  amplified	  rarely.	  However,	  to	  
date	  no	  clinical	  evidence	  for	  contribution	  of	  CRUMBS	  complex	  in	  human	  cancers	  exist	  despite	  of	  
the	  suggested	  in	  vivo	  and	  in	  vitro	  mechanisms	  associated	  with	  oncogenic	  events.	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2.1.1.3.	  SCRIB	  complex	  	  
Proteins	   of	   the	   basolateral	   SCRIB	   complex	   have	   been	   shown	   to	   have	   a	   role	   in	   human	   cancer.	  
Similar	  to	  CRUMBS	  complex	  proteins,	  also	  proteins	  of	  the	  SCRIB	  complex	  have	  been	  shown	  to	  be	  
targeted	  by	  oncogenic	   viruses	   (205).	   Interestingly,	   especially	   the	   SCRIB	   and	  DLG	  proteins	  of	   the	  
SCRIB	  complex	  have	  been	  shown	  to	  be	  targets.	  HPV	  genome	  encodes	  oncoproteins	  E6	  and	  E7	  (of	  
the	   high	   risk	   types	   HPV-­‐16	   and	   HPV-­‐18)	   and	   is	   associated	   with	   cervical	   cancer	   (211).	   These	  
proteins	  have	  been	   shown	   to	   interact	  with	  PDZ	  domains	  of	   SCRIB	  and	  DLG	  and	   target	   them	   for	  
degradation	  by	  ubiqitinylation	  (211-­‐214).	  Interestingly,	  if	  the	  PDZ-­‐binding	  domain	  of	  E6	  is	  mutated,	  
the	   virus	   can	   still	   target	   p53	   for	   degradation	   but	   not	   cause	   transformation	   and	   hyperplasia	   in	  
murine	  cells	  suggesting	  protective	  and	  tumour	  suppressive	  function	  for	  SCRIB	  and	  DLG	  (215,	  216).	  
In	  addition,	  also	  Tax-­‐protein	  of	  the	  Human	  T-­‐cell	  Leukemia	  Virus	  (HTLV)	  has	  been	  shown	  to	  target	  
SCRIB	  and	  DLG	  (217,	  218)	  and	  the	  E4-­‐ORF1	  of	  the	  adenovirus	  9	  DLG	  (219).	  The	  targeting	  by	  viral	  
proteins	   has	   been	   shown	   affect	   the	   protein	   levels	   and	   localization	   of	   these	   polarity	   proteins	   in	  
tumours	  characterized	  with	  HPV-­‐positivity	  thereby	  affecting	  their	  role	  in	  polarity	  regulation	  (213,	  
217).	  However,	   the	   E4-­‐ORF1	  of	   the	   adenovirus	   9	   does	   not	   cause	   traditional	   loss	   of	   the	   polarity	  
function	  of	  DLG,	   instead	   it	   specifically	   promotes	   the	   activation	  of	   PI3K	   through	  DLG,	   suggesting	  
this	  polarity	  protein	  to	  act	  as	  an	  oncogene	  despite	  it	  is	  traditionally	  viewed	  as	  tumour	  suppressor	  
(219).	  
As	  described,	  the	  studies	  in	  Drosophila	  originally	  prompted	  the	  idea	  that	  intact	  apico-­‐basal	  polarity	  
could	   act	   as	   a	   tumour	   suppressive	   mechanism.	   However,	   notion	   of	   great	   importance	   made	   in	  
those	  studies	  was	  that	  even	  though	  defective	  SCRIB	  complex	  genes	  cause	  ectopic	  proliferation	  in	  
the	   imaginal	   discs	   (166),	   the	   proliferation	   is	   counteracted	   by	   c-­‐Jun	   N-­‐terminal	   kinase	   (JNK)-­‐
mediated	   apoptosis	   and	   engulfment	   (165,	   220).	   Only	   when	   the	   defective	   polarity	   gene	   is	  
accompanied	  by	  oncogenic	  Ras	  (or	  Notch),	  the	  apoptosis	  is	   inhibited	  and	  invasive	  proliferation	  is	  
enabled,	   supporting	   the	   dogma	   of	   multistep	   carcinogenesis	   (165,	   166).	   Moreover,	   the	   link	  
between	  these	  polarity	  regulators	  and	  proliferation	  is	  demonstrated	  that	  they	  are	  able	  to	  suppress	  
cyclin	  E	  mutants	  and	  that	  their	  loss	  results	  in	  ectopic	  expression	  of	  cyclin	  E	  (165,	  221).	  	  
Even	   though	  not	  extensively	   studied	   in	  mammals,	   SCRIB	   complex	  proteins	  have	  displayed	   some	  
tumour	  suppressive	  properties	  also	  in	  mammalian	  systems.	  Interestingly,	  in	  3D-­‐culture	  in	  MCF10A	  
mammary	  epithelial	  cell	  line,	  depletion	  of	  SCRIB	  inhibits	  apoptosis	  induced	  by	  oncogene	  MYC	  and	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abrogates	   acinar	   development,	   even	   though	   SCRIB	   knockdown	   has	   no	   phenotype	   in	   2D,	  
underlining	   the	   importance	  of	  novel	   cell	   culture	   systems	   (Chapter	  3	  Three	  dimensional	   (3D)-­‐cell	  
culture	  method)	  (163).	  It	  has	  been	  also	  demonstrated	  that	  SCRIB	  inhibits	  the	  RAS	  pathway	  induced	  
invasion,	   by	   regulating	   the	   MEK-­‐ERK	   module,	   similar	   to	   Drosophila	   invasive	   Ras+Scribble-­‐
phenotype,	   in	  MCF10A	   cells	   (222).	   All	   of	   the	   SCRIB	   complex	   proteins	   have	   been	   shown	   inhibit	  
proliferation	  in	  cell	   lines	  to	  some	  extent	  but	   it	  may	  require	  some	  tissue	  specifity	  since	  even	  Dlg-­‐
null	  mice	  do	  not	  exhibit	  overproliferation	  on	  a	  system	  level	  (60,	  223,	  224)	  and,	  interestingly,	  DLG	  
depletion	   has	   even	   been	   shown	   to	   decrease	   proliferation	   (225).	   LGL-­‐dependent	   increase	   in	  
proliferation	  has	  been	  suggested	  to	  occur	  through	  defects	   in	  asymmetric	  cell	  division	  as	  LGL	  has	  
been	  shown	  to	  bind	  a	  regulatory	  protein	  and	  manipulating	  LGL	   levels	   leads	  to	  defects	   in	  mitotic	  
spindle	   organization	   (226).	   Similar	   to	   many	   apico-­‐basal	   polarity	   proteins,	   the	   SCRIB	   complex	  
proteins	  also	  play	  a	  role	  in	  migration.	  Consequently,	  the	  SCRIB	  complex	  proteins	  have	  been	  shown	  
to	   be	   needed	   for	   normal	  migrational	   processes	   such	   as	   palate	   closure	   in	  mice	   (227).	   However,	  
when	  polarity	  proteins	  acquire	  defects,	   also	  migration	   seems	   to	  go	  awry	  and	   lead	   to	  aggressive	  
invasion	   demonstrated	   by	   the	  Drosophila	   nTSG-­‐Ras	   tumours	   and	  mammalian	   systems	   (84,	   166,	  
222,	  228).	  On	  the	  other	  hand,	  once	  again	  some	  species	  and	  system	  specifity	  has	  been	  proposed	  
due	  to	  contradicting	  results,	  as	  for	  example,	  in	  Drosophila	  ovarian	  follicular	  border	  cells	  mutation	  
of	  Scribble	  decreases	  migration	  (60,	  221).	  The	  EMT	  process,	  characterized	  by	  increased	  migration,	  
loss	   of	   AJ	   function	   due	   to	   frequently	   observed	   loss	   of	   E-­‐cadherin	   and	   upregulation	   of	   certain	  
transcription	   factors,	   seems	   to	   be	   linked	   in	   part	   also	   to	   SCRIB	   complex	   (229,	   230).	   Firstly,	   as	  
described	  earlier	  in	  Chapter	  1	  section	  1.3.1.3	  SCRIB	  complex,	  SCRIB	  localization	  to	  AJs	  is	  E-­‐cadherin	  
dependent	  and	  SCRIB	  loss	  decreases	  cell	  adhesion	  in	  Caco2	  colon	  cancer,	  further	  supported	  by	  the	  
similar	  observations	  with	  DLG	  loss	  (61,	  70).	  Secondly,	  in	  EMT	  process	  transcription	  factors	  such	  as	  
Snail,	  basic	  helix	   loop	  helix	   (bHLH)	   transcription	   family	  members	   (most	  well-­‐known	  Twist),	   ZEB1	  
and	   Slug	   downregulate	   epithelial	   features	   of	   cells	   and	   increase	   expression	   of	   mesenchymal	  
markers	  such	  as	  vimentin	  (229,	  230).	  Interestingly,	  ZEB1	  has	  been	  shown	  to	  downregulate	  LGL	  and	  
bHLH	   family	   members	   DLG	   (231,	   232).	   To	   conclude,	   even	   though	   the	   role	   of	   SCRIB	   complex	  
proteins	   in	   oncogenic	   processes	   is	   not	   well	   characterized	   in	   mammals,	   and	   is	   yet	   somewhat	  
controversial,	   it	   is	   important	  to	  note	  that	  the	  SCRIB	  complex	  exhibits	  also	  a	  role	  as	  counteractor	  
for	  the	  apical	  PAR	  and	  CRUMBS	  complexes	  and	  therefore	  often	  when	  one	  of	  them	  is	  perturbed,	  
also	  the	  regulation	  of	  the	  others	  is	  disrupted	  as	  has	  been	  described	  previously.	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Also	  data	   from	  human	  cancers	  proposes	   that	  SCRIB	  complex	  genes	  have	  a	   role	   in	  cancer.	  SCRIB	  
protein	  has	  been	  shown	  to	  be	  mislocalized	  in	  various	  human	  cancer	  breast	  cancer	  cell	  lines	  (163).	  
In	   addition	   to	  mislocalization,	   also	   the	   SCRIB	  mRNA	   and	   protein	   levels	   have	   been	   shown	   to	   be	  
decreased	   in	  breast,	   cervical	   (possibly	  due	   to	  HPV)	   and	  endometrial	   cancer	   (61,	   163,	   233,	   234).	  
SCRIB	   has	   also	   been	   shown	   to	   become	  mislocalized	   in	   colon	   cancer	   together	   with	   DLG	   during	  
progression	   of	   the	   malignant	   process	   (65).	   The	   role	   of	   the	   SCRIB	   complex	   in	   cancer	   is	   further	  
supported	   by	   Catalogue	   of	   Somatic	   Mutations	   in	   Cancer	   (COSMIC)	   database	  
(http://www.sanger.ac.uk/genetics/CGP/cosmic/),	  which	  shows	  that	  SCRIB	  complex	  genes	  exhibit	  
mutations	   in	   significant	   amount	   of	   examined	   samples.	   However,	   also	   opposite	   results	   for	   this	  
proposed	  tumour	  suppressor	  have	  been	  presented,	  as	  locus	  encoding	  SCRIB	  has	  been	  shown	  to	  be	  
amplified	  in	  certain	  cancers	  and	  in	  some	  cases	  also	  increased	  expression	  is	  associated	  with	  cancer	  
progression	  (235-­‐237).	  Interestingly,	  amplifications	  or	  homozygous	  deletion	  of	  the	  SCRIB	  complex	  
genes	   are	   rare,	   but	   both	   existing,	   according	   to	   the	   CONAN,	   even	   though	   several	   studies	   for	  
especially	  DGL	   and	   LGL	   loss	   –	   or	   downregulation	   exist.	   DLG	  downregulation	   has	   been	  observed	  
oesophageal	  cancer	  cell	  lines,	  papillary	  thyroid,	  breast	  	  and	  gastric	  cancers	  of	  which	  in	  the	  last	  one	  
decreased	  DLG	  expression	  correlates	  with	  the	  more	  invasive	  phenotype	  (238-­‐241).	  As	  proposed	  by	  
the	   COSMIC	   data,	   DLG	   has	   additionally	   been	   shown	   to	   also	   exhibit	   point	   mutations	   in	   breast	  
cancer	   (239).	  Similarly,	  LGL	  downregulation	  has	  been	  observed	   in	  various	  malignancies	   including	  
colorectal,	   prostate	   and	   breast	   cancers	   (242)	   and	   also	   LGL	   loss	   is	   shown	   to	   correlate	  with	   high	  
tumour	  grade	  and	  metastasis	  in	  colon	  cancer	  (243).	  Importantly,	  as	  localization	  of	  these	  proteins	  
play	  a	  fundamental	  role	  for	  their	  function,	  LGL	  was	  shown	  to	  mislocalized	  in	  previously	  described	  
ovarian	  cancer	  study	  in	  co-­‐operation	  with	  mislocalization	  of	  its	  counterplayer	  	  aPKC	  (182).	  
Taken	   together,	   as	  previously	   reviewed	  by	  Humbert	   (60),	   various	   in	   vitro	  mechanisms	   for	   SCRIB	  
complex	  genes	  to	  be	  causative	  for	  oncogenic	  processes	  exist,	  but	  still	  evidence	  for	  their	  causal	  role	  
in	  cancer	  is	  fairly	  limited	  in	  mammals.	  One	  of	  the	  goals,	  for	  example,	  is	  to	  define	  the	  specific	  roles	  
and	  features	  of	  the	  different	  DGL	  and	  LGL	  encoding	  genes,	  and	  what	  is	  their	  redundancy	  in	  cancer	  
and	  in	  general.	  Consequently,	  more	  in	  vivo	  experiments	  and	  clinical	  data	  is	  needed.	  
2.1.2.	  Junctional	  proteins	  in	  cancer	  	  
Junctions	  between	  epithelial	  cells	  play	  a	  major	  role	  in	  life	  of	  a	  cell	  and	  homeostasis	  of	  the	  tissue	  as	  
has	   been	  described,	   and	   consequently,	   there	   is	   evidence	   showing	  defects	   in	   junctional	   proteins	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are	  associated	  with	  cancer.	   It	   is	  known	  that	  defects	   in	  cell-­‐cell	  and	  cell-­‐ECM	  contacts	  potentiate	  
cells	  to	  become	  invasive	  as	  they	  are	  not	  bound	  and	  regulated	  by	  their	  surroundings.	  This	  process	  is	  
thought	   to	   be	   one	   of	   the	   hallmark	   of	   cancers	   (244),	   which	   is	   often	   characterized	   by	   loss	   of	   E-­‐
cadherin	   expression,	   and	   is	   involved	   in	   EMT.	   Contribution	   of	   cadherins	   to	   cancer	   has	   been	  
excellently	  reviewed	  by	  Berx	  et	  al.	  (245).	  However,	  recently	  also	  tight	  junction	  proteins	  have	  been	  
linked	  to	  oncogenic	  processes	  and	  cancer.	  
Traditionally	   breast	   cancers	   have	  been	   classidied	   to	   five	   categories	   according	   to	   their	   estrogen-­‐
receptor,	  prolactin-­‐receptor,	  HER2,	  EGFR	  and	  cytokeratin	  5/6	  status	  (named	  Luminal	  A,	  Luminal	  B,	  
Basal-­‐like,	   HER2	   enriched	   and	   normal-­‐like)	   (246).	   Recently	   some	   additional	   classifications	   have	  
been	  suggested.	  Claudin,	  the	  other	  major	  component	  of	  TJs,	  has	  been	  proposed	  to	  be	  a	  significant	  
marker	   as	   subtype	   called	   ‘claudin-­‐low’	   has	   been	   identified	   by	   using	   combination	   of	   human	   and	  
murine	  breast	  cancer	  tumour	  microarrays	  characterized	  by	  low	  claudin	  3,4	  and	  7	  and	  E-­‐cadherin	  
expression	   (247).	   This	   subtype	   is	   enriched	   to	   the	   ER-­‐negative	   (ER-­‐ve)	   tumours.	  However,	   in	   the	  
context	  of	  breast	  cancer,	  also	  existence	  of	  opposite	  ‘claudin-­‐high’	  phenotype	  has	  been	  proposed	  
characterized	   by	   high	   expression	   of	   claudins	   1	   and	   4	   in	   ER-­‐ve	   tumours	   (246,	   248,	   249).	   This	   is	  
counterintuitive,	  since	  functional	  TJs,	  and	  consequently	  expression	  of	  TJ	  proteins,	  is	  thought	  to	  be	  
tumour	   suppressive.	   However,	   as	   no	   conclusive	   mechanistic	   models	   have	   been	   displayed,	  
possibility	   for	   defective	   interacting	   partner	   in	   deposition	   to	   membrane	   and	   consequent	  
accumulation	  to	  cytoplasm	  has	  been	  proposed	  (246).	  Additionally,	  the	  specific	  claudins	  within	  the	  
TJ	  are	  thought	  to	  dictate	  the	  strength	  of	  the	  junction,	  and	  thereby	  accumulation	  of	  certain	  claudin	  
could	  make	  junctions	  weaker	  and	  more	  prone	  to	  tumorigenesis	  (246,	  250).	  Thus,	  more	  research	  is	  
needed	   to	   elucidate	   the	   role	   of	   claudins	   in	   tumour	   suppression,	   as	   contradictory	   claudin	  
expression	   results	   have	   been	   also	   reported	   in	   other	   cancers	   in	   addition	   to	   breast	   cancer.	   For	  
example,	   overexpression	   of	   claudins	   in	   ovarian	   cancer	   whereas	   loss	   of	   expression	   in	   prostate	  
cancer	  have	  been	  demonstrated	  with	   correlations	   to	   the	   aggressiveness	   and	  progression	  of	   the	  
cancer	  (246,	  251,	  252).	  
TJ-­‐linked	   ZO	   proteins	   have	   also	   been	   associated	   with	   oncogenic	   processes.	   As	   previously	  
mentioned,	  ZO	  proteins	  have	  been	  shown	  to	  shuttle	  between	  nucleus	  and	  junctions.	  For	  instance,	  
ZO-­‐2	  has	  been	  shown	  to	  control	  transcription	  of	  cyclin	  D1	  by	  cooperating	  with	  MYC	  which	  binds	  to	  
cyclin	  D1	  promoter	  and	  thereby	  links	  ZO-­‐2	  protein	  directly	  to	  proliferation	  control	  (8).	  Moreover,	  
ZO-­‐1	  binds	  ZONAB	  protein	  and	  retains	  its	  association	  with	  membrane.	  If	  TJs	  are	  disrupted	  or	  ZO-­‐1	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lost,	  ZONAB	  is	  able	  to	  translocate	  to	  nucleus	  where	   it	  acts	  as	  a	  transcription	  factor	  for	  cell	  cycle	  
regulators	  and	  oncogenes	  such	  as	  ErbB2.	  ZONAB	  also	  binds	  CDK4	  helping	  it	  to	  accumulate	  in	  the	  
nucleus	  and	   thereby	  driving	  cell	   cycle	   (253,	  254).	   Importantly,	   the	   regulation	  between	  ZO-­‐1	  and	  
ZONAB	   is	   cell	   density	   dependent,	   giving	   possibility	   to	   halt	   proliferation	   in	   high	   densities	   (253).	  
Consequently,	   downregulation	   or	   loss	   of	   ZO	   protein	   expression	   has	   been	   demonstrated	   in	  
tumours	  and	  correlation	  to	  poor	  prognosis	  has	  been	  shown	  in	  breast	  cancer	  (255-­‐258).	  However,	  
in	  contrast	  to	  previous	  results,	  ZO-­‐1	  overexpression	  has	  been	  observed	  in	  pancreatic	  cancer	  (259).	  
To	   summarize,	   individual	   junctional	   proteins	   appear	   to	   have	   a	   role	   in	   cancer	   progression,	   and	  
imply	  a	  role	  for	  them	  outside	  the	  junctions.	  Importantly,	  junctional	  proteins	  are	  tightly	  regulated	  
by	   the	   polarity	   machinery,	   and	   both	   components	   need	   to	   be	   functional	   to	   maintain	   tissue	  
homeostasis.	  	  
2.1.3.	  RHO	  GTPases	  in	  cancer	  	  
As	  the	  RHO	  GTPases	  have	  been	  tightly	  linked	  to	  conveying	  messages	  within	  the	  polarity	  machinery,	  
it	  is	  obvious	  that	  they	  can	  also	  be	  deregulated	  and	  play	  a	  role	  in	  cancer.	  Function	  and	  expression	  
of	  RHO	  GTPases	   is	   thoroughly	  reviewed	  by	  Karlsson	   (260)	  but	   I	  will	  concentrate	  on	  RHOA,	  RAC1	  
and	  CDC42	  in	  this	  study.	  	  In	  addition	  to	  apicobasal	  polarity	  control,	  RHO	  GTPases	  affect	  processes	  
deregulated	  in	  cancers	  such	  as	  migration	  and	  cell	  survival.	  Therefore	  it	  is	  not	  surprising	  that	  RHO	  
GTPases	   are	   almost	   solely	   observed	   to	   be	   overexpressed	   in	   cancers	   and	   rarely	   downregulated	  
(260).	   Constituvely	   active	  mutants	   of	   RHOA,	   RAC1	   and	   CDC42	   have	   been	   shown	   to	   be	   able	   to	  
transform	   fibroblast	   cells	   similar	   to	   oncogenic	   RAS	   but	   more	   weakly,	   and	   dominant	   negative	  
mutants	  of	  these	  proteins	  inhibit	  RAS-­‐induced	  transformation	  (260-­‐263).	  However,	  despite	  these	  
proteins	   having	   active	   and	   inactive	   forms,	   there	   have	   not	   been	   observations	   of	   activating	  
mutations	  cancers,	  even	  considering	  their	  shown	  oncogenic	  role	  in	  vitro	  (260).	  It	  is	  also	  important	  
to	  note	  that	  as	  RHO	  GTPases	  are	  controlled	  by	  a	  set	  of	  regulating	  factors	  (GEFs,	  GAPs,	  GDIs),	  also	  
their	   defects	   can	   contribute	   to	   RHO	   GTPase	   activity	   in	   cancers.	   For	   example,	   TIAM1,	   GEF	  
associated	  with	  RAC1	  and	  PAR	  complex	  regulation	  has	  been	  shown	  to	  be	  overexpressed	  in	  breast	  
and	  nasopharyngeal	  cancers	  and	  to	  be	  associated	  with	  poor	  prognosis	  (264,	  265).	  	  
RHOA	   level	  has	  been	  shown	  to	  be	   increased	   	   in	  colon	  cancer,	  squamous	  cell	  carcinoma	  (SCC)	  of	  
head	  and	  neck	  and	  liver	  cancer,	  in	  which	  RHOA	  activity	  was	  also	  shown	  to	  be	  increased	  (266-­‐268).	  
Additionally,	   increase	   in	  RHOA	   level	   has	   also	  been	  observed	   in	  ovarian,	   breast,	   gastric,	   bladder,	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esophageal	   and	   testicular	   cancers	   (260,	   267,	   269-­‐273).	   In	  many	   studies	   also	   a	   correlation	   with	  
RHOA	  expression	  and	  cancer	  progression	  has	  been	  established.	  However,	  one	  breast	  cancer	  study	  
failed	   to	  establish	   link	  between	  RHOA	  expression	  and	  breast	  cancer	   (274).	  RHOA	   inhibition	  with	  
bacterial	   toxin	  C3	   transferase	  has	  been	  shown	  to	   lead	   lymphomas	   in	  mouse	   (inhibits	  also	  RHOB	  
and	   RHOC)	   (275).	   In	   studies	   with	   epithelial	   cells,	   overexpression	   of	   RHOA	   has	   been	   shown	   to	  
contribute	  dissemination	  of	  ovarian	  cancer	  cells	   injected	  to	  peritoneal	  cavity	  suggesting	  a	  role	  in	  
metastasis	   process	   (276).	   Furthermore,	   RHOA	   expression	   has	   been	   shown	   to	   be	   controlled	  
transcriptionally	  by	  a	  protein	  complex	   including	  MYC,	  SKP2	  and	  MIZ1	  proteins	  and	   this	   complex	  
and	   RHOA	   to	   contribute	   to	   breast	   cancer	   cell	   metastasis	   model	   and	   to	   be	   overexpressed	   in	  
metastatic	   human	  prostate	   cancer	   (277).	  However,	   to	   date,	   there	   is	   a	   lack	   of	   in	   vivo	   studies	   to	  
elucidate	  the	  role	  of	  RHOA	  in	  cancer.	  
Also	   RAC1	   is	   commonly	   overexpressed	   in	   cancers.	   RAC1	   overexpression	   has	   been	   implicated	   to	  
affect	  progression	  of	  testicular,	  gastric	  and	  breast	  cancers	  and	  also	  to	  be	  overexpressed	  in	  oral	  SCC	  
(270,	  273,	  278,	  279).	  Interestingly,	  RAC1	  has	  a	  splice	  variant	  RAC1b	  which	  is	  more	  often	  observed	  
in	   the	  active	   state.	  However,	   this	   form	  has	  been	   found	   to	  be	  equally	   expressed	   in	  both	  normal	  
mammary	  tissue	  and	  breast	  cancer,	  even	  though	  it	  has	  been	  shown	  to	  be	  overexpressed	  in	  colon	  
cancer	   (278,	   280).	   RAC1	   expression	   has	   also	   been	   shown	   to	   positively	   correlate	   with	   cancer	  
progression	  with	  orthotopic	   colorectal	   cancer	   cell	   injections	   (281).	   Interestingly,	  RAC1	  depletion	  
has	  been	  shown	  to	  protect	  from	  oncogenic	  K-­‐RAS	  induced	  lung	  tumour	  by	  using	  conditional	  Rac1	  
deletion	  in	  mouse	  (282).	  	  
Data	   of	   CDC42	   expression	   in	   cancers	   is	  more	   limited	   compared	   to	   RAC1	   and	  RHOA.	   CDC42	   has	  
been	  shown	  to	  be	  overexpressed	   in	  breast	  cancer	  and	  testicular	  cancer	  correlating	  with	   tumour	  
progression	   (267,	  273).	  However,	  experiments	  with	  conditional	  knockout	  mice	  suggest	  opposing	  
role,	  since	  Cdc42	  deletion	  has	  been	  observed	  to	  cause	  neoplasia	  in	  liver	  and	  hematopoietic	  system	  
and	  eventually	  tumours	  in	  the	  liver	  model	  (283,	  284).	   	  However,	  similar	  to	  RHOA,	  evidence	  from	  
animal	   experiments	   is	   lacking	   and	  more	   research	   is	   needed	   to	   shed	   light	  onto	   role	  of	  CDC42	   in	  
cancer.	  
To	   conclude,	   even	   though	   RHO	   GTPase	   overexpression	   has	   been	   clearly	   implicated	   in	   human	  
cancers,	  the	  exact	  role	  of	  these	  messengers	  in	  vivo	  remains	  to	  be	  elucidated.	  However,	  since	  these	  
molecules	   are	   in	   the	   crossroads	   of	   multiple	   pathways,	   and	   also	   cross	   regulate	   each	   other,	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pinpointing	   the	   most	   dominant	   pathway	   under	   their	   regulation	   in	   tumorigenesis	   and	   possible	  
clinical	  targeting	  of	  these	  molecules	  may	  prove	  difficult.	  	  
2.1.4.	  RAB	  GTPases	  in	  cancer	  	  
A	  number	  of	  the	  RAB	  GTPases	  have	  been	  implicated	  in	  cancers.	  For	  instance,	  RAB25	  is	  involved	  in	  
the	   integrin	   signalling,	   and	   it	   has	   a	   potent	   role	   to	   be	   involved	   in	   deregulated	   events	   of	   the	  
epithelial	   architecture.	  Consequently,	   it	  has	  been	   shown	   to	  be	  overexpressed	   in	  human	  cancers	  
such	  as	  breast	  and	  ovarian	  cancer	  (111,	  285).	  The	  overexpression	  correlates	  with	  aggressiveness	  
and	  decreased	  survival	  and	  this	  is	  at	  least	  in	  part	  thought	  to	  be	  caused	  by	  association	  with	  α5β1-­‐
integrin	   (285).	   This	   interaction	  has	  been	   shown	   to	   cause	   invasiveness	  of	   the	   tumour	   cells	   in	   3D	  
environment,	   thereby	  possibly	   playing	   a	   role	   in	   dissemination	   (111,	   116,	   286).	   Also	   the	   clathrin	  
and	  PI3K	  associated	  RAB5	  has	  been	  implicated	  in	  cancer	  and	  has	  been	  shown	  to	  be	  overexpressed,	  
for	  example,	  in	  lung	  and	  hepatocellular	  cancers	  (111,	  287,	  288).	  
2.1.5.	  PTEN-­‐PI3K	  pathway	  in	  cancer	  	  
PTEN/PI3K	  is	  widely	  established	  tumour	  suppressor-­‐oncogene	  pair	  in	  cancer	  biology	  and	  plays	  also	  
roles	  not	  associated	  with	  polarity	  (289).	  As	  with	  the	  Wnt	  and	  Hippo	  pathways,	  I	  will	  concentrate	  
here	   to	   review	   how	   the	   interactions	   with	   the	   polarity	   regulation	   of	   PTEN/PI3K	   have	   been	  
implicated	  in	  oncogenic	  events	  and	  summarize	  the	  implication	  of	  this	  pathway	  in	  human	  cancers.	  
Even	  though	  PTEN/PI3K	  pathway	   is	  well	  known	  to	  be	  deregulated	   in	  cancers,	   its	  perturbation	   in	  
polarity	   context	   is	   still	   not	   well	   known	   in	   cancer.	   The	  main	   role	   for	   the	   pathway	   in	   cancers	   is	  
thought	   to	   be	   overactivation	   of	   the	   AKT	   kinase	   caused	   by	   inactivating	   mutations	   of	   PTEN	   or	  
overactivity	  of	  PI3K	   (122,	  289).	  Active	  AKT	   in	   turn	  drives	  cell	   cycle	  progression	  by	   inhibiting	  p27	  
and	  prevents	  apoptosis	  by	  inhibiting	  BAD	  and	  enhances	  cell	  growth	  by	  activating	  mTOR	  pathway	  
(289).	   	   However,	   some	   interesting	   experiments	   have	   been	   made,	   which	   dissect	   the	   role	   of	  
PTEN/PI3K	  in	  polarity	  and	  cancer.	  Interestingly,	  malignant	  breast	  cancer	  T4-­‐2	  cells	  form	  in	  3D	  non-­‐
polar	  structures	  which	  do	  not	  exhibit	  growth	  arrest	  in	  3D	  typical	  to	  non-­‐malignant	  cells,	  and	  this	  
has	  been	   shown	   to	  be	  due	   to	  overactive	  PI3K	   signalling.	  However,	   the	  proliferation	   control	   and	  
polarity	   regulation	  downstream	  of	  PI3K	  was	   shown	   to	  be	   regulated	  by	  different	  pathways.	   PI3K	  
inhibitor	  mediated	  reversion	  of	  the	  malignant	  phenotype	  was	   inhibited	  differently	  by	  expression	  
dominant	  active	  RAC1	  (polarity)	  and	  dominant	  active	  AKT	  (proliferation)	  (290).	  RAC1	  link	  to	  PI3K	  is	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thought	   to	   be	   via	   integrin	   signalling	   since	   RAC1	   is	   involved	   in	   β1-­‐integrin	   signalling	   and	   PI3K	   is	  
associated	  also	  with	  β1-­‐integrin	  and	  Focal	  Adhesion	  Kinase	  (FAK)	  	  involved	  in	  integrin	  signalling	  (28,	  
29,	  291)).	  In	  line	  with	  the	  key	  role	  of	  these	  proteins	  downstream	  of	  PTEN/PI3K,	  it	  has	  been	  shown	  
that	  expression	  of	  constitutively	  AKT	  and	  RAC1	  is	  sufficient	  to	  convert	  high	  passage	  immortalized	  
non-­‐malignant	   mammary	   epithelial	   cells	   to	   malignant	   (292).	   Furthermore,	   PTEN	   knockdown	  
results	   in	   defective	   lumen	   morphogenesis	   via	   PIP2/CDC42	   mediated	   mechanism	   (117).	   As	  
PTEN/PI3K	  regulated	  AKT	  and	  GTPases	  are	  thought	  to	  exert	  different	  function	  downstream	  of	  the	  
regulatory	  pair,	  it	  has	  also	  been	  thought	  that	  there	  is	  distinction	  with	  reactions	  that	  depend	  on	  the	  
total	   level	   of	   these	   lipids	   (e.g.	   growth	   related)	   and	   reactions	   that	   depend	   on	   the	   defined	  
localization	  of	  the	  lipid	  (e.g.	  polarity)	  (122,	  293).	  It	  has	  been	  demonstrated	  that	  these	  functions	  are	  
mediated	  by	  different	  domains	  of	  the	  PTEN,	  as	  PDZ	  binding	  domain	   is	  needed	  for	   localization	  of	  
PTEN	   to	   junctions	  mediated	  by	  PAR3,	  which	   is	   further	  needed	   for	   establishment	  of	   cell	   polarity	  
(120,	   293).	   Therefore,	   it	   may	   play	   a	   functional	   role	   which	   part	   of	   PTEN	   protein	   is	   mutated	   in	  
cancers	  (293).	  
PTEN	   has	   also	   been	   shown	   to	   suffer	  mono	   and	   biallelic	  mutations	   and	   losses	   in	  wide	   range	   of	  
human	  cancers	  including	  brain,	  prostate	  and	  lung	  (289,	  294).	  Especially	  important	  PTEN	  seems	  to	  
be	  in	  endometrial	  cancers,	  as	  biallelic	  PTEN	  mutations	  have	  been	  observed	  in	  approximately	  50%	  
of	   the	  cases	   in	  some	  studies	   (289,	  295).	  As	   frequencies	   for	  monoallelic	  are	  often	  even	  higher	   in	  
certain	  cancers,	  PTEN	  has	  been	  shown	  to	  exhibit	  haploinsufficiency	  (289,	  296).	  Furthermore,	  the	  
importance	   of	   sufficient	   PTEN	   levels	   is	   underlined	   by	   the	   notions	   from	  mice	   that	   homozygotic	  
PTEN	  loss	  is	  embryonic	  lethal	  and	  heterozygous	  loss	  causes	  neoplasia	  in	  various	  tissues	  (297,	  298).	  
The	  counterplayer	  of	  the	  PTEN,	  PI3K,	  is	  also	  often	  observed	  to	  be	  mutated	  in	  cancers.	  The	  kinase	  is	  
comprised	  of	  the	  two	  subunits,	  regulatory	  subunit	  p85	  and	  catalytic	  subunit	  p110.	  Of	  these	  two,	  
the	   catalytic	   subunit	   p110α,	   encoded	   by	   PI3KCA,	   seems	   to	   suffer	   lots	   of	   potentially	   activating	  
mutations	  in	  several	  cancers	  including	  breast,	  lung,	  gastric,	  colon,	  brain	  and	  ovarian,	  consequently	  
driving	   the	  pathway	  activity	   (299),	   (289,	  300)	   in	   line	  with	   the	  observed	  amplifications	   in	  ovarian	  
cancer	  (301).	   Importantly,	  as	  the	  PI3K	  pathway	  is	  activated	  upstream	  by	  RAS	  and	  EGF-­‐receptors,	  
also	  their	  defects,	  which	  are	  often	  observed	  in	  cancers,	  can	  contribute	  to	  defective	  regulation	  of	  
this	   pathway	   (289,	   302).	   To	   conclude,	   it	  may	   prove	   to	   be	   interesting	  when	   future	   experiments	  
dissect	  the	  role	  of	  defective	  polarity	  due	  to	  deregulated	  PTEN/PI3K	  pathway	  in	  cancers.	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2.1.6.	  Hippo	  pathway	  in	  cancer	  	  
Although	   extensively	   characterized	   in	   Drosophila,	   the	   Hippo	   pathway	   has	   also	   been	   clearly	  
implicated	  in	  cancers	  of	  mammalian	  tissues.	  One	  of	  the	  regulatory	  proteins	  in	  the	  pathway,	  Merlin,	  
is	  known	  as	  neurofibromatosis	  2	  (NF2),	  and	  is	  an	  established	  tumour	  suppressor	  in	  human	  known	  
to	  cause	  neurofibromatosis	  type	  2	  in	  autosomal	  dominant	  fashion	  (303).	  Surprisingly,	  even	  though	  
NF2	   exhibits	   mutations	   in	   human	   cancers,	   other	   members	   of	   the	   Hippo	   pathway	   are	   more	  
commonly	   observed	   to	   be	   epigenetically	   silenced	   (304,	   305).	   For	   example,	   LATS1	   and	   LATS2	  
promoters	  were	  shown	  to	  be	  hypermethylated	  in	  over	  50%	  of	  studied	  breast	  cancer	  samples	  (306).	  
Similar	  observations	  have	  been	  made	  of	  MST1/2	  (307).	  	  Loss	  of	  MST1	  cytoplasmic	  expression	  was	  
found	  in	  colorectal	  cancer	  and	  the	  expression	  seems	  to	  decline	  with	  association	  to	  progression	  of	  
prostate	  cancer	  (308,	  309).	  Furthermore,	  the	  Hippo	  kinase	  cascade	  target	  YAP	  has	  been	  shown	  to	  
be	  amplified	  in	  mouse	  and	  mammary	  tumours	  and	  to	  be	  overexpressed	  and	  excessively	  nuclearly	  
localized	   in	   liver	   and	   prostate	   cancers	   (310,	   311).	   YAP	   overexpression	   also	   induces	   EMT	   (310).	  
Moreover,	   afore	   mentioned	   defects	   of	   LATS,	   MST	   and	   YAP	   have	   been	   associated	   with	   poor	  
prognosis	  in	  cancers.	  However,	  also	  contradicting	  results	  for	  oncogenic	  role	  of	  YAP	  exist	  in	  breast	  
cancer.	   The	   same	   chromosomal	   region	   (11q22),	   which	   includes	   YAP	   and	   was	   described	   to	   be	  
amplified	  above,	  has	  also	  been	  reported	  to	  be	  frequently	  lost	  in	  breast	  cancer	  (312).	  YAP	  was	  also	  
shown	   to	   possess	   tumour	   suppressive	   role	   in	   breast	   cancer	   possibly	   in	   part	   by	   influencing	   p73	  
mediated	  apoptosis	   (312,	  313).	  Clearly	   further	  research	   is	  needed	  to	  resolve	  these	  contradicting	  
results.	  Also	  the	  Drosophila	  Mats	  homologue	  MOBKL1A,	  which	  contributes	  to	  the	  kinase	  cascade	  
activity,	   has	   been	   shown	   been	   shown	   to	   suffer	   deletions	   in	   mouse	   mammary	   carcinoma	   and	  
human	  melanoma	  (314).	  Additionally,	  MOBKL1A	  downregulation	  has	  been	  observed	  in	  colorectal	  
cancer	  and	  lung	  cancers	  (315,	  316).	  Finally,	  Sav	  +/-­‐	  mice	  exhibit	  liver	  tumours	  but	  clinical	  evidence	  
for	  SAV	  contribution	  to	  cancer	  is	  lacking	  (305).	  	  
Even	   though	  Hippo	  pathway	   alterations	   are	   clearly	   implicated	   in	   various	   cancers,	  whether	   their	  
defective	  regulation	  is	  linked	  to	  polarity	  in	  cancers	  is	  not	  yet	  as	  well	  established.	  However,	  some	  
links	   exist.	   As	   previously	   described	   in	   Chapter	   1	   Section	   1.3.2.3.	   Hippo	   pathway,	   of	   the	   core	  
polarity	  regulators,	  especially	  CRUMBS	  complex	  seems	  to	  be	  linked	  to	  the	  regulation	  of	  the	  Hippo	  
pathway	   by	   regulating	   Ex	   in	  Drosophila	   and	   directly	   interacting	  with	   the	   pathway	   target	   YAP	   in	  
mammalian	  cells.	  Interestingly,	  the	  pathway	  component	  Merlin	  has	  also	  been	  linked	  to	  controlling	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cell	  density	  dependent	  cell	  growth	  in	  complex	  with	  transmembrane	  receptor	  CD44,	  and	  Merlin	  has	  
been	  shown	  to	  be	  needed	  for	  stable	  cadherin-­‐containing	  adherens	   junctions	   in	  various	  cell	   lines	  
and	  epithelial	  architecture	   in	  vivo	  (138,	  317,	  318).	  Moreover,	  Merlin	  has	  been	  shown	  to	  mediate	  
connection	  between	  PAR3	  and	  AJs	  during	  junctional	  formation	  which	  consequently	  is	  needed	  for	  
formation	   of	   functional	   AJs	   and	   TJs,	   and	   thereby	   plays	   a	   role	   in	   formation	   of	   epithelial	   polarity	  
(138).	  In	  conclusion,	  the	  Hippo	  pathway	  and	  the	  apico-­‐basal	  polarity	  machinery	  seem	  to	  be	  linked	  
through	   several	   mechanisms	   yet	   the	   contribution	   of	   defective	   polarity	   regulation	   via	   Hippo	  
pathway	  in	  cancers	  remains	  to	  be	  established.	  
2.1.7.	  Wnt	  pathway	  in	  cancer	  	  
The	  Wnt	  pathway	   is	   implied	  to	  be	  one	  of	  the	  most	  common	  pathways	  known	  to	  be	  activated	   in	  
cancers	   (319).	   Since	   Wnt	   pathway	   target	   genes	   include	   inducers	   of	   proliferation	   factors	   and	  
inhibitors	  of	  apoptosis,	  consequently	  overactivity	  can	  cause	  cancer	  (147).	  Therefore,	  I	  review	  here	  
the	   literature	  of	   the	  Wnt	  pathway	  members	   in	  cancer	   in	   the	  context	  of	  apico-­‐basal	  polarity	  and	  
shortly	  summarize	  Wnt	  pathway	  contribution	  to	  human	  cancer.	  
The	  target	  of	  the	  canonical	  Wnt	  pathway,	  β-­‐catenin,	  plays	  a	  dual	  role	  in	  the	  epithelium.	  It	  is	  linked	  
to	  the	  AJ	  molecular	  complex	  whereas	  it	  can	  also	  contribute	  to	  the	  transcriptional	  control	  as	  a	  part	  
of	   the	  Wnt	  pathway.	   It	  has	  been	  suggested	   that	   loss	  of	  AJs,	  which	   is	  often	  observed	   in	  cancers,	  
could	  release	  excessive	  amounts	  of	  β-­‐catenin	  and	  thereby	  cause	  unintended	  activity	  of	   the	  Wnt	  
pathway	  (145).	  Member	  of	  the	  β-­‐catenin	  destruction	  complex,	  APC,	  is	  especially	  known	  for	  its	  role	  
in	   colon	   cancers	   with	   specific	   implication	   in	   the	   familial	   cases.	   APC	   was	   first	   discovered	   to	   be	  
mutated	   at	   high	   frequency	   in	   cases	   of	   familial	   adenomatous	   polyposis	   (FAP),	   a	   form	   of	   colon	  
cancer	   (320).	   Patients	  with	   FAP	   also	   suffer	   from	   increased	   risks	   of	   developing	   cancers	   in	   other	  
tissues	  (321).	  Interestingly,	  considering	  the	  role	  in	  β-­‐catenin	  regulation,	  APC	  has	  also	  been	  shown	  
to	  associate	  with	  the	  AJs	  in	  Drosophila	  (322).	  Moreover,	  APC	  has	  also	  been	  observed	  to	  associate	  
basally	  with	  microtubules	  in	  addition	  to	  the	  association	  with	  microtubules	  in	  migrating	  cells	  (323).	  
As	  described	  earlier	  in	  Chapter	  1	  Section	  1.3.2.4.	  Wnt	  pathway,	  APC	  directly	  binds	  the	  basolateral	  
regulator	  DLG.	  In	  line	  with	  its	  tumour	  suppressor	  role,	  APC	  inhibits	  cell	  cycle	  progression,	  and	  this	  
cell	  cycle	  blocking	  effect	  has	  been	  shown	  to	  be	  in	  part	  contributed	  by	  the	  complex	  formation	  with	  
DLG	   (324).	   Since	   APC	   possesses	   PDZ-­‐binding	   domain,	   it	   may	   have	   additional	   contacts	   with	   the	  
polarity	  machinery	  as	  many	  of	  the	  core	  polarity	  proteins	  contain	  the	  PDZ-­‐domain	  (325).	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However,	  later	  APC	  has	  been	  found	  to	  mutated	  frequently	  also	  in	  sporadic	  colon	  cancers	  and	  also	  
sporadic	  cancers	  of	  other	  tissues	  such	  as	  breast	  and	  rarely	  in	  lung	  (320,	  326-­‐328).	  Also	  β-­‐catenin	  
has	   been	   shown	   to	   suffer	   mutations	   in	   a	   wide	   variety	   of	   cancers	   including	   hepatocellular	  
carcinoma,	  gastric,	  thyroid	  and	  ovarian	  cancers	  (321,	  329-­‐332).	  Certain	  mutations	  make	  β-­‐catenin	  
refractory	   to	   the	   destruction	   complex	   thereby	   forcing	   activation	   of	   the	   pathway	   (321,	   333).	  
However,	  in	  ovarian	  cancer,	  activating	  mutations	  and	  increased	  nuclear	  staining	  of	  β-­‐catenin	  have	  
been	  shown	  to	  be	  associated	  in	  some	  studies	  with	  less	  aggressive	  tumour	  and	  lower	  grade	  (334).	  
Interestingly,	   there	   seems	   to	   be	   exclusivity	   between	   APC	   and	   β-­‐catenin	   mutations	   (321,	   335).	  
Second	   member	   of	   the	   β-­‐catenin	   destruction	   complex,	   AXIN,	   has	   also	   been	   observed	   to	   have	  
mutations	   in	   many	   human	   cancers,	   including	   hepatocellular	   and	   colorectal	   carcinoma,	   thereby	  
sharing	  tumour	  suppressive	  role	  with	  APC	  (336-­‐338).	  Interestingly,	  only	  in	  recent	  years,	  the	  third	  
member	  of	  the	  destruction	  complex,	  GSK3β	  has	  been	  implicated	  in	  tumour	  suppression	  in	  human	  
cancers,	  of	  mainly	  head	  and	  neck	  and	  skin	  cancers	   (339,	  340).	  However,	   the	   tumour	  suppressor	  
role	   is	   still	  under	  debate	  due	   to	  contradicting	   results	  obtained	   in	  cancers	  of	  other	   tissues	   (339).	  
Additionally,	   as	   activating	   mutations	   of	   the	   receptor	   and	   co-­‐receptors	   of	   the	   Wnt	   pathway,	  
Frizzled	   and	   LRP5/LRP6	   respectively,	   should	   be	   oncogenic,	   no	   mutations	   in	   human	   cancers	   for	  
these	  proteins	  have	  been	  characterized	  (321,	  326).	  
Finally,	  as	  previously	  discussed	  for	  other	  pathways	  that	  demonstrate	  in	  some	  studies	  contradictory	  
results	   in	   contrast	   to	   their	   generally	   approved	   tumour	   suppressor/oncogenic	   role,	   also	   Wnt	  
pathway	   has	   been	   shown	   to	   be	   not	   purely	   oncogenic.	   As	   described	   above	   for	   the	   β-­‐catenin	  
localization	  in	  ovarian	  cancers,	  the	  same	  relationship	  has	  also	  been	  observed	  in	  medulloblastomas	  
(neural	   tumour),	  prostate	  cancer,	  and	  astonishingly	   in	   some	  cases	  of	   colorectal	   carcinoma	   (341-­‐
343).	   The	   role	   of	   the	   non-­‐canonical	  Wnt	   pathway	   in	   cancer	   is	   still	   unclear	   and	   not	   extensively	  
discussed	  in	  the	  context	  of	  cancer.	  However,	  it	  has	  been	  suggested	  to	  have	  a	  role	  in	  migration	  and	  
invasion	  as	  it	  functions	  in	  part	  through	  RHO	  GTPases	  and	  affects	  for	  example,	  planar	  cell	  polarity.	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3.	  Three	  dimensional	  (3D)-­‐cell	  culture	  method	  	  
For	  methodological	  purposes	  of	  this	  study,	  I	  briefly	  review	  the	  literature	  of	  3D-­‐cell	  culture	  method.	  
In	   vivo,	   cells	   are	   in	   three	   dimensional	   environment	   contacting	   ECM	   enriched	   with	   variety	   of	  
signalling	  molecules	  on	   the	  basal	   side,	  neighbouring	  cell	   in	   the	   lateral	   side	  and	   facing	   lumen	  on	  
their	  apical	  side.	  Sometimes	  cells	  can	  even	  contact	  other	  cells	  with	  all	  of	  their	  available	  surfaces	  as	  
in	   stratified	   epithelium.	   This	   differs	   significantly	   from	   the	   environment	   that	   cells	   face	   on	   a	  
traditional	   plastic	   cell	   culture	   dish.	  On	   a	   dish	   cells	   are	   arranged	   in	   two	   dimensions	   and	   contact	  
plastic,	   which	   is	   not	   a	   natural	   substrate	   for	   them.	   As	   a	   consequence	   of	   cells	   being	   not	   able	   to	  
contact	  ECM,	  cells	   fail	   to	  organize	  with	  each	  other	  as	   in	  vivo	  and	  fail	   to	  subsequently	  polarize	   in	  
apico-­‐basal	  manner.	  As	  described	  in	  Chapter	  1,	  this	  is	  important	  for	  the	  functional	  differentiation	  
of	   epithelial	   cells,	   such	   as	   mammary	   epithelium	   (344,	   345).	   However,	   modelling	   the	   tissue	  
structure	   in	   vivo	   is	   financially	   more	   challenging	   and	   does	   not	   allow	   the	   same	   extend	   of	  
manipulation	  and	  is	  not	  feasible	  for	  high-­‐throughput	  experiments.	  For	  these	  reasons	  methods	  for	  
3D-­‐cell	   culture	  have	  been	  developed	  enabling	  more	   in	  vivo-­‐like	  surrounding	   than	   traditional	  cell	  
culture.	  	  
In	  3D-­‐cell	  culture	  cells	  are	  embedded	   in	  a	  matrix	   rich	   in	  ECM	  components.	  The	  choice	  of	  matrix	  
depends	  on	  the	  cell	  type	  as	  some	  cell	  types	  are	  not	  able	  to	  grow	  on	  certain	  matrixes.	  One	  of	  the	  
most	  used	  matrixes	  commercially	  available	  is	  Matrigel™,	  which	  is	  derived	  from	  mouse	  Engelbreth-­‐
Holm-­‐Swarm	  (EHS)	  tumours	   (345).	  The	  MCF10A	  mammary	  epithelial	  cell	   line,	  used	   in	  this	  study,	  
forms	   acinar	   structures	   on	   this	   matrix	   which	   exhibit	   apico-­‐basal	   polarization	   and	   form	   hollow	  
lumens	   via	   apoptosis.	   Thus	   the	   structures	   recapitulate	   the	   organization	   and	  many	   aspects	   of	   in	  
vivo	  mammary	  acini.	  Importantly,	  in	  3D	  mammary	  epithelial	  acini	  become	  growth-­‐arrested	  after	  a	  
certain	  growth	  period	  –	  a	  feature	  not	  observed	  in	  2D	  (345-­‐347).	  During	  the	  last	  10	  to	  20	  years,	  3D	  
method	  has	  shown	  its	  profitability	  in	  various	  experiments,	  and	  has	  demonstrated	  results,	  in	  which	  
the	   key	   features	   and	   regulation	   of	   pathways	   are	   dependent	   on	   the	   3D	   context	   and	   apico-­‐basal	  
organization	   and	   not	   observed	   in	   2D	   (82,	   163,	   290).	   Combination	   of	   this	  method	  with	  modern	  
RNAi	  and	  drug/small	  molecule	   inhibitor	  methods	  has	  uncovered	  great	  amount	  of	   information	   in	  
cell	  and	  cancer	  biology.	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4.	  AIMS	  OF	  THE	  STUDY	  	  	  
i.	  Screen	  for	  the	  human	  epithelial	  architecture	  regulating	  genes	  by	  knocking	  down	  human	  
homologues	  of	  known	  Drosophila	  polarity	  associated	  genes	  
	  
ii.	  Identification	  of	  human	  epithelial	  architecture	  regulating	  genes	  with	  putative	  tumour	  
suppressor	  functions	  by	  using	  conditional	  MYC	  activation	  
	  
iii.	  Characterization	  of	  synthetic	  lethal	  phenotype	  caused	  by	  Rho	  GTPase	  RhoA	  knockdown	  and	  
MYC	  activation	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5.	  MATERIALS	  AND	  METHODS	  	  
Cell	  culture	  
MCF10A	  cells	  were	  obtained	  from	  ATCC,	  and	  cells	  were	  maintained	  in	  5	  %	  humidified	  atmosphere	  
at	   temperature	   of	   +37°C.	   The	   cells	   have	   been	   previously	   retrovirally	   infected	   with	  
pBabepuroMycERtm	   construct	   (82).	   The	   cells	   were	   cultured	   in	   human	   mammary	   epithelial	   cell	  
basal	   growth	   media	   MCDB	   170	   (US	   Biological)	   supplemented	   with	   70	   μg/ml	   bovine	   pituitary	  
extract,	   5	   μg/ml	   insulin,	   0.5	   μg/ml	   hydrocortisone,	   5	   ng/ml	   epidermal	   growth	   factor,	   5	   μg/ml	  
transferrin,	  0,01	  μM	  isoproterenol	  (all	  from	  Sigma),	  and	  antibiotics	  (50	  μg/ml	  amphotericin	  B	  and	  
50	   μg/ml	   gentamicin	   (both	   from	   Sigma).	   MCF10A-­‐MycERtm	   cells	   were	   trypsinized	   with	   0,05	   %	  
Trypsin	   EDTA	   (Gibco)	   and	   cultured	   on	   cell	   culture	   plates	   (Greiner).	   In	   both	   2D	   and	   3D	   culture	  
experiments	   100	   nM	   4-­‐OHT	   (Sigma;	   diluted	   from	   1	  mM	   stock)	   was	   used	   to	   activate	  MycERtm..	  
Absolute	  ethanol	  was	  used	  as	  carrier	  control.	  For	  selection	  of	  pDSL	  constructs,	  hygromycin	  (Sigma)	  
concentration	  of	  0,2	  mg/ml	  was	  used.	  	  
293FT	   cells	   were	   obtained	   from	   Invitrogen	   and	   cultured	   in	   Dulbecco’s	   modified	   eagle	   medium	  
(DMEM)	  (Lonza)	  supplemented	  with	  10	  %	  FCS	  (PromoCell	  or	  Biowest),	  2	  mM	  L-­‐Glutamine	  (Lonza),	  
1	  %	  Penisilline-­‐Streptomycine	  (Lonza)	  and	  culture	  on	  cell	  culture	  plates	  (Greiner).	  293FT	  cells	  were	  
trypsinized	   with	   0,05	   %	   Trypsin	   (house	   made,	   recipe	   from	   HUSLAB,	   Helsinki).	   Cells	   were	  
maintained	  in	  5	  %	  humidified	  atmosphere	  at	  temperature	  of	  +37°C.	  
3D	  organotypic	  cell	  culture	  	  
Basement	  membrane	  from	  Engelbreth-­‐Holm-­‐Swarm	  mouse	  sarcoma	  (Matrigel™,	  Becton	  Dickinson	  
(BD))	  was	  prepared	  as	  follows:	  Matrigel™	  was	  thawed	  overnight	  in	  +4°C	  on	  ice.	  The	  eight-­‐chamber	  
slides	  (Nunc),	  pipets	  and	  pipet	  tips	  were	  precooled	  in	  	  +4°C	  for	  at	   least	  one	  hour	  before	  starting	  
the	  experiment	  and	  31	  μl	  of	  Matrigel™	  was	  applied	   to	  each	  well	   in	  +4°C.	  Matrigel-­‐coated	  slides	  
were	  placed	  to	  +37°C	  for	  20-­‐30	  min	  in	  order	  to	  solidify	  Matrigel™.	  Confluent	  MCF10A	  cells	  were	  
trypsinized	  and	  1500	  cells	  per	  well	  were	  seeded	  on	  eight-­‐chamber	  slides	  coated	  with	  Matrigel™.	  
Media	  was	  refreshed	  every	  fourth	  day.	  
Egg	  white	  cultures:	  50	  μl	  of	  egg	  white	  was	  spread	  on	  each	  well	  on	  eight-­‐chamber	  slides	  in	  RT	  and	  
the	   egg	  white	  was	   solidified	   in	   +60°C	   for	   45	  min	   after	  which	   the	   cells	  were	   seeded	   similarly	   to	  
Matrigel	  cultures.	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Viral	  producuction	  and	  lentiviral	  infections	  
293FT	   cells	  were	   seeded	   200	  000	   cells/well	   on	   24-­‐well	   plate	   in	   1ml	   of	   DMEM	  media.	   Next	   day	  
0,5ml	  of	  fresh	  media	  was	  changed	  for	  the	  cells.	  Three	  component	  plasmid	  system	  was	  mixed	  with	  
[transfer	   plasmid	   :	   Delta	   8.9	   :	   CMV	   –	   4:3:2	   (wt)]	   25ul	   150mM	   NaCl	   (Sigma).	   1ul	   of	   JetPEI	  
transfection	  reagent	  (Polyplus	  Transfection)	  was	  mixed	  with	  25ul	  of	  150mM	  NaCL.	  The	  mixes	  were	  
incubated	  in	  room	  temperature	  for	  5	  minutes	  after	  which	  they	  were	  combined.	  The	  combined	  mix	  
was	   incubated	   in	  room	  temperature	  for	  20	  minutes	  after	  which	   it	  was	  added	  to	  cells	  drop	  wise.	  
The	  transfected	  cells	  were	  incubated	  in	  +37°C	  celsius	  and	  5	  %	  CO2	  for	  4	  hours	  after	  which	  0,5	  ml	  of	  
media	   was	   added.	   Viruses	   were	   harvested	   after	   72	   hours	   after	   by	   filtering	   the	   media	   through	  
0,41μm	  filter.	  For	  6-­‐well	  protocol	  the	  corresponding	  amounts	  were:	  293FT	  1	  million	  cells,	  100μl	  of	  
NaCl	  and	  6μl	  of	  JetPEI.	  
One	  day	  before	  the	  infection	  MCF10A	  MycER	  cells	  were	  seeded	  40	  000	  cells	  /well	  in	  1ml	  of	  MCDB	  
media	  with	   supplements.	   The	  media	  was	   aspirated	   and	   the	  harvested	   virus	   applied	   to	   the	   cells	  
with	  8μg/ul	  of	  polybrene	  (Sigma).	  The	  plate	  was	  sentrifuged	  for	  30	  min	   in	  2500	  rpm	  after	  which	  
the	  cells	  were	  incubated	  in	  the	  incubator	  for	  5	  hours.	  1ml	  of	  fresh	  MCDB	  media	  was	  changed	  and	  
the	   infected	   cells	   were	   incubated	   for	   72	   hours.	   For	   6-­‐well	   protocol	   corresponding	   amounts:	  
MCF10A	  MycER	  cells	  500	  000	  cells/well.	  
The	   shRNAs	   are	   in	   pGIPZ	   (Open	   Biosystems:	  




Antisense	  shRNA	  sequences	  (in	  5’-­‐3’	  order):	  
DVL3-­‐A:	   TGTAGTGGTGGCTAGAAGC,	   DVL3-­‐B:	   GATTCAAGCGATTCTTGTG,	   FAT4:	  
TCTGTCTTTGGAAATGAGC,	   GSK3β:	   GAAACATTGGGTTCTCCTC,	   MOBKL1A-­‐A:	  	  
TTATTCTTCCATTACTTGG,	  MOBKL1A-­‐B:	  CTTATTCTTCCATTACTTG,	  RhoA:	  ATCTGTTACGGAGTAAAGC.	  
Lkb1	   shRNA	   and	   pDSL	   shControl	   described	   in	   (82).	   Non-­‐targeting	   shControl	   pGIPZ	   (Open	  
Biosystems).	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Cell	  lysates	  and	  Western	  Blot	  Analysis	  
Before	  lysis	  cells	  were	  washed	  once	  with	  PBS	  [Phosphate	  buffered	  saline:	  8	  mM	  Na2HP04,	  1	  mM	  
KH2PO4,	  3	  mM	  KCl	  (all	  Riedel-­‐de-­‐häen),	  137	  mM	  NaCl,	  pH	  7.4].	  Cells	  in	  2D	  were	  lysed	  in	  ELB	  lysis	  
buffer	   [150	   mM	   NaCl,	   50mM	   HEPES	   (pH	   7,4)	   (Sigma),	   5	   mM	   EDTA	   (Sigma),	   1%	   Nonidet	   P-­‐40	  
(Fluka)]	  supplemented	  with	  protease	  inhibitor	  cocktail	  (complete	  mini-­‐EDTA	  free,	  Roche].	  The	  cells	  
were	  scraped	  and	  collected	  to	  an	  eppendorf	  tube.	  The	   lysate	  was	   incubated	  10	  min	  on	   ice	  after	  
which	  it	  was	  sentrifuged	  for	  15	  min	  with	  13	  000	  rpm	  in	  +4	  ̊C.	  The	  supernatant	  was	  transferred	  to	  a	  
new	   tube	   and	   the	   protein	   concentration	   was	   measured	   (BioRad	   DCtm	   Protein	   assay,	   Multiskan	  
Ascent	   (Thermo)	   by	   using	   the	   Ascent	   software).	   Samples	   were	   denaturated	   with	   5×	   Laemmli	  
sample	  buffer	   [40%	  glycerol	   (HUSLAB),	   345	  mM	  SDS	   (Serva),	   bromphenol	  blue	   (Sigma),	   20	  %	  β-­‐
mercaptoethanol,	  (Sigma),	  0,4	  M	  Tris-­‐HCl	  (pH6.9)	  (HUSLAB)]	   in	  +90°C	  for	  2	  min.	  10μg	  or	  20μg	  of	  
protein	  of	  each	  sample	  was	  used	  for	  analysis.	  The	  samples	  were	  analysed	  in	  10	  or	  12	  %	  SDS-­‐PAGE-­‐
gels.	  
Next,	  proteins	  were	  transferred	  onto	  a	  nitrocellulose	  membrane	  (Protran,	  Schleicher	  &	  Schuell)	  in	  
semidry	  transfer	  buffer	  [25	  mM	  Tris-­‐HCl,	  192	  mM	  glycine	  (Fluka),	  20	  %	  methanol	  (Berk),	  pH	  8.3]	  by	  
Trans-­‐Blot	   semi-­‐dry	   transfer	   blotter	   (Bio-­‐Rad	   Laboratories).	   Thereafter	   proteins	   were	   visualized	  
with	  Ponceau	  S	   (Sigma)	  after	  which	   the	   filter	  was	  washed	  with	  TBS	   to	  be	  cleaned	  of	  Ponceau	  S	  
(TBS,	  Tris	  buffered	  saline:	  0,5	  M	  NaCl,	  10	  mM	  Tris-­‐HCl,	  pH	  7,5).	  The	  membrane	  was	  blocked	   for	  
non-­‐specific	   binding	  with	   blocking	   solution	   containing	   [TBS	   containing	   5	  %	  milk	   powder	   (Valio),	  
0,1	  %	  BSA	  (MP	  Biomedicals)	  and	  0,05	  %	  Tween-­‐20	  (Sigma)]	  for	  1	  hour	  at	  RT.	  The	  primary	  antibody	  
was	   applied	   and	   the	   filter	   was	   incubated	   with	   primary	   antibody	   overnight	   in	   +4°C	   in	   rocker	  
(diluted	   into	   blocking	   solution,	   dilution	   depending	   on	   antibody	   1:500-­‐1:2500).	   The	   filter	   was	  
washed	   1x15min	   and	   3x5min	   in	   0,05	  %	   Tween-­‐20-­‐TBS	   after	  which	   the	   secondary	   antibody	  was	  
applied	  for	  1-­‐1,5h	   in	  RT	   in	  rocker	  (diluted	  into	  blocking	  solution,	  dilution	  depending	  on	  antibody	  
and	  protein	   amount,	   1:1000-­‐1:4000).	   The	   secondary	   antibody	  was	  washed	   similarly	   as	  with	   the	  
primary	   antibody.	   The	   filter	  was	   incubated	   in	   ECL	   detection	   solution	   (Super	   Signal	  West	   Femto	  
Maximum	  Sensitivity	  Substrate,	  Thermo)	  for	  5	  min	  and	  exposed	  onto	  X-­‐rayfilm	  (Fujifilm).	  
RT-­‐qPCR	  
RNA	  was	  extracted	  by	  using	  Qiagen	  RNeasy	  Mini	  Kit	  according	  to	  the	  manufacturer’s	  instructions.	  
The	  concentration	  and	  purity	  of	   the	  RNA	  was	  quantified	  with	  Nanodrop	  8000	   spectrofotometer	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(Thermo).	   cDNA	  synthesis	  was	  done	  by	  using	  either	  DyNAmo	  cDNA	  synthesis	   kit	   (Finnzymes)	  or	  
VILO	  cDNA	  synthesis	  kit	   (Invitrogen).	  The	  qPCR	  reaction	  was	  performed	  using	  Roche	  Light	  Cycler	  
480	   I	   Green	   Master	   Mix	   (Roche)	   and	   Roche	   Light	   Cycler	   480	   I	   qPCR	   system.	   Relative	   mRNA	  
amounts	  of	  the	  hEAL	  genes	  were	  assayed	  by	  comparing	  PCR	  cycles	  with	  β-­‐actin	  and	  normalizing	  
the	  samples	  to	  non-­‐targeting	  shControl	  levels.	  	  
TABLE	  1	  Primer	  sequences	  	  
	  
Immunofluorescence	  staining	  of	  3D	  and	  2D	  grown	  cells	  
3D	  cultures	  were	  washed	  twice	  with	  PBS	  and	  fixed	  for	  20	  min	  with	  2%	  (wt/vol)	  paraformaldehyde	  
(Sigma)	   in	   RT	   and	   washed	   again	   twice	   with	   PBS.	   Epithelial	   structures	   were	   permeabilized	   with	  
0,25%	  Triton	  X-­‐100	  (Sigma)	  in	  PBS	  for	  10	  min	  at	  RT	  and	  then	  washed	  with	  PBS.	  The	  structures	  were	  
blocked	  in	  blocking	  solution	  containing	  IF	  buffer	  [7.7	  mM	  NaN3	  (Riedel-­‐de-­‐Häen),	  0,1%	  BSA,	  0,2%	  
Triton	  X-­‐100,	  and	  0.05%	  Tween-­‐20	   in	  PBS]	   supplemented	  with	  10%	   (vol/vol)	  normal	  goat	   serum	  
(Gibco)	  for	  1–1.5	  h.	  The	  primary	  antibody	  was	  diluted	  into	  in	  the	  blocking	  solution	  and	  incubated	  
overnight	  at	  4°C.	  Following	  incubation,	  structures	  were	  washed	  three	  times	  with	  IF	  buffer	  (15	  min	  
each	   wash)	   and	   then	   incubated	   with	   appropriate	   Alexa	   Fluor	   secondary	   antibody	   diluted	   into	  
blocking	  solution.	  After	  40–50	  min	  of	  incubation	  in	  dark	  at	  RT,	  the	  structures	  were	  washed	  with	  IF	  
buffer	  as	  before	  and	  the	  nuclei	  were	  counterstained	  with	  Hoechst	  33258	  (Sigma).	  Slides	  containing	  
immunostained	  acinar	  structures	  were	  mounted	  with	  Immu-­‐Mount	  reagent	  (Thermo).	  
Cells	   grown	   on	   coverslips	   were	   washed	   twice	   with	   PBS	   and	   fixed	   with	   4	   %	   (wt/vol)	  
paraformaldehyde	  for	  15	  min	  in	  RT	  after	  which	  the	  cells	  were	  washed	  with	  PBS	  three	  times	  (5	  min	  
each	  wash).	  Next,	  the	  cells	  were	  permeabilized	  with	  0,1	  %	  Triton-­‐PBS	  for	  10	  min	  and	  washed	  with	  
once	  with	  PBS.	  Non-­‐specific	  binding	  was	  blocked	  with	  blocking	  solution	  [0,1	  %	  BSA-­‐PBS	  (wt/vol)]	  
for	  30	  min	  in	  RT	  and	  thereafter	  washed	  once	  with	  PBS.	  Primary	  antibody	  was	  diluted	  in	  blocking	  
solution	  and	  applied	  to	  the	  cells	  for	  60	  min	  in	  RT	  after	  which	  it	  was	  washed	  three	  times	  with	  PBS	  
(5	  min	  each	  wash).	  Appropriate	  Alexa	  Fluor	  secondary	  antibody	  was	  diluted	   in	  blocking	  solution	  
and	  applied	  to	  the	  cells	  for	  45	  min	  in	  dark	  at	  RT.	  Secondary	  antibody	  was	  washed	  three	  times	  with	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PBS	  of	  which	  the	  second	  wash	  supplemented	  with	  Hoechst	  33258	  (Sigma)	  for	  counterstaining	  the	  
nuclei.	  The	  coverslips	  were	  mounted	  with	  Immu-­‐Mount	  reagent.	  
Confocal	  imaging	  
Images	  of	  the	  acini	  were	  acquired	  with	  a	  Zeiss	  LSM	  Meta	  510	  confocal	  microscope	  equipped	  with	  
argon	   (488),	   helium-­‐neon	   (543	   and	   633),	   and	   diode	   (405)	   lasers.	   The	   objective	   used	   was	   Plan-­‐
Neofluar	  40x	  DIC	  objective	  (NA	  =	  1.3,	  oil).	  
Ki-­‐67	  and	  Active	  Caspase	  3	  quantification	  
The	   proliferation	   and	   apoptosis	   were	   quantified	   by	   counting	   the	   positive	   cells	   for	   Ki-­‐67/active	  
caspase	  3	  immunostaining	  in	  2D	  or	  3D	  acini.	  Zeiss	  Axioplan	  2	  upright	  epifluorescence	  microscope	  
with	  20x	  objective	  (NA=0,5/0,3,	  air)	  in	  the	  facilities	  of	  Biomedicum	  Imaging	  Unit	  and	  Zeiss	  Axiovert	  
200	   inverted	   microscope	   with	   Plan-­‐Apochromat	   20x	   objective	   (NA=0,8,	   air),	   provided	   by	   the	  
Department	  of	  Biochemistry	  and	  Developmenteal	  Biology.	  were	  used	  for	  the	  quantification.	  
Morphology	  analysis	  
Morphology	   analysis	   was	   performed	   with	   ImageJ	   software	   (NIH,	   http://rsbweb.nih.gov/ij/)	   of	  
pictures	   taken	  with	   Zeiss	  Axiovert	   200	   inverted	  microscope	   combined	  with	  ApoTome	  unit	   using	  
20x	   objective	   (NA=0,8,	   air).	   Pictures	   were	   taken	   of	   acini	   stained	   with	   β-­‐catenin	   antibody	   and	  
Hoecst.	   Images	  were	  converted	  to	  16-­‐bit	  black-­‐and-­‐white	  pictures	  in	  Image	  J	  and	  thresholded	  to	  
the	   level	   in	  which	  black	  areas	  corresponded	  acini	   in	  the	  original	  pictures.	  To	  quantify	  changes	   in	  
the	  acinar	  morphology,	  area,	  perimeter	  and	  shape	  descriptors	  were	  selected	  of	  the	  measurement	  
parameters	  and	  minimum	  of	  20	  acini	  were	  analysed	  in	  every	  treatment.	  
Inhibitor	  assay	  
3D	  
Cells	  were	   seeded	   on	   eight-­‐chamber	   slides	   (as	   in	   3D	   organotypic	   cell	   culture).	  On	   the	   next	   day	  
inhibitors	  in	  combination	  with	  4-­‐OHT	  or	  absolute	  ethanol	  were	  added	  to	  cells	  in	  concentrations	  of	  
U0126	  500	  nM	   (Promega),	  ML-­‐7	  2,5	  μM	   (Calbiochem)	  and	  Y-­‐27632	  50	  μM	   (Calbiochem).	  DMSO	  
(Sigma)	  was	  used	  for	  carrier	  control	  for	  U0126	  and	  ML-­‐7.	  H2O	  was	  used	  for	  Y-­‐27632.	  Treatments	  
were	   repeated	   as	   media	   was	   changed.	   On	   the	   fifth	   day,	   cells	   were	   fixed	   after	   which	   their	  
morphology	  was	  analyzed	  and	  imaged.	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FACS	  
MCF10A	  cells	  were	  infected	  with	  pGIPZ	  shRhoA.	  Confluent	  cells	  were	  trypsinized	  and	  collected	  by	  
centrifugation.	  The	  cells	  were	  resuspended	  in	  5ml	  of	  media	  and	  top	  15	  %	  GFP-­‐intensity	  cells	  were	  
selected	  with	  FACS	  Aria	  (BD)	  provided	  by	  the	  Biomedicum	  FACS	  Core	  facility.	  Confluent	  15cm	  cell	  
culture	  plate	  yielded	  approximately	  2	  million	  cells.	  	  
Validation	  of	  downregulation	  
Downregulation	   was	   validated	   by	  Western	   blotting	   or	   qRT-­‐PCR	   from	   cells	   which	   were	   cultured	  
until	   tested	   to	   be	   Replication	   Competent	   Virus-­‐negative	   (RCV).	   Cells	   containing	   pDSL	   based	  
construct	  were	  selected	  with	  hygromycin.	  The	  RCV-­‐test	  was	  provided	  by	  the	  Functional	  Genomics	  
Unit.	  In	  the	  primary	  screen,	  25	  %	  downregulation	  in	  RT-­‐qPCR	  was	  considered	  significant.	  
Statistical	  analysis	  
Statistical	  analysis	  were	  performed	  as	   indicated	   in	  the	  figures	  and	  text	  by	  using	  GraphPad	  Quick	  



















	  	  	  
Antibody Clone/Catalogue	  numberSpecies Source MW	  (kDa) Application
α-­‐β-­‐tubulin ab6046 Rabbit/polyclonal Abcam 50-­‐55 WB
α-­‐Gsk3α/β 1H8/368662 Mouse/monoclonal Calbiochem 51/47 WB
α-­‐MLC 3672 Rabbit/polyclonal Cell	  signaling 18 WB
α-­‐pMCL 3675 Mouse/monoclonal Cell	  signaling 18 WB
α-­‐MYPT 2634 Rabbit/polyclonal Cell	  signaling 140 WB
α-­‐pMYPT 5163 Rabbit/polyclonal Cell	  signaling 140 WB
α-­‐RhoA ab54835 Mouse/monoclonal Abcam 22 WB
α-­‐RhoA 67B9/2117 Rabbit/monoclonal Cell	  signaling 21 WB
α-­‐ROCK1 EP786Y/ab45171 Rabbit/polyclonal Abcam 158 WB
p44/42	  MAPK 9102 Rabbit/polyclonal Cell	  signaling 42,	  44 WB
p-­‐p44/42	  MAPK 197G2/4377 Rabbit/monoclonal Cell	  signaling 42,	  44 WB
α-­‐Cleaved	  Caspase	  3 5A1E/9664 Rabbit/monoclonal Cell	  signaling 12,17 IF
α-­‐α-­‐6integrin 4F10/CBL458 Mouse/monoclonal Millipore 127 IF
α-­‐β-­‐catenin 14/610153 Mouse/monoclonal BD 92 IF
α-­‐GM130 35/610823 Mouse/monoclonal BD 130 IF




AP132P Monoclonal Millipore WB	  (secondary
Alexa	  Fluor
α-­‐mouse	  488 A11001 Goat Invitrogen IF	  (secondary)
α-­‐rabbit	  488 A11008 Goat Invitrogen IF	  (secondary)
α-­‐mouse	  546 A11003 Goat Invitrogen IF	  (secondary)
α-­‐rabbit	  546 A11010 Goat Invitrogen IF	  (secondary)
α-­‐mouse	  647 A21235 Goat Invitrogen IF	  (secondary)
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6.	  RESULTS	  	  
We	  have	  previously	   established	   a	   lentiviral	   shRNA	   library	   (human	  epithelial	   architecture	   library,	  
hEAL)	  by	  designing	  oligos	  with	  in-­‐house	  developed	  algorithm,	  and	  by	  cloning	  them	  into	  lentiviral	  
backbone	  vectors	  (Partanen,	  Myllynen	  et	  al.	  in	  preparation)	  (Fig.	  4).	  The	  library	  consists	  of	  shRNAs	  
targeting	  human	  homologues	  of	  the	  genes	  involved	  in	  several	  pathways	  associated	  with	  epithelial	  
polarity	   in	   Drosophila	   e.g.	   core	   polarity	   complexes,	   Hippo	   pathway,	   Wnt	   pathway	   and	   RHO	  
GTPases.	   The	   efficiency	   of	   the	   oligos	   to	   downregulate	   their	   target	   was	   initially	   validated	   in	  
collaboration	  between	  core	  unit	  Functional	  Genomics	  Unit	  (formerly	  Biomedicum	  Genomics)	  and	  
our	   laboratory	   by	   real	   time	  quantitative	   PCR	   (RT-­‐qPCR)	   and	  Western	  Blotting	   (for	   proteins	  with	  
antibody	   available).	   Of	   the	   219	   designed	   shRNA	   constructs	   against	   77	   genes,	   52	   were	   initially	  
shown	   to	   downregulate	   their	   target	   (targeting	   34	   different	   genes).	   With	   the	   validated	   shRNA	  
constructs,	  an	  initial	  3D	  cell	  culture	  morphology	  screen	  was	  performed	  (Fig.	  4).	  In	  the	  screen	  25/52	  
of	  the	  functional	  shRNAs	  resulted	   in	  morphological	  phenotype.	  Thereafter,	  the	  phenotypes	  have	  
been	   validated	   by	   further	   rounds	   of	   experiments.	   Validation	   and	   characterization	   of	   defined	  
subset	   (pDSL	   n=6,	   pGIPZ	   n=1)	   of	   the	   phenotypes	   found	   in	   the	   primary	   screen	   comprise	   the	  
experimental	  part	  of	  this	  study	  (Fig.	  4).	  	  
	  
Figure	   4	  Workflow	  of	   the	   hEAL	   project.	   Steps	   shown	   in	   blue	   have	   been	   completed	   previously,	  whereas	   phases	   shown	   in	   orange	   constitute	   the	  
validation	  phase	  of	  the	  project	  and	  experimental	  part	  of	  this	  study.	  
The	   subset	   of	   shRNAs	   used	   in	   this	   study	   consists	   of	   two	   constructs	   against	   DVL3	   (Dishevelled	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against	   GSK3β	   	   (all	   in	   pDSL)	   and	   one	   pGIPZ	   construct	   against	   RHOA.	   Additionally,	   as	   positive	  
control,	  an	  shRNA	  against	  LKB1	  was	  used	  as	  we	  have	  previously	   shown	  LKB1	   to	  affect	  epithelial	  
architecture	   and	   that	   its	   inactivation	   enables	   growth-­‐arrested	   acini	   to	   re-­‐enter	   cell	   cycle	   when	  
MYC	  is	  activated	  thus	  proposing	  tumour	  suppressive	  role	  for	  intact	  epithelial	  architecture	  (82).	  	  
6.1.	  Re-­‐validation	  of	  the	  downregulation	  	  
First,	   as	   the	   subset	   shRNAs	   described	   above	   were	   identified	   to	   cause	   a	   change	   in	   acinar	   size,	  
perimeter	   and/or	   symmetry	   in	   the	  primary	   screen	   the	  downregulation	   and	  phenotype	  were	   re-­‐
validated.	  All	  6/6	  of	  the	  pDSL	  shRNAs	  showed	  downregulation	  in	  the	  re-­‐validation	  assayed	  by	  RT-­‐
qPCR	   or	   Western	   Blotting	   (Fig.	   5).	   DVL3	   shRNA	   resulted	   in	   60	   %	   (DVL3-­‐A)	   and	   58	   %	   (DVL3-­‐B)	  
downregulation	   in	   the	   DVL3	  mRNA	   level,	   whereas	   shRNAs	   against	  MOBKL1A	  were	   observed	   to	  
downregulate	   MOBKL1A	   mRNA	   by	   35	   %	   (MOBKL1A-­‐A)	   and	   25	   %	   (MOBKL1A-­‐B)	   (Fig	   5).	   With	  
western	  blotting,	  a	  significant	  reduction	  in	  the	  GSK3β	  protein	  level	  was	  detected	  (Fig	  5).	  Yet,	  the	  
downregulation	   levels	   observed	   were	   lower	   compared	   to	   the	   primary	   validation	   (25	   %	  
downregulation	  considered	  to	  be	  significant	   in	  primary	  validation,	  data	  not	  shown),	  which	  could	  
reflect	  possible	  role	  of	  counterselection	  in	  the	  infected	  cells.	  	  
	  
Figure	  5	  Western	  Blot	  and	  qRT-­‐PCR	  analysis	  showing	  downregulation	  of	  target	  genes	  by	  hEAL	  shRNAs.	  GSK3β	  (48	  kDa)	  corresponds	  to	  the	   lower	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6.2.	  Acinar	  morphology	  validation	  	  
After	   validation	   of	   the	   constructs,	   3D-­‐cell	   culture	   experiments	   were	   carried	   out	   to	   determine	  
whether	  knockdown	  of	  the	  genes	  affects	  acinar	  morphology	  in	  MCF10A	  cells.	  In	  addition,	  effect	  of	  
the	  activated	  MYC	  oncogene	  was	  tested	  by	  chronic	  and	  acute	  activation	  of	  the	  MycERtm	  construct	  
which	  can	  be	  activated	  with	  4-­‐OHT	  (Fig	  4).	  In	  the	  experiments	  cells	  were	  applied	  on	  reconstituted	  
basement	   membrane	   (Matrigel™	   or	   egg	   white)	   after	   which	   cell	   were	   grown	   for	   10	   days.	  
Alternatively,	   MYC	   was	   activated	   with	   4-­‐OHT	   on	   day	   1	   (chronic	   activation)	   for	   the	   rest	   of	   the	  
experiment.	   After	   10	   days,	   acini	   were	   immunostained	   and	   imaged.	   The	   acini	   with	   β-­‐catenin	  
immunostaining	   were	   analysed	   with	   ImageJ	   by	   quantifying	   the	   acinar	   size,	   perimeter	   and	  
circularity.	   The	   shRNAs	   causing	   significant	   changes	   in	   any	   of	   these	   paremeters	   (threshold:	   fold	  
change	  0,2	  for	  size	  and	  perimeter	  and	  0,1	  for	  circularity)	  were	  selected	  for	  re-­‐validation.	  
Quantification	   of	   the	   effects	   of	   the	   shRNAs	   on	   the	   morphology	   parameters,	   showed	   that	  
knockdown	   of	   3/6	   of	   the	   hEAL	   genes	   caused	   increase	   in	   the	   size	   of	   the	   acini	   (Fig.	   6).	   Most	  
significantly,	  the	  knockdown	  of	  DVL3	  with	  two	  different	  shRNAs	  caused	  a	  dramatic	  increase	  in	  the	  
size	   compared	   to	   control	   (fold	   change	   (FC):	   shDVL3-­‐A	  3,11	   ;	   shDVL3-­‐B	  2,88)	   (Fig	   6).	  As	   size	   and	  
perimeter	  are	  dependent	  on	  each	  other,	   the	  shRNAs	  that	  showed	  to	  cause	   increase	   in	  size,	  also	  
showed	  similar	  trend	  with	  perimeter	  (FC	  shDVL3-­‐A:	  1,90	  and	  shDVL3-­‐B:	  1,82,	  respectively)(Fig	  6).	  
The	  relationship	  between	  size	  and	  circularity	  did	  not	  show	  similar	  correlation	  as	  FCs	  of	  circularity	  
were	   relatively	   small	   and	   larger	   size	   did	   not	   equal	   in	   decreased	   circularity	   (e.g.	   shLkb1	   FC	  
1,36/1,01)	  (Fig	  6).	  However,	  as	  knockdown	  of	  DVL3	  with	  both	  of	  the	  constructs	  caused	  formation	  
of	  enlarged	  multiacinar	  structures,	  also	  the	  circularity	  was	  observed	  to	  be	  significantly	  decreased	  
(FC	   shDVL3-­‐A:	   0,86	   and	   shDVL3-­‐B:	   0,88)	   (Fig	   6,	   Fig	   7).	   In	   addition	   to	   DVL3,	   the	   knockdown	   of	  
GSK3β	  resulted	   in	  enlarged	  acini,	  however	   the	   result	  was	  not	  statistically	   significant	   (FC	  2,04,	  p-­‐
value	  0,056)	  (Fig	  6).	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Figure	   6	  Quantification	  of	  changes	   in	  acinar	  morphology	  parameters	  caused	  by	   the	  hEAL	  shRNAs.	  Cells	  were	  grown	   for	  10	  days	   in	   reconstituted	  
basement	  membrane,	  after	  which	  the	  morphology	  was	  analyzed	  with	  ImageJ	  software.	  shRNAs	  against	  DVL3	  cause	  significant	  increase	  in	  acinar	  size	  
and	  perimeter	  and	  decrease	  in	  circularity.	  Values	  represent	  means	  of	  fold	  changes	  compared	  to	  the	  shControl	  ±	  Standard	  Error	  of	  Mean	  (SEM)	  in	  
three	  independent	  experiments	  where	  minimum	  of	  20	  acini	  were	  analyzed.	  Asterisk	  corresponds	  to	  the	  Student’s	  t-­‐test	  P-­‐value	  <0,05.	  
Interestingly,	  analysis	  of	  ultrastructure	  of	  the	  acini	  by	  confocal	  microscopy	  revealed	  that	  the	  apico-­‐
basal	   polarity	   was	   unaffected	   in	   all	   of	   the	   cases	   (6/6),	   as	   depicted	   by	   the	   apical	   Golgi	   protein	  
GM130	   immunostaining	   (Fig	   7).	   The	   luminal	   cells	   in	   shDVL3-­‐A/B	   and	   shGSK3β	   also	   express	   the	  
GM130	   but	   it	   is	   more	   randomly	   positioned,	   underlining	   the	   importance	   of	   ECM	   connection	   in	  
polarization.	  Interestingly,	  even	  the	  multiacinar	  DVL3	  downregulated	  structures	  seem	  to	  maintain	  
to	  great	  extend	  the	  apical	  localization	  of	  GM130	  in	  the	  individual	  lobes	  even	  though	  the	  structure	  
itself	   in	   the	   acini	   is	   deformed	   (Fig	   7).	   Additionally,	   the	   shGSK3β	   acini	   were	   observed	   with	  
repeatability	   to	   form	  enlarged	  acini	  which	   lumen	  were	   filled	  with	  cells	  at	  day	  10	  at	  which	  point	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Figure	   7	   Ultrastructural	   analysis	   of	   the	   acini	   grown	   for	   10	   days.	   Representative	   images	   show	   acini	   immunostained	   for	   apical	   marker	   GM130.	  
Downregulation	   of	   the	   hEAL	   	   target	   genes	   does	   not	   cause	   significant	   changes	   in	   apicobasal	   polarity	   but	   shDVL3-­‐A	   and	   B	   result	   in	   multiacinar	  
structures	  and	  shGsk3β	  causes	  defect	  in	  clearance	  of	  the	  cells	  from	  the	  lumen.	  
6.3.	  Effects	  of	  chronic	  MYC	  activation	  on	  acinar	  morphology	  	  
Activated	   oncogenes	   have	   been	   used	   to	   exacerbate	   found	   phenotypes	   e.g.	   Ras	   and	   nTSGs	   in	  
Drosophila(166).	   Prompted	   by	   the	   finding	   of	   synergy	   between	   LKB1	   inactivation	   and	   activated	  
MYC	  previously	  in	  our	  laboratory,	  we	  investigated	  the	  effects	  of	  chronic	  MYC	  activation	  combined	  
with	   the	   shRNAs	   used	   in	   this	   study.	   Importantly,	   as	   previously	   described	   (82),	   the	   chronic	  MYC	  
activation	   resulted	   in	   slightly	   larger	   control	   acini	   (FC:	   shControl	   +/-­‐	   4-­‐OHT	   1,23).	   Furthermore,	  
visual	  analysis	  by	  microscopy	  revealed	  that	  the	   luminal	  clearance	  of	  the	  control	  acini	  was	  not	  as	  
efficient	  with	  MYC	  activation	  confirming	  that	  MYC	  activation	  in	  immature	  acini	  causes	  overgrowth	  
(Fig	   7,	   Fig	   9).	   Chronic	   activation	   of	   MYC	   did	   not	   alter	   the	   trends	   observed	   in	   the	   morphology	  
phenotypes,	  and	  this	  observation	  was	  similar	  to	  the	  primary	  screen	  (Fig	  8	  and	  unpublished	  data).	  
None	   of	   the	   shRNAs	   in	   the	   subset	   studied	   produced	   notable	   changes	   in	   the	   morphology	  
phenotypes	   when	   combined	   with	   chronic	   MYC	   activation	   (0/6).	   Even	   though	   DVL3	   constructs	  
resulted	   in	   enlarged	   multiacinar	   structures	   also	   in	   combination	   with	   MYC	   activation,	   the	  
experiments	   contained	   more	   variation	   between	   experiments,	   rendering	   the	   results	   statistically	  
non-­‐significant	   (Fig	   8,	   Fig	   9).	   However,	   together	   with	   MYC	   activation,	   shDVL3-­‐B	   was	   able	   to	  
produce	  slightly	  larger	  increase	  in	  the	  size	  than	  without	  MYC	  (FC	  +/-­‐	  4-­‐OHT	  2,94	  vs.	  2,88)	  whereas	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2,04)	  (Fig	  6,	  Fig	  8).	  Interestingly,	  combination	  of	  the	  shFAT4	  and	  MOBKL1A-­‐B	  constructs	  with	  MYC	  
activation	  caused	  slight	  but	  statistically	  non-­‐significant	  decrease	  in	  acinar	  size	  and	  perimeter	  (Fig	  
8).	  To	  conclude,	  MYC	  did	  not	  have	  a	  significant	  effect	  on	  the	  phenotypes	  observed	  previously	  nor	  
did	  it	  produce	  any	  phenotypes	  specific	  for	  it.	  
	  
Figure	  8	  Quantification	  of	  changes	  in	  acinar	  morphology	  parameters	  caused	  by	  the	  hEAL	  shRNAs	  combined	  with	  chronic	  MYC	  activation.	  Experiment	  
and	  analysis	  was	  conducted	  as	  in	  figure	  6.	  Treatment	  with	  100	  nM	  4-­‐hydroxytamoxifen	  (4-­‐OHT)	  or	  ethanol	  as	  carrier	  control	  was	  started	  at	  day	  1.	  	  
Changes	  in	  acinar	  morphology	  parameters	  are	  similar	  to	  figure	  6.	  Values	  represent	  means	  of	  fold	  changes	  compared	  to	  the	  shControl	  ±	  Standard	  
Error	  of	  Mean	  (SEM)	  in	  three	  independent	  experiments	  where	  minimum	  of	  20	  acini	  were	  analazed.	  Asterisk	  corresponds	  to	  the	  Student’s	  t-­‐test	  P-­‐
value	  <0,05.	  
Similar	   to	   what	   was	   observed	   for	  morphology,	   the	   chronic	  MYC	   activation	   did	   not	   significantly	  
affect	  the	  observed	  ultrastructure	  of	  acini	  depicted	  by	  GM130	  staining	  (immunofluorescence	  (IF)	  
images	  of	  representative	  constructs	  Fig	  9).	  	  
To	  summarize,	  knockdown	  of	  two	  of	  the	  genes,	  DVL3	  and	  GSK3β,	  seems	  to	  cause	  defects	  in	  acinar	  
maturation	  as	   visualized	  by	   the	  multiacinar	   structure	  of	  DVL3	   knockdown	  acini,	   and	   the	   lumen-­‐
filled	  Gsk3β	   acini.	   However,	   the	   apicobasal	   polarity	   in	   regards	   of	   apical	  GM130,	   remains	   intact.	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Figure	  9	  Ultrastructural	  analysis	  of	  the	  acini	  grown	  for	  10	  days	  with	  chronic	  MYC	  activation.	  Downregulation	  of	  the	  hEAL	  	  target	  genes	  	  combined	  
with	  chronic	  MYC	  activation	  does	  cause	  changes	  to	  the	  phenotypes	  observed	  in	  Figure	  7.	  Representative	  images	  of	  acini	  immunostained	  for	  apical	  
marker	  GM130	  for	  selected	  constructs.	  
6.4.	  Effects	  of	  acute	  MYC	  activation	  on	  proliferation	  and	  apoptosis	  	  
We	   have	   previously	   shown	   that	   LKB1	   inactivation	   enables	   MYC	   induced	   cell	   cycle	   re-­‐entry	   of	  
growth-­‐arrested	  acini	  (82).	  To	  determine	  if	   loss	  of	  the	  hEAL	  genes	  similarly	  cooperate	  with	  MYC,	  
MYC	  was	  activated	  for	  three	  days	  on	  quiescent	  acini	  in	  day	  15,	  a	  time	  point	  which	  was	  previously	  
determined.	  The	  shLkb1	  construct,	  which	  was	  used	  as	  positive	  control,	   resulted	   in	  sharp,	  almost	  
2,5	  fold	  increase	  	  in	  proliferation-­‐positive	  acini	  upon	  three	  days	  of	  MYC	  activation,	  as	  depicted	  by	  
proliferation	  marker	  Ki67	  immunostaining	  (+/-­‐	  4-­‐OHT:	  shLkb1	  67,3	  %/	  27,5	  %,	  shControl	  24,7	  %	  /	  
21,3	   %)(Fig	   10A	   and	   10B).	   The	   levels	   of	   Ki67	   positivity	   with	   shLkb1	   +/-­‐	   4-­‐OHT	   correlated	   with	  
previously	  observed	  levels	  (82),	  thereby	  validating	  the	  system	  (Fig	  10).	   Interestingly,	  none	  of	  the	  
shRNA	   constructs	   behaved	   similarly	   to	   shLKB1	  when	  MYC	  was	   activated	   (Fig	   10).	   However,	   the	  
shDVL3	  constructs	  resulted	  in	  significantly	  increased	  Ki67-­‐positivity	  at	  day	  18	  already	  without	  MYC	  
activation	  (+/-­‐	  4OHT:	  shDVL3-­‐A	  50,6	  %	  /	  41,8	  %	  and	  shDVL3-­‐B	  48,4	  %	  /	  43,9	  %)	  (Fig	  10	  and	  10B).	  
Thus	  the	  MYC	  activation	  does	  not	  cooperate	  with	  shDVL3	  which	  thereby	  implies	  that	  loss	  of	  DVL3	  
alone	  drives	  the	  increased	  proliferation	  in	  this	  context.	  	  
Also	  apoptosis	  was	  quantified	  by	  counting	   the	  acini	  containing	  active	  caspase	  3	   immunostaining	  
(Fig	   10B).	   Since	   we	   did	   not	   observe	   significant	   size	   reduction	   in	   chronic	   MYC	   activation	  
experiments,	  we	  did	  not	  expect	  to	  find	  any	  of	  the	  shRNAs	  to	  cause	  significant	  increase	  in	  apoptosis.	  
Indeed,	  no	  dramatic	   changes	   in	   apoptosis	   levels	  were	  observed	  with	  or	  without	  MYC	  activation	  
(Fig	  6	  and	  10C).	  However,	  both	  of	  the	  shMOBKL1A	  exhibited	  slightly	  increased	  apoptosis	  level	  (+/-­‐	  
4-­‐OHT:	  MOBKLI1A-­‐A	  59,4	  %	  /	  56,1	  %	  and	  MOBKL1A-­‐B	  54,2	  %	  /	  53,4	  %,	  shControl	  41,6	  %	  /	  33,4	  %)	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difference	  caused	  by	  MYC	  in	  shControl	  was	  consistent	  and	  statistically	  significant)	  yet	  clear	  trend	  
was	   evident	   (Fig	   10C).	   To	   summarize,	   the	  MYC	   activation	   in	   quiescent	   acini	   shows	   that	   at	   least	  
from	  this	  specific	  subset	  of	  hEAL	  genes,	  none	  of	  potential	  polarity	  regulators	  behave	  similarly	  with	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Figure	  10	  Quantification	  of	  proliferation	  and	  apoptosis	  observed	  with	  acute	  MYC	  activation.	  Cells	  were	  grown	   in	  reconstituted	  basement	  membrane	   for	  15	  days	  after	  which	  100	  nM	  4-­‐OHT	  was	  applied	   for	  three	  days.	  A)	  Shown	  are	  percentages	  of	   the	  acini	  exhibiting	  ≥	  1	  positive	  cells	  for	  Ki-­‐67	  immunostaining	  at	  day	  18.	  B)	  Representative	  pictures	  of	  acini	  immunostained	  for	  Ki-­‐67	  for	  selected	  shRNAs.	  The	  cell	  cycle	  re-­‐entry	  driven	  by	  MYC	  in	  LKB1	  inactivated	  acini	  previously	  observed	  by	  us	  validated	  the	  system.	  DVL3	   shRNAs	   cause	   increased	  proliferation	  with	   and	  without	  MYC.	   C)	   Shown	   are	   percentages	   of	   the	   acini	   exhibiting	  ≥	   1	   cells	  positive	   for	   active	   caspase	   3	   immunostaining.	   Values	   represent	   l	   ±	   Standard	   Error	   of	   Mean	   (SEM)	   in	   three	   independent	  experiments	  where	  minimum	  of	  20	  acini	  were	  analazed.	  Asterisk	  corresponds	  to	  the	  Student’s	  t-­‐test	  P-­‐value	  <0,05.	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6.5.	  Validation	  and	  characterization	  of	  the	  synthetic	  lethal	  interaction	  between	  
knockdown	  of	  RHOA	  and	  MYC	  activation	  	  
One	  of	  the	  most	  interesting	  phenotypes	  observed	  in	  the	  primary	  screen	  was	  produced	  by	  shRhoA.	  
Therefore	  at	  later	  point,	  the	  subset	  of	  hEAL	  genes	  investigated	  in	  this	  study	  was	  added	  with	  one	  
construct	  against	  RHOA.	  As	  the	  shRhoA	  construct	  was	  in	  pGIPZ	  vector	  whereas	  rest	  of	  the	  subset	  
was	   in	   pDSL	   vectors,	   the	   RHOA	   experiments	  were	   therefore	   done	   individually.	   The	   reason	  why	  
RHOA	   was	   added	   to	   the	   subset	   was	   the	   observation	   in	   the	   primary	   screen,	   where	   RHOA	  
downregulation	  combined	  with	  chronic	  MYC	  activation	  caused	  synthetic	  lethality	  (data	  not	  shown)	  
–	   situation	   in	  which	   neither	   of	   the	   genes/treatments	   is	   lethal	   by	   itself	   but	   their	   combination	   is	  
(348).	  As	  this	  concept	  could	  be	  relevant	  for	  instance	  in	  cancer	  treatment,	  the	  last	  part	  of	  this	  study	  
was	  aimed	  to	  validate	  and	  further	  characterize	  the	  phenotype	  observed	  in	  the	  10	  day	  chronic	  MYC	  
activation	  experiment.	  
Importantly,	   the	   pGIPZ	   constructs	   and	   MycER	   construct	   have	   the	   same	   puromycin	   selection	  
marker,	   and	   therefore	   we	   enriched	   the	   population	   of	   shRhoA	   containing	   GFP-­‐positive	  MCF10A	  
MycER	   cells	   by	   FACS-­‐sorting	   (fluorescence	   activated	   cell	   sorting).	   The	  downregulation	  was	   after	  
sorting	   determined	  by	  Western	  Blotting	   from	  2D	  monolayer	   cultures.	   Interestingly,	   despite	   two	  
rounds	  of	  FACS-­‐sorting,	  the	  downregulation	  of	  RHOA	  protein	  was	  modest	  (Fig	  11A).	  However,	  the	  
low	   level	  of	  downregulation	  seemed	  to	  be	  functionally	  sufficient.	  Additionally,	   total	  RHOA	  levels	  
were	  monitored	  in	  plain	  MCF10A	  MycER	  cells	  at	  different	  time	  points	  up	  to	  24	  hours	  in	  2D	  cultures.	  
RHOA	  protein	  levels	  were	  consistently	  observed	  to	  decrease	  with	  prolonged	  (24h)	  MYC	  activation	  
(Fig	  11B).	  However,	  also	  in	  the	  control	  cells	  the	  total	  RHOA	  levels	  had	  minor	  fluctuations	  (Fig	  11B).	  
Importantly,	  these	  changes	  in	  the	  RHOA	  levels	  in	  2D	  cannot	  be	  explained	  by	  increased	  confluence	  
as	  the	  assay	  was	  made	  by	  activating	  MYC	  at	  different	  times	  and	  lysing	  the	  cells	  at	  once.	  The	  results	  
supported	   the	   notion	   that	   RHOA	   and	   MYC	   regulation	   seem	   to	   be	   connected	   (Section	   6.6.	  
Recapitulation	   of	   synthetic	   lethality	   phenotype	   with	   RHOA	   associated	   inhibitors	   and	   Chapter	   7	  
Discussion).	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Figure	   11	  Analysis	  of	   the	  effects	  of	  MYC	  activation	  on	   total	  RHOA	   level	   in	  2D	  and	  validation	  of	   the	  downregulation	  with	   shRhoA.	  A)	  GIPZ	  based	  
shRhoA	  downregulates	  RHOA	  protein	  level	  compared	  to	  shControl	  +/-­‐	  4-­‐OHT.	  	  B)	  Prolonged	  MYC	  activation	  for	  24	  hours	  downregulates	  the	  total	  
level	  of	  RHOA	  protein	  (21kDa).	  Representative	  blot	  of	  three	  independent	  experiments	  	  	  
The	   synthetic	   lethal	   phenotype	   with	   combined	   RHOA	   downregulation	   and	  MYC	   activation	   was	  
recapitulated	  in	  the	  validation	  experiments.	  As	  observed	  in	  the	  primary	  screen,	  the	  shRhoA-­‐MYC	  
combination	  resulted	  in	  greatly	  decreased	  acinar	  size	  and	  perimeter	  (FC	  size:	  0,66	  and	  perimeter	  
0,81)	  (Fig	  12).	  Without	  MYC,	  shRhoA	  acini	  grew	  slightly	  bigger	  than	  the	  control	  acini	  (FC	  1,23)	  yet	  
the	   result	   was	   not	   statistically	   significant	   (Fig	   12).	   However,	   in	   the	   primary	   screen,	   also	   the	  
circularity	   of	   the	   shRhoA	   acini	   with	   activated	  MYC	   was	   observed	   to	   be	   significantly	   decreased	  
(data	  not	   shown).	   In	   the	  validation	   step	  major	   changes	   in	   the	   circularity	  were	  not	  observed	   (FC	  
0,95),	  even	  though	  majority	  of	  the	  acini	  were	  clearly	  apoptotic	  (Fig	  12,	  Fig	  13,	  Fig	  14).	  	  
	  
Figure	  12.	  Quantification	  of	  changes	  in	  acinar	  morphology	  parameters	  caused	  by	  the	  shRhoA	  and	  chronic	  MYC	  activation.	  shRhoA	  combined	  with	  
chronic	  MYC	   activation	   causes	   significant	   decrease	   in	   acinar	   size	   and	  perimeter.	   The	   experiment	   and	   analysis	  were	   done	   as	   in	   Figures	   6	   and	   8.	  
Values	   represent	  means	   of	   fold	   changes	   compared	   to	   the	   shControl	   ±	   Standard	   Error	   of	  Mean	   (SEM)	   in	   three	   independent	   experiments	  where	  
minimum	  of	  20	  acini	  were	  analazed.	  Asterisk	  corresponds	  to	  the	  Student’s	  t-­‐test	  P-­‐value	  <0,05.	  
As	  the	  increase	  of	  apoptosis	  was	  evident	  from	  the	  acinar	  morphology,	  we	  quantified	  the	  apoptosis	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apoptosis	  which	  can	  mask	  phenotypes	  of	  mildly	  increased	  apoptosis.	  However,	  in	  the	  shRhoA	  acini	  
with	  activated	  MYC	  the	  distinction	  with	  the	  control	  was	  evident	  and	  warranted	  quantification.	  As	  
expected,	   the	   quantification	   revealed	   that	   the	   combination	   of	   shRhoA	   and	   MYC	   activation	  
significantly	   increased	  the	  percentage	  of	  acini	  positive	  for	  apoptosis	  marker	  staining	  (shRhoA	  +/-­‐	  
4-­‐OHT	   62	   %	   /	   37,7	   %)(Fig	   13A).	   However,	   as	   immature	   acini	   are	   sensitive	   for	   MYC-­‐induced	  
apoptosis,	   the	   amount	   of	   apoptosis	   was	   increased	   with	   MYC	   activation	   also	   in	   control	   acini	  
(shControl	   39,8	   %	   /	   30,9	   %)(Fig	   13A).	   Apoptosis	   analysis	   also	   hinted	   that	   there	   could	   be	  
quantitative	  difference	  in	  the	  amounts	  of	  apoptotic	  cells	  within	  acini	   in	  control	  cells	  and	  shRhoA	  
cells	   when	   MYC	   was	   activated.	   The	   closer	   quantification	   suggests	   that	   the	   amount	   of	   acini	  
containing	  more	   than	   three	  active	  caspase	  3	  positive	  cells	  could	  be	   increased,	  as	   the	  acini	  were	  
divided	  into	  three	  classes	  according	  the	  amount	  of	  positive	  cells	  (≥	  3	  positive,	  +/-­‐	  4-­‐OHT	  shControl	  
2%	   /	   1,5	  %,	   shRhoA	  15,5	  %	   /	   3	  %)	   (Fig	   13B).	  However,	   due	   to	   variation	  between	   the	   individual	  
experiments,	  the	  difference	  was	  not	  statistically	  significant,	  yet	  clear	  difference	  was	  evident,	  and	  
requires	   further	   validation.	   As	   the	   smaller	   size	   of	   the	   acini	   could	   also	   be	   due	   to	   decreased	  
proliferation,	  the	  amount	  of	  Ki67-­‐positive	  acini	  was	  quantified.	  MYC	  is	  able	  to	  boost	  proliferation	  
in	  both	  control	  and	  shRhoA	  cells	  (Ki-­‐67	  positive	  acini	  +/-­‐	  4-­‐OHT	  shControl	  58,7	  %	  /	  40,8	  %,	  shRhoA	  
63,4	  %	  /	  49,7	  %)	  (Fig	  13A).	  	  
Next,	  we	  asked	  whether	   the	  synthetic	   lethality	   is	   context	  dependent	  or	  does	   it	  occur	  also	   in	  2D	  
monolayer	   culture.	   This	   is	   interesting	   question	   as	   previously	   studies	   have	   shown	   3D	   specific	  
phenotypes	  as	  exemplified	  by	  the	  ability	  of	  the	  intact	  3D	  epithelial	  architecture	  to	  suppress	  MYC,	  
Scribble	  knockdown	  to	  specifically	  disrupt	  polarity	  in	  3D	  culture	  or	  specific	  inhibiton	  of	  EGFR	  and	  
β1-­‐integrin	  pathways	  by	  PI3K	   inhibitor	   in	  3D	   (82,	  163,	  290).	  The	  cells	  were	  plated	   to	  monolayer	  
culture	  in	  low	  and	  high	  confluencies,	  MYC	  was	  activated	  for	  24h	  and	  the	  amount	  of	  apoptotic	  cells	  
was	   quantified.	   Even	   though	  MYC	   activation	   slightly	   increased	   the	   apoptosis	   in	   the	   sparse	   and	  
confluent	  cultures	  (sparse	  +/-­‐	  4-­‐OHT	  shControl	  15,2	  %	  /	  9,8	  %,	  shRhoA	  14,6	  %	  /	  7,1	  %)(Fig	  13C),	  
similar	  considerable	  changes	  as	  in	  3D	  were	  not	  observed	  (Fig	  13A).	  To	  conclude,	  the	  results	  show	  
that	  combination	  of	  RHOA	  downregulation	  and	  MYC	  activation	  causes	  synthetic	  lethal	  phenotype,	  
which	  is	  characterized	  by	  smaller	  acinar	  size	  and	  increased	  apoptosis.	  The	  results	  also	  suggest	  that	  
this	   phenotype	   involves	   increased	   amount	   of	   apoptotic	   cells	   within	   a	   single	   acini	   and	   that	   the	  
observed	  synthetic	  lethality	  is	  specific	  to	  the	  3D	  context.	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Figure	  13	  Quantification	  of	  apoptosis	  and	  proliferation	  in	  shRhoA	  acini	  +/-­‐	  4-­‐OHT.	  A)	  Quantitative	  difference	  in	  apoptosis	  with	  shRhoA	  and	  chronic	  
MYC	  activation.	   shRhoA	  combined	  with	   chronic	  MYC	  activation	   causes	   increase	   in	   the	  percentage	  of	   acini	   exhibiting	  ≥	  1	   cells	  positive	   for	  active	  
caspase	  3	  immunostaining.	  Relationship	  between	  RHOA	  knockdown	  and	  chronic	  MYC	  activation	  implies	  synthetic	   lethal	   interaction.	  shRhoA	  does	  
significantly	  increase	  the	  percentage	  of	  acini	  exhibiting	  ≥	  1	  cells	  positive	  for	  Ki-­‐67	  immunostaining	  when	  combined	  with	  chronic	  MYC	  activation.	  B)	  
Quantitative	  difference	   in	  apoptosis	  with	   shRhoA	  and	  chronic	  MYC	  activation.	   shRhoA	  causes	   increase	   in	   the	  amount	  of	   cells	  positive	   for	   active	  
caspase	  3	   immunostaining	  within	  acinus	  when	  combined	  with	  chronic	  MYC	  activation	  C)	  Quantification	  of	  apoptosis	   in	  2D	  cultures	   in	  sparse	  and	  
confluent	   cultures	   after	   24h	   MYC	   activation.	   shRhoA	   does	   not	   significantly	   increase	   the	   percentage	   of	   cells	   positive	   for	   active	   caspase	   3	  
immunostaining	  +/-­‐	  4-­‐OHT	  showing	  the	  specifity	  of	  the	  synthetic	  lethality	  for	  3D	  context.	  Values	  represent	  mean	  ±	  Standard	  Error	  of	  Mean	  (SEM)	  in	  
three	  independent	  experiments	  (two	  for	  qualitative	  apoptosis	  analysis	  and	  2D	  apoptosis	  analysis)	  where	  minimum	  of	  20	  acini	  or	  three	  fields	  (2D)	  
were	  analazed.	  Asterisk	  corresponds	  to	  the	  Student’s	  t-­‐test	  P-­‐value	  <0,05.	  
To	   study	   the	   requirements	   for	   the	   synthetic	   lethality,	   we	   asked	   whether	   the	   chronic	   MYC	  
activation	  on	  day	  1	  is	  needed	  for	  the	  phenotype.	  To	  this	  end,	  we	  activated	  MYC	  on	  day	  7	  for	  three	  
days	   and	   analyzed	   the	   morphology	   of	   the	   acini	   as	   well	   as	   quantified	   the	   apoptosis	   and	  
proliferation.	  It	  seems	  that	  despite	  the	  acinar	  structure	  has	  time	  to	  form	  until	  day	  7	  when	  MYC	  is	  
activated,	  possibly	  protecting	  from	  the	  apoptosis,	  the	  similar	  trends	  in	  morphology	  and	  apoptosis	  
can	   be	   seen	   as	   in	   the	   chronic	   activation	   experiment	   as	   the	   acinar	   size	   decreases	   (FC	   +4-­‐OHT	  
shRhoA	  0,85)(Fig	  12	  and	  14)	  and	  percentage	  of	  acini	   containing	  apoptotic	   cells	   increases	   (+/-­‐	  4-­‐
OHT	   shControl	   50,5	   %/	   52,3	   %,	   shRhoA	   66,6	   %/	   42,9	   %)	   (Fig	   13	   and	   15).	   Interestingly,	   the	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proliferation	  analysis	  results	  slightly	  differ	  from	  the	  previous	  observations	  with	  the	  day	  1	  chronic	  
activation	  as	  MYC	  does	  not	  increase	  the	  proliferation	  in	  the	  shRhoA	  cells	  for	  unknown	  reason	  (+/-­‐	  
4-­‐OHT	   shControl	   73,9	  %/56,1	  %,	   shRhoA	   52,3	  %/64,0	  %)	   (Fig	   15).	   Additionally,	   the	   circularity	   is	  
unexpectedly	   statistically	   significantly	   decreased	   in	   the	   shRhoA-­‐MYC	   combination	   in	   contrast	   to	  
the	  day	  1	  activation	  (Fig	  14).	  The	  results	  suggest	  that	  combination	  of	  RHOA	  downregulation	  and	  
MYC	  activation	  can	  induce	  synthetic	  lethality	  also	  in	  the	  preformed	  acini	  yet	  further	  dissecting	  of	  
the	  events	  is	  needed.	  
	  
	  
Figure	  14	  Quantification	  of	  changes	   in	  acinar	  morphology	  parameters	   in	  the	  shRhoA	  acini	  with	  MYC	  activation	  at	  day	  7.	  Experiment	  and	  analysis	  
done	   as	   in	   Figure	   6.	   Acini	   are	   let	   to	   form	  and	  MYC	   is	   activated	   at	   day	   7	   for	   three	   days.	   shRhoA	  with	  MYC	   activation	   decreases	   acinar	   size	   and	  
circularity	  also	   in	   this	  setting	  similar	   to	  Figure	  12.	  Values	  represent	  means	  of	   fold	  changes	  compared	  to	  the	  shControl	  ±	  Standard	  Error	  of	  Mean	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Figure	  15.	  Quantification	  of	  apoptosis	  and	  proliferation	  in	  shRhoA	  acini	  with	  MYC	  activation	  at	  day	  7.	  shRhoA	  causes	  increase	  in	  the	  percentage	  of	  
acini	  exhibiting	  ≥	  1	  cells	  positive	  for	  active	  caspase	  3	  immunostaining	  with	  MYC	  activation	  at	  day	  7.	  Significant	  changes	  in	  the	  percentage	  of	  acini	  
exhibiting	  ≥	  1	  cells	  positive	  for	  Ki-­‐67	  immunostaining	  are	  not	  observed	  with	  MYC	  activation	  at	  day	  7.	  	  Values	  represent	  mean	  ±	  Standard	  Error	  of	  
Mean	  (SEM)	  in	  two	  independent	  experiments	  where	  minimum	  of	  20	  acini.	  
Next	  we	  wanted	  to	  explore	  molecular	  mechanisms	  contributing	  to	  the	  synthetic	  lethality	  observed.	  
As	   a	  major	   difference	   between	   3D	   and	   2D	   cultures	   is	   the	   contact	   of	   the	   cells	   to	   the	   ECM	   and	  
integrin	  signalling,	  to	  which	  RHOA	  has	  been	  linked	  to,	  we	  determined	  what	  is	  the	  organization	  and	  
localization	  of	   the	   integrin(s)	   in	   the	   shRhoA	  acini.	   Interestingly,	  we	  observed	   that	   in	   the	   control	  
acini	   the	   normally	   basally	   located	   α6-­‐integrin	   is	   abnormally	   distributed	   between	   the	   cells	   and	  
inside	  the	  acini	  in	  shRhoA	  acini	  (Fig	  16A).	  However,	  it	  is	  not	  clear	  whether	  this	  is	  relevant	  for	  the	  
apoptotic	  phenotype	  as	  the	  perturbed	  localization	  of	  α6-­‐integrin	  was	  also	  observed	  in	  absence	  of	  
MYC	   activation	   (Fig	   16A).	   To	   conclude,	   the	   ultrastructure	   analyses	   suggest	   that	   the	   integrin	  
localization	  is	  perturbed	  by	  RHOA	  downregulation	  in	  MCF10A	  cells	  in	  3D	  culture	  implying	  defects	  
in	  cell-­‐ECM	  conctacts.	  Whether	  this	  contributes	  to	  the	  observed	  synthetic	  lethal	  phenotype	  is	  yet	  
to	  be	  clarified.	  Additionally,	  the	  intensity	  of	  actin	  staining	  is	  diminished	  in	  the	  shRhoA	  acini	  even	  
though	   the	   cell	   surrounding	   pattern	   of	   staining	   remains	   normal	   (Fig	   16B).	   The	   diminished	   actin	  
staining	   was	   in	   accordance	   to	   previous	   data	   as	   major	   function	   of	   RHOA	   is	   to	   control	   actin	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Figure	  16	  Ultrastructural	  analysis	  of	  shRhoA	  acini	  with	  chronic	  +/-­‐	  chronic	  Myc	  activation.	  A)	  shRhoA	  perturbs	  the	  localization	  of	  the	  basal	  marker	  
α6-­‐integrin	   immunostaining.	   shRhoA	   in	   combination	   with	   chronic	   Myc	   activation	   increases	   the	   amount	   of	   cells	   positive	   for	   active	   caspase	   3	  
immunostaining.	  B)	  shRhoA	  causes	  decrease	   in	   the	   intensity	  of	  actin	  staining	  with	  phalloidin.	  Shown	  are	  representative	   images	   for	   the	   indicated	  
immunostainings.	  	  
6.6.	  Recapitulation	  of	  synthetic	  lethality	  phenotype	  with	  RHOA	  associated	  inhibitors	  	  
Finally,	   we	   wanted	   investigate,	   which	   pathways	   associated	   with	   RHOA	   are	   responsible	   for	   the	  
synthetic	  lethality.	  We	  thus	  combined	  inhibitors	  of	  different	  pathways	  with	  MYC	  activation	  in	  plain	  
MCF10A	  MycERtm	   cells.	  We	   selected	   inhibitors	   targeting	   ROCK	   pathway	   (Y-­‐27632),	  Myosin	   light	  
chain	  kinase,	  MLCK	  (ML-­‐7)	  and	  MEK	  pathway	  (U0126),	  all	  of	  which	  are	  associated	  with	  RHOA,	  MYC	  
and	  apoptosis,	   to	  be	  used	   in	   chronic	  MYC	  activation	  3D	  assay.	   Firstly,	  RhoA	  has	  been	   shown	   to	  
prevent	   apoptosis	   in	   zebrafish	   embryogenesis	   by	   activating	   the	   MEK/ERK	   pathway	   (349).	  
Furthermore,	  MEK/ERK	  signalling	  has	  been	  shown	  to	  be	  suppressed	  by	  overexpression	  of	  MYC	  in	  
chicken	  embryo	  fibroblasts	  (350)	  raising	  a	  question	  of	  possible	  ‘double-­‐hit’	  for	  survival	  and	  growth	  
pathway	   in	   our	   setting.	   As	   RHOA	   largely	   talks	   through	   the	   ROCK	   pathway	   affecting	   actin	   and	  
myosin	  interactions	  and	  inhibition	  of	  these	  molecules	  (ROCK,	  MLC/Myosin	  II)	  has	  been	  shown,	  for	  
example,	   to	   counteract	   the	   classical	   integrin	   related	   RAC1	   mutant	   caused	   inverted	   polarity	  
phenotype,	   their	   inhibitors	  were	   also	   selected	   for	   the	   assay	   (28).	   Interestingly,	   one	   study	   in	   2D	  
context	  with	  MFC10A	   cells	   showed	   that	  MCLK	   inhibitor	  ML-­‐7	   induces	   apoptosis	   whereas	   ROCK	  
inhibitor	   Y-­‐27632	   did	   not	   have	   an	   apoptosis	   inducing	   effect	   suggesting	   also	   other	   kinases	   in	  
addition	  to	  ROCK	  have	  significance	  in	  myosin	  light	  chain	  signalling	  (351).	  ROCK	  has	  been	  proposed	  
to	   connect	   the	   signalling	   between	   cell	   anchorage	   and	   cell	   cycle	   controlling	   mTOR	   pathway	   in	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has	  been	  shown	  to	  transcriptionally	  partly	  inhibit	  the	  ROCK	  pathway	  according	  to	  biochemical	  and	  
microarray	   data	   from	   cells	   expressing	   constitutively	   active	   RHOA	   mutant	   (353).	   Furthermore,	  
RHOA	  and	  MYC	  have	  been	  shown	  to	  affect	  each	  other	  levels	  and	  activity	  (277,	  354-­‐356))	  
The	  concentrations	  of	   the	   inhibitors	  used	  were	   tested	   to	  be	  sublethal	   (data	  not	   shown).	  Due	   to	  
technical	  difficulties	  related	  to	  the	  cell	  culture/model	  system	  (Chapter	  7.	  Discussion),	  the	  inhibitor-­‐
MYC	   combination	   experiments	  were	   restricted	   to	   five	   days	   instead	   of	   the	   ten	   day	   experiments	  
performed	  with	  shRhoA	  cells.	  After	  five-­‐day	  chronic	  inhibitor-­‐MYC	  activation	  experiment,	  in	  which	  
both	  4-­‐OHT	  and	  inhibitors	  were	  applied	  on	  day	  1,	  the	  morphology	  parameters	  were	  quantitated	  
and	  the	  ultrastructure	  analyzed	  similarly	  to	  the	  previous	  experiments.	  	  
When	   compared	   to	   decreased	   size	   of	   acini	   with	   shRhoA	   cells	   with	   MYC	   activation,	   the	   best	  
candidate	  was	  the	  MEK	  inhibitor	  U0126	  as	  it	  is	  the	  only	  inhibitor	  exhibiting	  synergistic	  action	  when	  
accompanied	   with	   MYC	   activation	   (FC	   size	   control	   vs.	   inhibitor/4-­‐OHT/inhibitor+4-­‐OHT:	  
1,11/0,71/0,40)	   even	   though	   the	   ROCK	   and	  MLC	   inhibitors	   decreased	   the	   acinar	   size	   almost	   as	  
effectively	   when	   compared	   to	   the	   control	   (FC	   ML-­‐7:	   0,77/0,50/0,44,	   Y-­‐27632:	   0,93/0,32,/0,41)	  	  
(Fig	  17).	  However,	  as	  was	  seen	  with	  shRhoA	  cell	  with	  activated	  MYC,	  even	  though	  the	  acinar	  size	  is	  
greatly	  decreased	  with	  U0126	  combined	  with	  MYC,	  the	  circularity	  remains	  fairly	  normal	  (FC	  0,95).	  
This	  is	  in	  contrast	  to	  the	  observed	  circularity,	  for	  example,	  with	  the	  ML-­‐7	  inhibitor	  (FC	  0,83)	  and	  to	  
the	  primary	  screen	  of	  the	  hEAL	  where	  shRhoA	  associated	  synthetic	  lethality	  was	  shown	  to	  exhibit	  
decreased	  acinar	  circularity	  (Fig	  17	  and	  data	  not	  shown).	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Figure	  17	  Inhibitor	  assay	  for	  MEK,	  ROCK	  and	  MLCK	  inhibtion	  in	  3D	  environment	  in	  combination	  with	  chronic	  MYC	  activation.	  Shown	  are	  changes	  in	  
the	  acinar	  morphology	  parameters	  with	  +/-­‐	   inhibitor	   (inh./vehic.)	  and	  +/-­‐	  4-­‐OHT.	   Inhibitors	  and	  4-­‐OHT	  were	  applied	  on	  day	  1	   for	   four	  days	  after	  
which	   the	   analysis	   was	   done.	  MEK-­‐inhibitor	   U0126	   exhibits	   synergistic	   relationship	   in	   decrease	   of	   acinar	   size	   and	   perimeter	   with	   chronic	  MYC	  
activation	  similar	  to	  shRhoA	  cells.	  	  Used	  concentrations	  were	  ML-­‐7	  (MLCK	  inh.)	  2,5	  μM,	  U0126	  (MEK	  inh.)	  500	  nM	  and	  Y-­‐27632	  (ROCK	  inh.)	  50	  μM.	  
Values	   represent	  means	   of	   fold	   changes	   compared	   to	   the	   Control	   (EtOH/carrier	   control)	   ±	   Standard	   Error	   of	  Mean	   (SEM)	   in	   two	   independent	  
experiments	  where	  minimum	  of	  20	  acini	  were	  analysed.	  Asterisk	  corresponds	  to	  the	  Student’s	  t-­‐test	  P-­‐value	  <0,05.	  
Next	  we	   explored,	  whether	   the	   inhibitors	   used	   also	   affect	   α6-­‐integrin	   localization	   as	   in	   shRhoA	  
acini	  and	  the	   integrin	  staining	  pattern	  was	  visualized.	  Comparing	  to	  the	  perturbed	  α6-­‐integrin	   in	  
the	  shRhoA	  cells,	  the	  ROCK	  inhibitor	  appeared	  to	  result	  in	  most	  similar	  pattern	  (Fig	  18).	  However,	  
due	   to	   the	   relative	   shortness	  of	   the	  experiment,	  many	  of	   the	  acini	  were	   still	  maturing	  and	  only	  
forming	  the	  apico-­‐basal	  polarity	  and	  depositing	  α6-­‐integrin	  basally,	  the	  analysis	  can	  considered	  to	  
be	   only	   preliminary.	   Additionally,	   small	   changes	   in	   apoptosis	   induced	   by	   the	   inhibitors	   can	   be	  
masked	  by	   the	   endogenous	   apoptosis	   in	   the	  developing	   acini	   and	   therefore	   it	   is	   not	   reliable	   to	  
conclude	  which	  of	  the	  inhibitors	  would	  increase	  apoptosis	  in	  combination	  with	  MYC	  in	  this	  context.	  
Furthermore,	   the	  observed	  technical	  problems	  and	  consequently	   (Chapter	  7.	  Discussion)	  shorter	  
length	  of	   the	  experiment	  made	   the	  quantification	  of	   the	  cell	  death	   irrelevant	  at	   this	  point	  even	  
though	   it	   will	   be	   of	   key	   interest	   in	   future	   experiments.	   To	   summarize,	   synergistic	   relationship	  
between	   MYC	   and	   MEK	   inhibitor	   U0126	   was	   observed	   as	   measured	   by	   the	   quantification	   of	  
decreased	   acinar	   size	   similar	   to	   the	   shRhoA-­‐MYC	   combination.	   However,	   according	   to	   the	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with	  shRhoA	  cells	  but	  instead	  ROCK	  inhibition	  with	  Y-­‐27632	  affects	  more	  acinar	  ultrastructure	  and	  
α6-­‐integrin	  distribution.	  	  
	  
Figure	   18	  Ultrastructural	   analysis	   of	   the	   acini	  with	  MEK,	  ROCK	  and	  MLCK	   inhibitors	   and	   chronic	  MYC	  activation.	   ROCK	   inhibitor	   Y-­‐27632	   causes	  
defects	  in	  α6-­‐integrin	  localization	  whereas	  MEK	  inhbitor	  U0126	  causes	  apoptosis	  depicted	  by	  the	  active	  caspase	  3	  immunostaining	  with	  chronic	  Myc	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7.	  DISCUSSION	  	  
Screens	  of	  this	  magnitude	  have	  not	  yet	  been	  done	  in	  the	  context	  of	  mammalian	  epithelial	  polarity	  
and	  architecture.	  However,	  as	  the	  genes	  have	  been	   implicated	   in	  polarity	  regulation	  and	  part	  of	  
them	  in	  tumour	  suppression	  in	  Drosophila,	  it	  is	  interesting	  to	  reflect	  the	  findings	  of	  this	  study	  on	  
that	  knowledge.	  Additionally,	  some	  of	  the	  genes	  have	  also	  been	  studied	  in	  mammalian	  systems	  in	  
smaller	   studies	  and	  all	   of	   them	  have	  been	   studied	   in	  other	   contexts	   than	  polarity,	   also	  often	   in	  
relation	   to	   oncogenic	   events.	   Therefore	   the	   hEAL	   project,	   and	   this	   study	   aimed	   to	   determine	   i.	  
whether	  the	  chosen	  genes	  regulate	  epithelial	  architecture	  and	  apico-­‐basal	  polarity	  in	  mammalian	  
cells	   and	   ii.	   exhibit	   tumour	   suppressive	   features	   in	   mammalian	   cells	   in	   the	   context	   of	   MYC	  
activation.	  Lastly,	  iii.	  we	  aimed	  to	  characterize	  the	  synthetic	  lethal	  phenotype	  produced	  by	  shRhoA	  
and	  MYC	  activation.	  
7.1.	  Advantages	  and	  disadvantages	  of	  the	  shRNA	  and	  3D	  culture	  approach	  	  
The	  entire	  hEAL	  library	  established	  by	  our	  laboratory	  encompasses	  77	  genes	  and	  219	  constructs	  in	  
total.	  To	  evaluate	  how	  efficient	  our	  shRNA	  approach	  was	  in	  general,	  at	  the	  moment	  it	  seems	  that	  
the	  hit-­‐rate	  of	   finding	   shRNA	  with	  efficient	   knockdown	  of	   the	   target	   is	   around	  25	  %.	   	  However,	  
further	  research	  has	  been	  carried	  out	  to	  find	  working	  shRNAs	  against	  genes,	  which	  did	  not	  have	  
any	   functional	   shRNAs	   in	   our	   library.	   Luckily,	   in	   the	   subset	   studied	   here,	   the	   shRNAs	   found	   to	  
efficiently	  downregulate	   their	   target	  gene,	  proved	  to	  do	  so	  also	   in	   the	  re-­‐validation	  step	  carried	  
out	   in	   this	   study.	   The	   fact	   that	   the	   level	   of	   downregulation	   is	   in	   all	   of	   the	   cases	   lower	   than	  
observed	  in	  primary	  testing	  of	  the	  shRNAs,	  may	  arise	  at	  least	  from	  two	  possibilities.	  Firstly,	  in	  this	  
study	  the	  downregulation	  was	  assayed	  from	  cells	  cultured	  until	  they	  were	  Replication	  competent	  
virus	  (RCV)-­‐negative,	  suggesting	  possibility	  of	  counterselection,	  even	  though	  in	  principle	  lentiviral	  
shRNAs	   should	   be	   stably	   expressed.	   The	   prolonged	   culture	   time	   on	   the	   other	   hand	   enables	  
antibiotic	   selection,	   but	   similarly	   may	   raise	   problems	   with	   counterselection.	   Secondly,	   as	   the	  
analysis	   in	   the	   primary	   testing	   phase	   was	   made	   out	   of	   single	   round	   of	   infections	   to	   test	   the	  
constructs,	   the	  observed	  difference	  may	  also	  represent	  experimental	  variation.	  To	  deal	  with	  the	  
problem	   in	   this	   study,	   in	   addition	   to	  using	   the	   selected	  or	   sorted	   cells,	   part	   of	   the	  experiments	  
were	  also	  performed	  directly	  after	  the	  infection	  in	  order	  to	  minimize	  the	  possible	  counterselection	  
effect.	   The	   results	   obtained	  with	   these	   two	   approaches	  were	   highly	   similar	   and	   thereby	   in	   this	  
study	   we	   have	   not	   differentiated	   these	   results.	   The	   counterselection	   appears	   to	   be	   especially	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strong	  in	  the	  case	  of	  shRhoA,	  as	  the	  observed	  level	  of	  downregulation	  was	  fairly	  low	  despite	  two	  
rounds	   of	   FACS	   sorting	   and	   selection	   of	   the	   highest	   GFP-­‐positive	   population.	   	   However,	   as	   the	  
constructs	   resulted	   in	  weaker	   downregulation	   also	   in	   the	   re-­‐validation	   step	  made	   in	   this	   study,	  
and	  as	  the	  morphology	  parameters	  and	  ultrastructural	  analysis	  quite	  closely	  resemble	  the	  values	  
and	  phenotypes	  from	  the	  primary	  screening	  of	  the	  hEAL,	  it	  can	  be	  argued	  that	  the	  observed	  level	  
of	   downregulation	   was	   functionally	   sufficient.	   This	   applies	   also	   for	   the	   used	   positive	   control	  
shLkb1	   which	   has	   been	   previously	   shown	   to	   produce	   efficient	   downregulation	   and	   result	   in	  
significantly	  enlarged	  acini	  as	  well	  as	  potentiate	  MYC	  to	  drive	  cell	  cycle	  re-­‐entry	  in	  growth	  arrested	  
acini	  (82).	   In	   line	  with	  previous	  observations	  the	  size	  phenotype	  was	  observed	  also	  in	  this	  study,	  
yet	  it	  was	  not	  statistically	  significant	  even	  though	  the	  proliferation	  phenotype	  was.	  
Next,	   I	   shortly	  discuss	   and	  evaluate	   the	  methodological	   aspects	  of	   this	   study.	  As	   it	   can	  be	   seen	  
from	   the	   results,	   even	   though	   we	   were	   able	   to	   observe	   evident	   differences	   in	   the	   acinar	  
morphology	  parameters,	  proliferation	  and	  apoptosis	  compared	   to	  control	   in	  many	  of	   the	  assays	  
and	   also	   repeat	   them,	  many	  of	   the	  differences	  were	  not	   statistically	   significant	   as	   the	   variation	  
between	   the	   absolute	   values	   within	   treatment	   between	   experiments	   was	   large,	   including	   the	  
control	  shRNA.	  Even	  though	  nearly	  all	  of	  the	  assays	  done	  in	  this	  study	  were	  repeated	  at	  least	  three	  
times,	  the	  level	  p-­‐value	  ≤	  0,05	  was	  not	  reached	  in	  all,	  clearly	  phenotype	  exhibiting	  cases	  (such	  as	  
the	  shGSK3β	  in	  morphology	  validation).	  However,	  this	  has	  been	  observed	  also	  in	  other	  3D	  studies	  
by	  other	   researchers	   in	  our	   laboratory.	  The	  minimum	  of	   three	   repeats	  usually	   considered	   to	  be	  
needed	  for	  scientific	  validity	  does	  not	  often	  seem	  to	  be	  enough	  when	  doing	  3D	  assays.	  	  
There	  exists	  also	  a	  rational	  explanation	  for	  this.	  The	  used	  ECM	  replacement,	  Matrigel™,	  is	  derived	  
from	  mouse	   and	   therefore	   constitution	  may	   vary	   between	   lots,	   consequently	   having	   a	   possible	  
impact	  on	  the	  outcomes	  of	  the	  assays.	  In	  fact,	  during	  this	  study	  we	  had	  to	  face	  the	  situation	  when	  
we	  were	  not	  anymore	  able	  to	  find	  a	  lot	  of	  Matrigel™	  in	  which	  the	  MCF10A	  cells	  would	  have	  grown	  
well	   enough	   to	   form	  polarized	  acini.	   To	  deal	  with	   this	  problem,	  we	  utilized	  a	   study	   (357)	  which	  
described	  3D-­‐cell	  culture	  being	  possible	  in	  normal	  egg	  white.	  As	  egg	  white	  derived	  from	  a	  standard	  
market	   bought	   egg	   is	   clearly	   to	   have	   even	   more	   non-­‐defined	   constitution,	   it	   is	   clear	   that	   this	  
results	   in	  even	  more	  variation	  between	  the	  experiments.	  However,	  as	  we	  tested	  the	  usability	  of	  
egg	   white,	   it	   was	   shown	   that	   the	  MCF10A	   cells	   behave	   in	   egg	   white	   in	   3D	   context	   sufficiently	  
similar	  to	  Matrigel™	  (data	  not	  shown)	  as	  was	  also	  noticed	  in	  the	  original	  publication	  of	  the	  method	  
(357).	   Sometimes	   the	   clearance	   of	   lumen	   was	   slowed	   compared	   to	   Matrigel™	   and	   the	   size	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variation	  is	  larger	  but	  most	  significantly,	  the	  acini	  seemed	  still	  to	  form	  clear	  epithelial	  architecture	  
and	   polarize	   apico-­‐basally	   also	   in	   this	   substrate.	   Considering	   the	   highly	   similar	   3D	   behavior	  
(polarization,	  growth	  arrest)	  and	  similar	   results	  compared	  to	  which	  were	  obtained	   in	  Matrigel™,	  
we	  consider	  these	  two	  different	  substrates	  being	  comparable	  in	  this	  study	  and	  do	  not	  differentiate	  
the	   results	  obtained	   in	   them.	  However,	   for	   the	   reasons	   stated	  above,	  we	  chose	   to	  visualize	   the	  
morphology	  results	  as	  fold	  changes	  in	  which	  control	  was	  set	  as	  1	  in	  every	  experiment	  to	  be	  better	  
able	   to	   show	   and	   characterize	   the	   differences,	   although	   the	   statistical	   significance	   values	  were	  
calculated	  from	  the	  absolute	  averages	  of	  the	  experiments.	  
Another	  problem,	  which	  we	  faced	  with	  growing	   intensity	  during	  the	  summer/early	  autumn,	  was	  
the	   observation	   that	   in	   some	   experiments	   4-­‐OHT	   alone	   was	   sufficient	   to	   induce	   significant	  
apoptosis	  also	  in	  the	  control	  cells	  in	  egg	  white.	  The	  concentration	  used	  for	  4-­‐OHT	  was	  identical	  in	  
both	  Matrigel™	  and	  egg	  white.	  Physical	  differences	  between	  these	  two	  substrates	  may	  play	  a	  role.	  
Consequently,	   for	   this	   reason	   it	  was	  not	   feasible	   to	  continue	   further	   the	  characterization	  of	   the	  
RHOA-­‐MYC	   phenotype	   and	   restricted	   the	   inhibitor	   experiments	   to	   the	   length	   of	   five	   days	  
(compared	   to	   10	   in	   shRhoA	   experiments,	   inhibitor	   experiments	  were	   done	   last)	   even	   though	   it	  
made	   the	   interpretation	   of	   the	   inhibitor	   experiments	   harder	   and	   less	   conclusive.	   Moreover,	  
because	  of	  the	  problem	  the	  inhibitor	  experiments	  were	  done	  only	  in	  duplicate	  and	  the	  apoptosis	  
was	  not	  quantified	  as	  it	  was	  evident	  by	  eye	  that	  no	  clear	  differences	  would	  be	  found.	  	  
In	   general	   about	   our	   approach	   of	   screening	   the	   shRNA	   library	   for	   epithelial	   architecture	   and	  
polarity	   regulators,	   it	   can	  be	  said	   the	  primary	   results	   identified	  previously	   in	  our	   laboratory	  had	  
high	  repeatability	  and	  the	  robust	  morphology	  analysis	  method	  used	   in	  this	  project	  proved	  to	  be	  
functional	  and	  catch	  phenotypes.	  Of	  the	  validity	  of	  the	  morphology	  parameters,	  it	  is	  of	  notice	  that	  
in	  most	  cases	   the	  size	  and	  perimeter	   strongly	  correlate	  and	   rarely	  give	  different	   results	   thereby	  
raising	  question	  for	  need	  for	  both.	  The	  circularity	  parameter	  exhibits	  smaller	  absolute	  and	  relative	  
differences	  even	  in	  extreme	  phenotypes.	  On	  the	  other	  hand	  the	  variation	  is	  also	  smaller	  thereby	  
giving	   possibility	   to	   catch	   significant	   changes.	   Importantly,	   often	   the	   defective	   architecture	   and	  
polarity	  can	  lead	  to	  transformed	  and	  morphologically	  distorted	  structures	  and	  this	  strongly	  stands	  
for	  using	  the	  circularity	  parameter	  also	  in	  future	  (DVL3	  in	  this	  study	  and	  (82).	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7.2.	  Morphology	  validation	  and	  MYC	  activation	  imply	  a	  role	  in	  epithelial	  architecture	  for	  
Wnt	  pathway	  –	  no	  role	  for	  Hippo	  pathway	  	  
The	   most	   striking	   phenotype	   observed	   in	   the	   morphology	   analysis,	   measured	   by	   acinar	   size,	  
perimeter	   and	   circularity,	   was	   the	   multiacinar	   phenotype	   caused	   by	   downregulation	   of	   Wnt	  
pathway	   gene	  DVL3	  by	   two	   independent	   constructs.	   Importantly,	   as	   the	   similar	   phenotype	  was	  
observed	   with	   two	   shRNA	   constructs	   in	   this	   study,	   and	   has	   also	   been	   replicated	   by	   a	   third	  
construct	   by	   others	   in	   our	   laboratory,	   there	   is	   a	   strong	   argument	   against	   possibility	   of	   any	   off-­‐
target	  effects.	  	  This	  is	  a	  novel	  finding	  as	  the	  role	  for	  DVL3	  in	  3D	  acinar	  morphogenesis	  has	  not	  been	  
reported	  previously.	  Moreover,	  the	  fact	  that	  DVL3	  downregulation	  causes	  striking	  morphological	  
abnormality	   implies	   a	   role	   for	   it	   as	   a	   regulator	   of	   epithelial	   architecture	   and	   as	   a	   tumour	  
suppressor	  when	  combined	  with	   the	  observation	  of	   increased	  proliferation.	  Mechanistically,	   the	  
tumour	  suppressor	  role	  is	  unanticipated	  for	  DVL3	  as	  the	  gene	  causes	  inability	  to	  target	  β-­‐catenin	  
for	   destruction	   by	   the	   multiprotein	   complex	   and	   consequently	   drives	   the	   Wnt	   pathway	   and	  
induces	  its	  target	  genes,	  which	  are	  for	  example	  proliferation	  related.	  In	  line	  with	  this	  reasoning,	  no	  
mutations	  of	  DVL3	  have	  been	  observed	  in	  human	  cancers	  (321).	  One	  study	  has	  showed	  DVL3	  to	  be	  
overexpressed	   in	  tissue	  samples	  of	  non-­‐small	  cell	   lung	  cancer,	  undermining	   its	  possible	  role	  as	  a	  
tumour	  suppressor	  proposed	  by	  our	  experiments	  (358).	  In	  biological	  sense,	  it	  would	  be	  interesting	  
to	   investigate	   the	  mechanism	   behind	   the	   formation	   of	   the	  multiacinar	   structure.	   The	   structure	  
seems	  to	  contain	  an	  acinus	  with	  multiple	  individual	  lobules	  which	  are	  fairly	  well	  organized	  despite	  
the	  deformity	  of	  the	  whole	  structure.	  As	  DVL3	  is	  in	  part	  thought	  to	  control	  the	  selection	  between	  
canonical	  and	  non-­‐canonical/planar	  cell	  polarity	  routes	  of	  the	  Wnt	  pathway,	   it	  might	  be	  possible	  
that	   downregulation	   of	   DVL3	   changes	   this	   balance	   and	   remaining	   amounts	   of	   DVL3	   is	   able	   to	  
perform	  deregulated	  functions	  (149).	  
However,	   at	   this	   point	   we	   cannot	   rule	   out	   the	   possibility	   of	   this	   being	   a	   fusion	   of	   multiple,	  
originally	  individual,	  acini.	  Collective	  movement	  of	  cells	  in	  3D	  environment	  has	  been	  documented,	  
which	  can	  contribute	  to	  the	  phenotype	  by	  bringing	  growing	  acini	  closer	  to	  each	  other	  and	  making	  
them	   prone	   grow	   together	   and	   fuse	   (345,	   359).	   Closer	   dissection	   and	   quantification	   is	   needed.	  
Interestingly,	   recently	   a	   computer	   based	   method	   for	   linking	   oncogenic	   mutations	   with	  
morphogenic	   events	   was	   introduced	   by	   using	  MCF10A	   cells	   (360).	   Similar	   approach	   with	   time-­‐
lapse	  microscopy	   could	  provide	  evidence	  whether	   the	   lobular	   structure	  originates	   from	  a	   single	  
acinus	  or	  is	  a	  result	  of	  fusion	  of	  several	  acini.	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Similarly,	  the	  phenotype	  of	  acini	  with	  downregulated	  GSK3β	  proposes	  a	  role	  for	  it	  as	  a	  regulator	  of	  
epithelial	   architecture	   and	   as	   a	   tumour	   suppressor	   in	   the	   human	  mammary	   epithelial	   cell	   line	  
MCF10A.	  However,	  similarly	  to	  DVL3,	  there	  has	  not	  been	  a	  clear	  role	  for	  it	  in	  human	  cancers	  (339).	  
As	  GSK3β	  is	  a	  member	  of	  the	  β-­‐catenin	  destruction	  complex,	  therefore	  it	  would	  be	  a	  good	  tumour	  
suppressor	  candidate	  in	  contrast	  to	  DVL3.	  However,	  the	  observed	  role	  in	  human	  cancers	  seems	  to	  
be	   ambiguous	   as	   both	   overexpression	   and	   inactivation	   have	   been	   observed	   to	   associate	   with	  
cancer	   (339).	   Intrestingly,	   in	   breast	   cancer	   GSK3β	   functions	   as	   a	   tumour	   suppressor	   consistent	  
with	   our	   findings	   (361,	   362).	   GSK3β	   has	   also	   been	   implicated	   in	   apoptosis	   regulation	   by	  
demonstrating	   pro-­‐apoptotic	   function	   in	   normal	   cells	   (339).	   Therefore	   the	   observation	   that	  
shGSK3β	   acini	   often	   exhibit	   filled	   lumens	   is	   in	   line	   with	   the	   literature,	   as	   the	   lumens	   become	  
hollow	  via	  apoptosis	   in	   the	  MCF10A	  3D-­‐model	   (345).	   Surprisingly,	  decreased	   levels	  of	   apoptosis	  
were	  not	  observed	   in	  the	   late	  MYC	  activation	  experiment,	  but	   instead	  the	  apoptosis	   levels	  were	  
similar	  to	  control	  and	  thus	  the	  phenotype	  calls	  for	  further	  clarification.	  
As	   the	   results	   with	   other	   constructs	   in	   the	   pDSL	   subset	   were	   statistically	   less	   significant,	   their	  
direct	  reflection	  on	  the	  current	  knowledge	   is	   less	   intriguing.	  However,	  as	  some	  amounts	  of	  data	  
exist	   of	   those	   also	   in	   mammalian	   and	   oncogenic	   contexts	   it	   is	   worthwhile	   to	   summarize	   their	  
relation	   to	   the	   knowledge	   in	   the	   field.	   Interestingly,	   the	   constructs	   described	   above,	   which	  
resulted	  in	  more	  statistically	  significant	  phenotypes,	  were	  all	  linked	  to	  Wnt	  pathway,	  whereas	  the	  
three	   other	   constructs	   were	   associated	   with	   the	   Hippo	   pathway.	   Both	   of	   the	   genes	   (FAT4,	  
MOBKL1A)	   are	   thought	   to	   enhance	   the	   activity	   of	   the	   Hippo	   pathway	   kinase	   cascade,	   FAT4	   by	  
acting	  as	  sensor	  for	  extracellular	  cues	  and	  MOBKL1A	  by	  enhancing	  activity	  of	  LATS	  thereby	  leading	  
to	   inactivation	   of	   the	   transcription	   factor	   YAP,	   which	   causes	   proliferation	   and	   inhibition	   of	  
apoptosis,	   and	   therefore	   a	   role	   for	   them	   as	   tumour	   suppressor	   would	   be	   rational	   (132-­‐134).	  
However,	  we	  did	  not	  observe	  major	  changes	  in	  the	  morphology	  parameters	  or	  in	  the	  polarization	  
of	   the	  acini.	  Depletion	  of	  MOBKL1A	  seemed	  to	  result	   in	   increased	  apoptosis	   in	  conjunction	  with	  
acute	  MYC	  activation,	  which	  would	  be	  counterintuitive	  considering	  the	  activating	  role	  in	  the	  Hippo	  
pathway,	  which	  leads	  to	  inhibition	  of	  pro-­‐apoptotic	  Hippo	  pathway	  target	  genes.	  However,	  due	  to	  
high	  level	  of	  variation	  between	  the	  experiments	  more	  work	  is	  required	  to	  fully	  clarify	  the	  role	  of	  
MOBKL1A.	  Nonetheless,	  the	  increased	  apoptosis	  observed	  when	  MYC	  was	  activated	  acutely	  with	  
the	  shMOBKL1A-­‐B	  construct	   is	   in	  accordance	  with	  the	  slightly	  smaller	  acinar	  size	  observed	  when	  
MYC	   was	   activated	   chronically.	   The	   fact	   that	   the	   MOBKL1A	   constructs	   display	   size	   trends	   of	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different	  direction	  in	  the	  chronic	  MYC	  activation	  experiment,	  may	  be	  due	  to,	  in	  addition	  to	  it	  being	  
in	  the	  limits	  of	  experimental	  variation,	  the	  notion	  that	  the	  in	  primary	  testing	  the	  shRNAs	  the	  two	  
different	   constructs	   showed	   significantly	   different	   knockdown	   efficacies.	   This	   being	  
methodologically	   interesting,	   it	   is	   of	   interest	   to	   further	   investigate	   the	   effects	   of	   MOBKL1A	  
knockdown	   as	   in	   this	   study	   the	   observed	   level	   on	  MOBKL1A	   dowregulation	  was	   fairly	   low	  with	  
both	  of	  the	  constructs.	  
As	   the	   literature	   similarly	   proposes	  mechanistically	   a	   tumour	   suppressor	   role	   FAT4,	   it	   is	   slightly	  
surprising	  that	  our	  results	  suggest	  no	  such	  role	  for	  FAT4.	  More	  specifically,	  Ft	  deficient	  cells	  have	  
been	   shown	   to	   overproliferate	   in	  Drosophila	   model	   (363).	   However,	   when	  MYC	   was	   activated	  
acutely	  the	  amount	  of	  Ki67	  positive	  shFAT4	  acini	  was	  comparable	  to	  control,	  which	  may	  be	  due	  to	  
differences	  in	  model	  and	  cell	  types.	   Importantly,	   in	  mammals	  six	  different	  MOBKL	   (1,2,3	  /	  A,B,C)	  
genes	  are	  expressed	  and	  some	  of	  them	  share	  interacting	  partners	  and	  therefore	  some	  redundancy	  
may	   exist	   (364).	   Additionally,	   there	   is	   still	   some	   debate	   what	   is	   the	   exact	   role	   of	   the	   FAT4	   in	  
mammals	  and	  the	  required	  set	  of	  upstream	  regulators	  of	  the	  Hippo	  pathway	  and	  therefore	  future	  
research	  will	  shed	  light	  on	  the	  validity	  of	  the	  observations	  in	  this	  study	  (131,	  132).	  
7.3.	  shRhoA	  and	  the	  concept	  of	  synthetic	  lethality	  	  
The	  current	  project	  originally	  aimed	  to	  find	  mammalian	  regulators	  of	  epithelial	  architecture	  and	  to	  
investigate	  the	  proposed	  tumour	  suppressive	  function	  of	  these	  regulators.	  The	  finding	  of	  synthetic	  
lethality	   with	   combination	   of	   RHOA	   knockdown	   and	   MYC	   activation	   was	   thus	   interesting	   and	  
unexpected.	   Moreover,	   as	   RHOA	   is	   often	   overexpressed	   in	   human	   cancers,	   it	   does	   not	   fit	   the	  
criteria	   of	   classical	   tumour	   suppressors,	   which	   are	   often	   observed	   to	   be	   lost	   or	   inactivated	   by	  
mutations	   (244,	   260).	   However,	   in	   cancer	  models	   overexpression	   of	   RHOA	   has	   been	   shown	   to	  
cause	   disruption	   of	   architecture	   for	   example	   by	   contributing	   to	   migrational	   events,	   which	   are	  
important	  in	  spreading	  of	  the	  cancer	  thereby	  destroying	  the	  protective	  function	  of	  intact	  epithelial	  
structure	  (167,	  260,	  263).	  	  
Despite	  the	  extensive	  research	  done,	  there	  is	  a	   lack	  of	  cancer	  drugs,	  which	  would	  target	  specific	  
molecular	  defects	  observed	  in	  cancer	  cells.	  Therefore	  in	  the	  recent	  years	  the	  findings	  of	  synthetic	  
lethal	  interactions	  have	  been	  proposed	  to	  have	  future	  clinical	  potential	  in	  cancer	  treatment	  (365).	  
The	  concept	  has	  already	   reached	   the	  clinics,	   since	   in	  breast	  cancer	   treatment	  synthetic	   lethality	  
has	   been	   utilized	   by	   combining	   poly	   (ADP-­‐ribose)	   polymerase	   (PARP)	   inhibitors	   with	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BRCA1/BRCA2-­‐mutated	   breast	   cancers	   (348,	   366,	   367).	   Other	   established	   synthetic	   lethal	  
interactions	  in	  mammalian	  cells	  include	  inactivation	  of	  Skp2	  in	  Rb-­‐deficient	  cells	  and	  inhibition	  of	  
Aurora	  Kinase	  B	   in	  MYC	  overexpressing	  cells	   (368-­‐370).	  Recently,	   in	  a	  screen	  for	  synthetic	   lethal	  
interactions	   with	   MYC,	   SUMOylation	   related	   enzyme	   SAE1/2	   was	   identified.	   Interestingly,	  
significance	   of	   this	   interaction	   was	   also	   validated	   in	   MYC-­‐driven	   mouse	   tumour	   model	   and	   in	  
patient	   tumours,	  as	  high	  MYC-­‐expression	  correlated	  with	   low	  SAE1/2	   level	   in	  patients	  with	   long	  
metastasis	  free	  survival	  (371).	  Similarly,	  suggested	  by	  results	  of	  this	  study,	  it	  would	  be	  interesting	  
to	  investigate	  RHOA	  levels	  in	  tumour	  samples	  which	  are	  known	  to	  contain	  MYC	  overexpression	  or	  
amplification.	   Further	   genetic	   and	   chemical	   screens	   are	   thought	   to	   be	   able	   to	   reveal	   more	   of	  
synthetic	  lethal	  interactions	  (365,	  367).	  However,	  the	  screens	  are	  rarely	  done	  in	  3D	  environment	  
possibly	   missing	   potential	   interactions	   or	   catching	   interactions	   that	   do	   not	   translate	   to	   in	   vivo	  
experiments.	   However,	   our	   finding	   of	   synthetic	   lethality	   with	   RHOA	   downregulation	   and	   MYC	  
activation	  seems	  to	  be	  specific	  for	  the	  3D	  context.	  Even	  though	  over	  the	  years	  several	  phenotypes	  
have	  been	  described	  to	  be	  3D	  specific,	   it	   is	  surprising	  for	  the	  cells	  to	  exhibit	  this	  kind	  of	  context	  
dependence	  when	  it	  comes	  to	  cell	  viability	  (82,	  163,	  290).	  	  
Although	   RHOA	   has	   somewhat	   established	   role	   in	   cell	   biology	   and	   in	   regulation	   of	   epithelial	  
architecture	   largely	   through	   its	   actions	   on	   cytoskeleton,	   in	   addition	   to	   its	   connection	   to	   MYC	  
(Chapter	   1	   Section	   1.3.2.1.1.3.	   RHOA	   and	   Chapter	   6	   Section	   6.6.	   Recapitulation	   of	   synthetic	  
lethality	  phenotype	  with	  RHOA	  associated	   inhibitors),	   similar	  observations	  on	   synthetic	   lethality	  
have	  not	  been	  published.	  This	  study	  shows	  deregulation	  of	  integrin	  localization	  in	  MCF10A	  shRhoA	  
cells	   in	   3D	   context.	   Interestingly,	   RHOA	   has	   been	   firmly	   been	   linked	   to	   the	   integrin-­‐related	  
phenotypes	  in	  3D	  context	  by	  regulation	  of	  acinar	  polarity	  by	  dominant	  negative	  mutant	  of	  RAC1	  as	  
described	  earlier	  (Chapter	  1	  Section	  1.3.2.1.1.4.	  RHO	  GTPase	  effects	  on	  epithelial	  morphogenesis	  
in	  vitro).	   In	  addition,	   the	   fact	   that	  part	  of	   the	   integrin	  based	  cell-­‐matrix	   related	  connections	  are	  
linked	   to	   actin	   cytoskeleton,	   largely	   regulated	   by	   RHOA,	   instead	   of	   intermediate	   filaments	   in	  
hemidesmosomes	  cannot	  be	  forgotten	  (372).	  However,	  contribution	  of	  this	  integrin	  perturbation	  
to	   the	  synthetic	   lethality	   remains	  unclear	  at	   this	  point,	  as	   the	   integrin	  defect	  was	  observed	  also	  
without	  MYC	  activation.	  Moreover,	  RHOA	  is	  also	  linked	  to	  protection	  from	  apoptosis	  via	  activation	  
of	  the	  MEK/ERK	  pathway	  in	  a	  zebrafish	  study	  (349).	  	  However,	  also	  a	  study	  presenting	  an	  opposite	  
role	   in	   apoptosis	   for	   RHOA	   in	   cardiomyocytes	   has	   been	   published	   showing	   overexpression	   of	  
active	   RHOA	   to	   cause	   apoptosis	   (373).	   In	   conclusion,	   all	   the	   components	   for	   the	   observed	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phenotype	   seem	   to	  be	   in	   place.	  However,	  what	   is	   their	   relationship	   and	   their	   effects	   in	   the	   3D	  
context	   in	   MCF10A	   in	   the	   synthetic	   lethal	   phenotype	   is	   unknown.	   Additionally,	   the	   observed	  
lethality	   could	   be	   a	   result	   of	   defective	   proliferation	   as	   RHOA	   is	   linked	   to	   the	  mechanics	   of	   cell	  
division.	   However,	   the	   regulation	   of	   proliferation	   did	   not	   warrant	   further	   investigation	   as	   the	  
results	   did	   not	   show	   difference	   compared	   to	   control	   specifically	   when	   MYC	   was	   activated.	  
Importantly,	  it	  has	  been	  previously	  shown	  by	  us	  that	  MYC	  activation	  causes	  increased	  proliferation	  
in	  immature	  acini	  which	  was	  also	  observed	  in	  this	  study	  (82).	  
Finally,	   when	  we	   activated	  MYC	   at	   later	   time	   point	   (day	   7),	   we	   observed	   similar	   size	   decrease	  
trend	  and	   increase	   in	  apoptosis	  as	  when	  MYC	  was	  activated	  chronically	  on	  day	  1.	  However,	   the	  
fact	  that	  the	  lethal	  combination	  of	  activated	  MYC	  and	  shRhoA	  has	  less	  time	  to	  act	  in	  this	  setting	  
and	  apoptosis	   protective	   effect	   of	   preformed	  acinar	   structure	   can	   contribute	   to	   the	   less	  drastic	  
phenotype.	   Additionally,	   the	   variation	   in	   apoptosis	   levels	   is	   slightly	   greater	   compared	   to	   the	  
chronic	   activation	   experiments	   therefore	   erasing	   the	   statistical	   significance	   of	   the	   results.	   The	  
observation	  suggests	  that	  the	  synthetic	  lethality	  is	  not	  dependent	  on	  the	  chronic	  MYC	  activation.	  
Experiments	  performed	  in	  this	  study	  fail	  to	  pinpoint	  the	  crucial	  mechanistic	  factor	  for	  causing	  the	  
synthetic	   lethality.	  On	  the	  other	  hand,	   it	  can	  be	  argued	  that	  the	  phenotype	  would	  be	  a	  result	  of	  
additive	  apoptotic	  burden	  through	  the	  sensitization	  to	  apoptosis	  of	  the	  early	  acini	  by	  MYC	  and	  the	  
suggested	  protection	  of	  apoptosis	  by	  MEK/ERK	  activation	  by	  RHOA	  expression,	  which	  is	  abolished	  
with	   shRNA.	  However,	   this	  does	  not	   seem	  probable	   in	   this	   setting	  as	  we	  did	  not	  observe	  RHOA	  
downregulation	   by	   itself	   significantly	   increase	   apoptosis	   in	   the	   acini.	  Moreover,	   open	   questions	  
regarding	  MYC	   and	   RHOA	   relationship	   in	   general	   are	   still	   unsolved	   as	  MYC	   has	   been	   shown	   to	  
increase	  RHOA	  expression	  transcriptionally	  whereas	  it	  has	  been	  showed	  to	  decrease	  RHOA	  levels	  
and	  ROCK	  signalling	  in	  other	  studies	  (277,	  353,	  356)	  –	  our	  findings	  in	  this	  study	  being	  in	  line	  with	  
the	  latter	  observation	  in	  2D.	  	  	  
7.4.	  Inhibitor	  studies	  suggest	  a	  role	  for	  MEK/ERK	  and	  ROCK	  pathways	  in	  synthetic	  lethal	  
phenotype	  	  
The	   preliminary	   inhibitor	   studies	   suggest	   a	   synergistic	   role	   for	   MEK	   pathway	   inhibition	  
downstream	  of	  RHOA	  inactivation	  and	  MYC	  activation.	  This	  seems	  to	  be	  plausible	  as	  the	  studies	  on	  
which	   basis	   the	   inhibitors	   were	   selected,	   showed	  MYC	   to	   cause	  MEK/ERK-­‐downregulation	   and	  
MEK/ERK	  to	  be	  related	  in	  apoptosis	  protection,	  hinting	  a	  possibility	  for	  synergistic	  targeting	  of	  the	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MEK/ERK	   survival	   pathway.	   Supposing	   that	   the	   decrease	   in	   acinar	   size	   observed	   with	   MEK	  
inhibition	   combined	   to	   activated	   MYC	   is	   related	   to	   increased	   amounts	   of	   apoptosis	   due	   to	  
sensitivity	   of	   the	   early	   acini,	   and	   not	   to	   decreased	   proliferation,	   the	   U0126-­‐MYC	   combination	  
could	  potentially	  show	  synergy	  in	  apoptosis	  induction	  in	  further	  experiments.	  MEK/ERK	  pathway	  is	  
in	  part	  activated	  by	  extracellular	   cues	   relayed	  by	   integrins	   (374).	  However,	   in	   the	  present	   study	  
MEK	   inhibition	   does	   not	   affect	   integrin	   deposition	   but	   instead	   ROCK	   inhibition	   appeared	   to	  
contribute	   to	   the	   integrin	   localization	   and	   modification	   of	   epithelial	   architecture.	   This	   raises	  
interesting	   question	   to	   be	   validated	   in	   future:	   knockdown	   of	   RHOA	   signalling	   disrupts	   integrin	  
signalling,	   leading	   to	   hampered	   MEK/ERK	   signalling	   by	   disrupted	   integrins	   and	   directly	   by	  
knockdown	  of	  RHOA	  after	  which	  the	  torture	  is	  finished	  by	  downmodulation	  of	  MEK/ERK	  by	  MYC	  
combined	   with	   its	   apoptosis	   sensitizing	   effect	   (Fig	   19).	   An	   important	   concept	   to	   keep	   in	   mind	  
when	  considering	  this	  phenotype	  is	  anoikis,	  which	  is	  a	  form	  of	  apoptosis	  occuring	  when	  anchorage	  
dependent	   cells	   lose	   their	   contact	   with	   their	   substrate	   (physiologically	   ECM)	   (375).	   Anoikis	   has	  
been	  shown	  to	  be	  crucially	  regulated	  by	  integrins	  and	  for	  example,	  the	  active	  MEK/ERK	  pathway	  
downstream	  of	  integrin	  signalling	  protects	  from	  anoikis	  (375,	  376).	  Anoikis	  has	  been	  also	  studied	  
in	   3D	   context	   and	   importantly,	   apicobasal	   polarization	   seems	   to	   play	   a	   role	   in	   survival	   as	   acini	  
grown	   in	   collagen	   I	   gels	   are	   not	   protected	   from	   apoptosis	   to	   same	   extend	   as	   cells	   grown	   in	  
reconstituted	  basement	  membranes	  such	  as	  Matrigel™	  (375).	  Moreover,	  RHOA	  has	  been	  directly	  
linked	   to	   anoikis	   in	   Φ293-­‐Nx	   cells	   in	   2D,	   although	   in	   contrast	   to	   our	   results	   RHOA	   activation	  
appears	   to	   cause	   anoikis	   (377).	   However,	   considering	   current	   knowledge,	   the	   integrin	   related	  
phenotype	  observed	  in	  this	  study	  seems	  to	  be	  valid	  leaving	  still	  open	  question	  for	  future	  research	  
to	  resolve	  the	  synergistic	  action	  observed	  when	  combined	  with	  MYC	  activation.	  
7.6.	  Conclusion	  and	  future	  prospects	  	  
The	   aim	   of	   this	   study	   was	   to	   explore	   whether	   Drosophila	   epithelial	   architecture	   and	   polarity	  
regulating	   genes	   are	   also	   important	   for	   epithelial	   architecture	   regulation	   in	   mammalian	   cells.	  
Additionally,	  as	  many	  of	  the	  epithelial	  architecture	  genes	  have	  been	  linked	  to	  tumour	  suppression,	  
we	   wanted	   to	   determine	   whether	   they	   also	   exhibit	   similar	   feature	   in	   mammalian	   cells.	  
Interestingly,	  this	  subset	  of	  the	  hEAL	  project	  did	  not	  find	  genes	  that	  would	  clearly	  affect	  apicobasal	  
polarization	   in	  human	  mammary	  epithelial	  cells	  MCF10A.	  However,	  this	  study	  demonstrates	  and	  
validates	   the	   primary	   screen	   findings,	   clear	   effects	   on	   epithelial	   architecture	   and	   acinar	   growth	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with	   shRNA	   downregulation	   of	   the	  Wnt	   pathway	   related	   gene	   DVL3	   and	   to	   lesser	   extent	   with	  
Gsk3β	  which	  acts	  in	  the	  same	  pathway.	  In	  the	  case	  of	  DVL3	  the	  knockdown	  leads	  to	  also	  enhanced	  
proliferation,	   however	   not	   being	   able	   to	   conclude	   in	   this	   study	   whether	   in	   this	   context	   the	  
proliferation	  is	  due	  to	  direct	  regulation	  of	  the	  proliferation	  machinery	  or	  through	  the	  disruption	  of	  
the	  architecture	   (as	  has	  been	  shown	  by	  our	   laboratory	   for	  LKB1).	  However,	  we	  did	  not	   find	  any	  
genes	  that	  would	  synergistically	  act	  together	  with	  MYC	  activation	  and	  exhibit	  tumour	  suppressive	  
role	   in	  MYC	   context	   as	   LKB1	   does.	   This	   study	   also	   aimed	   to	   characterize	   significant,	   seemingly	  
synergistic,	   interaction	   between	   RHOA	   downregulation	   and	  MYC	   activation	   causing	   a	   synthetic	  
lethal	  phenotype	  possibly	  having	  clinical	  relevance	  in	  future.	  	  
Future	  directions	  for	  the	  project	  will	  be	  related	  to	  closer	  characterization	  of	  the	  most	  interesting	  
phenotypes	   showing	   tumour	   suppressive	   features.	   Firstly,	   characterization	   of	   morphogenetic	  
events	   in	   the	   formation	   of	   the	  multiacinar	   structure	  with	   shDVL3	   cells,	   for	   example,	  with	   time-­‐
lapse	  microscopy	  is	  of	  interest.	  Even	  though	  the	  finding	  of	  tumour	  suppressive	  role	  for	  DVL3	  was	  
unexpexted	  in	  the	  light	  of	  literature,	  the	  fact	  the	  same	  phenotype	  has	  been	  produced	  by	  multiple	  
shRNAs,	  argues	  the	  phenotype	  to	  be	  produced	  specifically	  by	  DVL3	  knockdown.	  Characterization	  
of	  the	  DVL3	  acini	  in	  addition	  to	  the	  lumen	  filled	  shGSK3β	  acini	  can	  provide	  more	  knowledge	  about	  
Wnt	  pathway	  in	  acinar	  morphogenesis	  and	  oncogenic	  events.	  Of	  great	  interest	  will	  also	  be	  to	  more	  
closely	  dissect	  the	  synthetic	   lethal	  phenotype	   in	  MYC	  activated	  shRhoA	  cells	  and	  characterize	   its	  
requirements,	   for	  example,	  by	  using	   collagen	  based	  matrix,	  which	  does	  not	  enable	  polarization.	  
Moreover,	   it	   is	  of	   interest	  also	  to	  perform	  late	  (acute)	  MYC	  activation	  for	  the	  shRhoA	  cells	  to	  be	  
able	  to	  see	  if	  the	  phenotype	  is	  observed	  also	  in	  growth-­‐arrested	  acini.	  This	  is	  a	  valid	  point	  as	  RHOA	  
is	   also	   involved	   in	   mechanics	   of	   cell	   division	   even	   though	   we	   did	   not	   observe	   differences	   in	  
proliferation	   when	  MYC	   was	   activated	   chronically	   (378).	   	   To	   enable	  more	   options	   for	   studying	  
RHOA,	   I	   screened	   a	   number	   of	   pLKO	   based	   vectors	   for	   RHOA	   downregulation	   and	   carried	   out	  
cloning	   of	   the	   oligo	   into	   to	   the	   pDSL	   vector	   which	   can	   be	   selected	   in	   our	   systems.	   Future	   will	  
demonstrate	   whether	   this	   approach	   enables	   more	   efficient	   and	   conclusive	   research	   on	   this	  
phenotype.	   Of	   interest	   would	   be	   also	   acquisition	   of	   inducible	   shRhoA	   vector	   to	   be	   better	   able	  
dissect	  and	  characterize	  the	  requirements	  and	  dynamics	  of	  the	  phenotype.	  Closer	  pinpointing	  of	  
the	  affected	  pathways	  by	  using	  chemical	  inhibitors	  will	  also	  be	  a	  key	  experiment.	  Approaching	  the	  
RHOA-­‐MYC	   phenotype	   from	   a	   more	   biochemical	   point	   of	   view	   will	   be	   also	   available	   once	   we	  
establish	   working	   antibodies	   in	   our	   systems	   for	   the	   RHOA	   related	   pathways,	   which	   was	   not	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possible	  during	  this	  study.	  Finally,	  our	   laboratory	  has	  also	  a	  parallel	  project	  with	  a	  similar	   library	  
targeted	  against	   the	  mouse	  genes	   (mouse	  epithelial	  architecture	   library,	  mEAL)	  and	   therefore	   it	  
will	  be	  of	  great	   interest	  to	  see	  whether	  the	  most	  significant	  phenotypes	  will	  be	  observed	  also	   in	  
vivo	  by	  using	  fat	  pad	  transplantion	  method.	  
To	   conclude,	   in	   this	   study	   we	   were	   able	   to	   validate	   the	   findings	   of	   the	  multiacinar	   phenotype	  
produced	  by	  DVL3	  knockdown	  with	  two	  different	  shRNA	  and	  enlarged	  and	  lumen-­‐filled	  phenotype	  
in	  shGSK3β	  acini.	  Additionally,	  synthetic	  lethal	  phenotype	  caused	  by	  shRHOA	  and	  MYC	  activation	  
was	   characterized	   to	   have	   deregulated	   integrin	   localization	   and	   increased	   apoptosis,	   and	  
interestingly	  suggested	  to	  be	  3D	  specific	  in	  this	  study.	  Additionally,	  targeting	  the	  RHOA	  associated	  
pathways	   suggested	   the	   synthetic	   lethal	   phenotype	   seen	   in	   shRhoA	   cells	   to	   be	   associated	  with	  
MEK/ERK	  and	  ROCKpathways.	  Further	  studies	  and	  in	  vivo	  experiments	  may	  reveal	  the	  RHOA-­‐MYC	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Figure	  19	  Model	  of	  the	  molecular	  defects	  observed	  in	  shRhoA-­‐MYC	  synthetic	  lethal	  phenotype	  in	  3D	  context	  in	  combination	  with	  literature	  mining.	  
RHOA	  and	  RAC1	  are	  connected	  to	  actin	  cytoskeleton	  and	  integrin	  signalling.	  RHOA	  and	  integrin	  signalling	  are	  known	  to	  protect	  from	  apoptosis	  by	  
activating	  MEK	  pathway	  and	  MYC	  suppresses	  both	  RHOA	  and	  MEK.	  MYC	  activation	  sensitizes	  immature	  acini	  to	  apoptosis	  which	  can	  enhanced	  the	  
defects	  in	  integrin	  localization	  seen	  shRhoA	  cells	  implying	  defects	  in	  ECM	  contact	  and	  possibility	  of	  anoikis.	  In	  the	  pictures	  depicting	  acini	  (upper),	  
observed	  changes	  in	  acinar	  morphology	  in	  with	  shRhoA	  cells	  and	  Myc	  activation	  are	  visualized.	  (Left)	  Control	  cells.	  (Right)	  shRhoA	  cells	  +	  chronic	  
MYC	   activation.	   Pink	   shows	   the	   observed	   pattern	   of	   α6-­‐integrin	   immunostaining	   and	   red	   corresponds	   the	   apoptosis	   marker	   active	   caspase	   3	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